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 Monocytic leukaemia zinc-finger protein (MOZ) is a histone acetyltransferase 
(HAT) implicated in haematopoiesis and acute myeloid leukaemia, as well as 
embryonic and postnatal development. MOZ contains multiple domains, including a 
MYST HAT domain and a double PHD finger domain (DPF) suggesting it interacts 
with histones. This work has established for the first time that the MOZ DPF exhibits 
dual functionality in establishing and sensing post-translational modifications 
(PTMs) of histones. Firstly, our data detected the direct interaction of MOZ with the 
N-terminal tails of histones H3 and H4 and shows that the MOZ DPF domain 
mediates such binding. Both PHD fingers are required and functionally cooperate to 
establish the DPF histone binding preference in terms of PTMs. We demonstrate that 
H3K4me3 prevents MOZ DPF association with H3, although H3K4me2 is tolerated. 
Similarly, H4Kac acts as a dominant exit signal that excludes MOZ from chromatin. 
This ability to sense H3K4 PTM status was confirmed in a collaborative effort 
establishing the crystal structure of MOZ DPF in complex with an unmodified H3 
SHSWLGH 7KH + SHSWLGH DGRSWHG DQ Į-helical conformation in the complex, which 
has not previously been observed. 
Secondly, we present novel data showing that the MOZ DPF domain exhibits 
a mild histone H3-specific acetyltransferase activity. This provides the first report of 
a possible enzymatic role in chromatin modification attributed to a PHD finger. 
Furthermore, the combined DPF and MYST domains were found to influence the 
reaction rate and substrate specificity of MOZ-induced histone acetylation. 
iii 
 
Our studies revealed that the MOZ DPF could associate with heterochromatic 
PTMs, namely H3K9me3. We report here that both the H3K9-specific 
methyltransferase SUV39H1 and heterochromatin protein 1 (HP1) form interactions 
with MOZ, implicating its function in both corepressor and coactivator complexes. 
Thus, our data suggest that like several other chromatin-associated proteins, MOZ is 
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Chapter One: Introduction 
 




The stringent control of gene expression during development, differentiation, 
and the maintenance of cellular function, is ultimately essential for the survival and 
evolution of complex multi-cellular organisms. Transcription is one of the first steps 
in gene expression and this involves molecular events to copy the genes encoded in 
eukaryotic chromosomes into RNA.  Indeed, many biological processes in living cells 
and organisms are regulated primarily at the level of transcription. 
The transcriptional process relies upon a basal machinery of evolutionary 
conserved transcription factors and polymerases, which collectively reconstitute a 
transcription initiation complex. Within the eukaryotic cell nucleus there are five 
functionally distinct RNA polymerases (RNAP), designated RNA polymerase I, II, 
III, IV and V.  RNAP I and its transcription machinery function in the nucleolus to 
synthesise ribosomal (r)RNA. rRNA biogenesis regulates ribosome production that in 
succession guides cell growth and proliferation (Drygin et al., 2010; Grummt, 1999). 
RNAP III is required for the production of short RNA molecules, including transfer 
(t)RNA and rRNA which are implicated in protein synthesis and RNA maturation 
(Canella et al., 2010; Willis, 1993). RNAP IV and V synthesise short interfering 
(si)RNA that are required for heterochromatin formation in plants (Herr et al., 2005; 
Wierzbicki et al., 2009). Finally, RNAP II is responsible for the synthesis of all 
eukaryotic messenger (m)RNA and most small nuclear (sn)RNA and microRNA, 
which are respectively utilised as templates for protein synthesis, RNA processing 
and the regulation of gene activity to name but a few.  The functional importance of 
Chapter One: Introduction 
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RNAP II is further reflected by the fact that it is the most extensively studied of this 
class of enzymes.  
As discussed, the initiation of RNA synthesis has emerged as a primary event 
in determining cellular gene expression levels (Tjian, 1996), and therefore it is not 
surprising that RNAP II is the end target of a vast array of signal transduction 
pathways.  It is this elaborate regulation of RNAP II transcription that underlies the 
control of cellular development and differentiation (Hahn, 2004). RNAPII is unable 
to activate transcription on its own: the enzyme is capable of uncoiling and recoiling 
DNA, and the synthesis of RNA, but is incapable of recognising and binding a 
promoter sequence (Kornberg, 2007). This role requires the participation of the 
general transcription factors (GTFs). Many groups contributed towards the isolation 
of the RNAP II transcription proteins and these findings were critical for the solution 
of the structure and regulation of the RNAP II machinery (Thomas and Chiang, 
2006). Further, recent advances in structure determination have led to an increased 
understanding of the precise assembly of transcription proteins at the promoter and 
the molecular events that occur during the initiation of transcription (Hahn, 2004).   



















The high level of control required over transcription is dictated by regions of 
eukaryotic protein coding genes. Each gene carries a core promoter region and a 
unique array of proximal and distal regulatory elements, which are recognised by 
sequence specific DNA binding factors critical for the activation or repression of 
transcription initiation. For illustration, activators bind to enhancer sequences (e.g 
Upstream Activation Sequences - UAS), located near to or far removed from gene 
promoters, triggering a cascade of recruitment of coactivator complexes; including 
histone modification enzymes, chromatin remodelers and Mediator (Figure 1.1).  
Figure 1.1. Model of PIC formation during transcriptional initiation. Upon 
targeting to the Upstream Activation Sequence (UAS), activators recruit 
coactivators (including SAGA, Mediator, Swi/Snf). This recruitment further 
augments the binding of activators, triggers hyperacetylation of histones and the 
subsequent remodelling of nucleosomes. Unmethylated CpG Islands (CGIs) also 
promote a permissive chromatin state. The resulting exposure of the entire core 
promoter and the SAGA/Mediator complexes facilitate the assembly of GTFs and 
RNAP II to form the PIC and initiate transcription. (Figure adapted and updated 
from Hahn, 2004). 
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Many genes transcribed by RNAP II have well defined nucleosomal positioning at 
promoters, thus SAGA histone acetyltransferase activity, histone acetylation and the 
Swi/Snf remodeler act prior to Pre-Initiation Complex (PIC) formation, in order to 
overcome this nucleosomal barrier and make DNA more accessible (Reinke et al., 
2001). Mediator, a large multi-subunit complex conserved in all eukaryotes, interacts 
directly with enhancer bound activator proteins and, consequently, contacts RNAP II 
and GTFs at the promoter to stimulate the initiation of transcription (Kornberg, 
2005). Mediator is not only the basis for regulated transcription at almost all RNAP II 
promoters; but is comparable with RNAP II in its importance for transcription. 
Previously, Mediator has been viewed solely as a coactivator in function, however it 
is now evident that it can also function as a corepressor and GTF. Mediator can be 
viewed as a signal processor, relaying both positive and negative regulatory 
information from enhancers to promoters (Takagi and Kornberg, 2006).  
The discovery of CpG islands (CGIs) added greater complexity to our 
understanding of transcriptional control. The mammalian genome is punctuated with 
a high frequency of DNA sequences rich in G/C base composition and a high density 
of CpG dinucleotides (Figure 1.1). CGIs encompass the transcription start site (TSS) 
and promoter regions of 60-70% of human genes (Illingworth and Bird, 2009) and 
often lack DNA methylation.They also coincide with sites of histone H3 Lysine 4 tri-
methylation and colocalise with RNAP II (Thomson et al., 2010). These elements 
annotate active gene promoters but are refractory to epigenetic silencing by DNA 
methylation. The link between unmethylated CGIs and transcriptional activation has 
long been observed, however it has only recently been shown that the underlying 
sequence of CGIs genetically influences the chromatin modification status through 
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the recruitment of protein mediators (CpG binding proteins). It has thereby been 
proposed that the DNA sequence at CGIs simplifies genome function by 
manipulating chromatin structure directly (Thomson et al., 2010). 
After specific positive regulatory events of activator recruitment and 
nucleosomal rearrangement, promoter DNA is made transiently available for the 
interaction with the transcription machinery. Typically, the RNAP II transcription 
cycle begins with the binding of gene-specific regulatory factors at sequence 
elements within the core promoter; these elements include the TATA box. Core 
promoter recognition is required for the correct positioning and assemblage of RNAP 
II and GTFs to form the PIC (Figure 1.1).  
TFIID consists of the TATA-box binding protein (TBP), which allows 
attachment at the promoter sequence and approximately 14 TBP associated factors 
(TAFs) that modulate promoter recognition. The sequential binding of the TFIIA and 
TFIIB transcription factors further stabilise the TFIID-promoter attachment. In a 
stepwise manner, the pre-formed RNAPII-TFIIF complex, TFIIE and TFIIH bind. 
TFIIH possesses DNA helicase activity, which exposes the template strand at the 
transcription start point. The subunits of TFIIH are also important in nucleotide base 
excision repair, and ultimately promoter clearance that results in the start of the 
elongation phase (Zhovmer et al., 2010). The assembly of the complete closed PIC is 
not in an active conformation to begin transcription, it is not until a clear 
conformational change occurs, in which 11-15 base pairs (bp) of DNA surrounding 
the TSS is melted and the template strand is exposed to the active site of RNAP II to 
form the open complex  (Hahn, 2004). Transcriptional initiation is set in motion with 
the formation of the first phosphodiester bond of RNA.  
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The regulation of transcription is a multi-step process, with stringent control 
being exerted at the elongation and termination phases as well as the initiation stage. 
RNAP II clears the promoter and enters early elongation phase, after releasing 
contacts with the core promoter and the rest of the transcription machinery. Studies 
including ChIP-chip and permanganate footprinting, were used to analyse the 
distribution of transcriptionally engaged RNAP II across the genome (Core and Lis, 
2008). Results revealed an enriched RNAP II density positioned witKLQWKH¶ERG\RI
the gene. This concept, named promoter-proximal pausing describes how 
transcriptionally engaged RNAP II transcribes 20-50bp downstream of the TSS, 
producing an RNA and pauses (Core and Lis, 2008). This pause correlates with the 
action of the pausing factors DSIF (DRB- sensitivity inducing factor) and NELF 
(negative elongation factor), which aid in stabilising RNAP II in the paused form 
(Yamaguchi et al., 1999). Activator proteins lead to the attraction of factors that 
promote RNA chain synthesis, processing, export and chromatin modification to 
release RNAP II from its paused state. RNAP II and its associated pausing factors are 
hyperphosphorylated, allowing the enzyme to escape the pause and either enters 
productive elongation or RNA synthesis terminates. Promoter-proximal pausing is a 
post-recruitment regulation stage that allows promoters to be held in an open and 
accessible configuration, ensuring the rapid and synchronous transition into 
productive elongation and activation of gene expression upon stimuli from additional 
factors (Fuda et al., 2009). More recently, the deep sequencing RI WKH ¶ HQGV RI
nascent RNA transcripts, associated with RNA polymerase, has allowed the 
visualisation of transcription at a nucleotide resolution. Nascent RNA sequencing has 
revealed that pervasive polymerase pausing and backtracking is widespread, both at 
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human promoters and throughout the entire body of the transcript (Core et al., 2008; 
Churchman and Weissman, 2011).  
During elongation, nucleosomes are displaced and redeposited to allow the 
passage for RNAP II to transcribe throughout the entire gene body. After the RNAP 
II complex has transcribed the gene, transcription is terminated, RNAP II removed 
from the DNA and the RNA released. Freed RNAP II can then be recycled and 
reused in subsequent rounds of transcriptional initiation (Fuda et al., 2009). 
Current models establish that polymerases are recruited to their target genes 
wherever their location may be. However, novel revelations in the field of gene 
regulation are emerging, providing evidence for alternative mechanisms for 
polymerase action. Cook and colleagues have provided evidence, through mapping 
with nucleases and chromosome conformation capture, that active RNA polymerases 
DQG DVVRFLDWHG IDFWRUV FOXVWHU LQWR µIDFWRULHV¶ :LWKLQ WKHVH IDFWRULHV PDQ\ RI WKH
functions needed to produce mature RNA transcripts are carried out (Faro-Trindade 
and Cook, 2006).  This clustering into distinct cellular compartments ensures efficient 
interaction between molecules, leading consequently to increased reaction rates and 
HQKDQFHG UHJXODWLRQ &RRN¶V FXUUHQW PRGHO VWDWHV WKDW JHQHV DV SDUW RI FKURPDWLQ
loops, must diffuse to the appropriate transcription factory before expression can take 
place (Faro-Trindade and Cook, 2006). Active, hyperphosphorylated polymerases are 
tethered to these factories and act both to maintain the structural integrity of the 
chromatin loops and as motors, reeling in their template DNA (Cook, 1999). 
Recently, it has been shown that factories specialise in the production of a specific 
type of transcript depending on promoter type, whether or not the gene contains an 
intron (Xu and Cook, 2008) and whether the gene products are expressed co-
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ordinately (Carter et al., 2008): however, how many different types of factory there 
are remains to be established. In the absence of transcription these RNAPII foci 
remain, indicating they are not simple accumulations of RNAPII on transcribed genes 
but exist as independent nuclear subcompartments (Mitchell and Fraser, 2008). 
Our knowledge of nuclear organisation and transcriptional regulation is ever 
expanding; however it is important to highlight work carried out over the past few 
years outlining the biological importance of the main interfaces between transcription 
and mechanisms maintaining genome integrity. High levels of transcription correlate 
with common fragile site breakage within chromosomal regions (Yu et al., 2000), 
mutagenesis within a regulatory element or coding region of an individual or group of 
genes (Epstein, 2009; Saxowsky and Doetsch, 2006), and elevated levels of DNA 
recombination (Aguilera, 2002); thus fundamentally impinging on genome stability. 
In order to maintain genome integrity, an invariable cross-talk is required between 
transcription and other basic cellular processes, including DNA damage and repair 
pathways and chromatin remodelling (Svejstrup, 2010). Certification for the 
biological significance of this cross-talk comes from the finding that mutations in the 
genes encoding those proteins that mediate cross-talk can cause severe human 
diseases; such as the skin malignancy Xeroderma pigmentosum or Cockayne 
syndrome which is characterised by growth retardation, premature aging and an 
impairment to nervous system development (Nouspikel, 2008). This relatively poorly 
understood area of DNA research is still in its infancy, however researchers are 
beginning to consider and understand how processes have evolved to guarantee that 
the genome destabilising effect of transcription is minimised. 
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1.2. Chromatin Structure and Dynamics Govern Cellular 
Processes 
All eukaryotic organisms have elaborate ways of organising and packaging 
approximately two metres of DNA within a volume of several microns (Peterson and 
Laniel, 2004). This hierarchical scheme of compression is performed by nuclear 
proteins that successively coil and fold the DNA into higher order structures. This 
complex consisting of DNA, nuclear histones and an array of different chromosomal 
proteins is known as chromatin.  
Chromatin is a structural polymer that not only solves the basic packaging 
problem, but also provides a dynamic platform that assists and dictates the 
progression of nuclear processes; such as transcription, replication, cell-cycle 
progression, DNA repair and recombination. The basic repeating structure of this 
nucleoprotein complex is the evolutionary conserved nucleosome. The nucleosome 
core particle (NCP) consists of 147bp of DNA wrapped nearly twice around a histone 
octamer core, comprising two copies each of the histones H2A, H2B, H3 and H4 
(Luger, 2003) (Figure 1.2).  
The S-phase synthesised core histones are predominantly globular in 
structure, except for an amino-terminal 20-35 residue segment that protrudes from the 
surface of the nucleosome (Peterson and Laniel, 2004). The central globular domain 
mediates both inter-nucleosomal, histone-histone interactions and the direct contact 
with the DNA backbone, allowing consequent organisation of the two wraps of 
nucleosomal DNA. These multiple interactions make the nucleosome one of the most 
stable protein-DNA complexes under physiological conditions (Li et al., 2007a). The 
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unstructured N-terminal tails are rich in basic amino acid residues and are required 
for the ordered condensation of nucleosomal arrays into higher-compacted structures. 
Histone proteins play structural and functional roles in the regulation of many nuclear 
processes including transcriptional control. Tight regulation prevails in the form of 
small molecule, reversible modifications of histones, especially on their N-terminal 
tails.  These modifications serve as an epigenetic code, signalling for changes in 
chromatin architecture. This topic will be discussed in greater detail in subsequent 
sections.  
In addition to the four core histones constituting the NCP, a fifth histone H1 
(linker histone) is present in nuclei. Histone H1 associates with the non-constrained 
linker DNA within the nucleosome array, offering partial nuclease protection 
(Woodcock and Ghosh, 2010). However, linker histones are best classified as 
chromatin architectural proteins; proteins which stabilise and promote higher order 
structures by converting nucleosomal arrays into stable 30nm structures with 
enhanced compaction and regularity (Routh et al., 2008). Recently, accumulating 
evidence portrays that aside from its well-established role in chromatin fibre 
stabilisation, linker histones can act as recruitment hubs for many non-histone nuclear 
and cytosolic proteins involved in overlapping processes centred on genomic DNA. 
Many cases have been documented showing linker histone potential to mediate 
multiple simultaneous interactions when bound to the nucleosome (McBryant et al., 
2010).  
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Figure 1.2. X-Ray structure of the nucleosome core particle at 1.9Å 
resolution. Figure taken from (Luger, 2003). Copyright clearance obtained 
from Elsevier publishing (licence number: 2798250403120). The nucleosome 
core particle as viewed down the superhelical axis. The core histone octamer 
is composed of a central heterotetramer of histones H3 (blue) and H4 (green), 
flanked by two heterodimers of histones H2A (yellow) and H2B (red). The 
DNA helix is shown in light blue and protruding histone N-terminal tails in 
cream.  
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  The nucleosomal array is further condensed by forming a helical coil (30nm 
fibre) stabilised, in part, by the externally core associated linker histone H1 (Routh et 
al., 2008) and the histone octamer surface of the nucleosome. Nucleosome arrays are 
additionally stabilised by the introduction of disulphide crosslinks and show that the 
chromatin fiber comprises two stacks of nucleosomes, which zig zag back and forth 
in a two-start helix organisation (Dorigo et al., 2004). In vitro experimentation 
showing the formation of polynucleosomes into a bona fide 30nm chromatin 
secondary structure is generally accepted. However, this level of compaction is the 
subject of intense debate and remains controversial due to the difficulty in obtaining 
in vivo evidence. Careful examination of isolated 30nm fibres have failed to reveal a 
consistent, precise arrangement of nucleosomes (Woodcock and Ghosh, 2010) and 
data from new experimental techniques including chromatin conformation capture 
and cryo-electron microscopy are beginning to question past evidence of higher order 
chromatin assemblies based on the 30nm fiber (Fussner et al., 2010). 
Due to the lack of clarity and definitive information on chromatin secondary 
structure, models of higher hierarchical structures become complex. However, current 
evidence concludes that the final condensation of chromatin involves the in vivo 
formation of 100-400nm interphase fibers (Peterson and Laniel, 2004) or the more 
highly compacted (10,000-20,000X), consistent manifestation of chromatin; the 
metaphase chromosome structures (Woodcock and Ghosh, 2010). 
In addition to nucleosomes, an array of histone variants and accessory 
proteins constitute the chromatin fiber and aid the modulation of chromatin structure. 
Histone variants are non-allelic isoforms of the canonical core histones  that have the 
potential to adjust the stability of nucleosomes and nucleosomal arrays (Park and 
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Luger, 2008). Further, structural studies disclose that these variants may facilitate 
intranucleosomal interactions, thereby contributing to the alteration of higher-order 
chromatin structures (Luger, 2003). Histone variants are mainly distinguished from 
core histones in that they are expressed outside of S-phase and incorporated into 
chromatin in a DNA-replication-independent manner (Li et al., 2007a). These 
variants are not randomly distributed in chromatin but are expressed in 
developmentally constrained or cell type specific patterns (Verdone et al., 2006).  
H2A.Z, a variant of the core histone H2A, can be deposited into a nucleosome either 
through ATP-dependent histone exchange reactions (Mizuguchi et al., 2004) or with 
the help of the histone chaperone NAP1 (Park et al., 2005). Depending on the 
position of the nucleosome in which it has been placed, H2A.Z has been shown to 
exert critical functions to facilitate either transcriptional repression at the 
heterochromatin boundary, or transcriptional activation at gene promoters. Its 
importance as a modulator of chromatin structure is reinforced by the fact that it 
cannot be substituted for by the bona fide H2A core histone (Clarkson et al., 1999).  
As described previously in section 1.1, the nucleosome and higher order 
chromatin structures impede the access of enzymes and factors that assist DNA-
mediated processes such as transcription, DNA damage and repair. The maintenance 
of chromatin structure is therefore fundamental for eukaryotic gene regulation. 
Another group of proteins, the histone chaperones, are mainly responsible for 
retaining a balance between the assembly and the partial or complete disassembly of 
nucleosomes in order to sustain genome integrity (Park and Luger, 2008). In general, 
the chaperones bind histones in order to prevent non-specific interactions between the 
DNA and histones and promote specific interactions that initiate nucleosome 
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assembly through ATP-independent reactions (Eitoku et al., 2008). To maintain the 
balance, histone chaperones also cooperate with chromatin remodelling and 
modifying enzymes to facilitate the eviction of nucleosomes at promoter regions 
where DNA-mediated processes can then commence (Park and Luger, 2008). 
The literature ubiquitously utilises the terms heterochromatin and euchromatin 
when discussing chromatin structures. However, it should be documented that these 
terms refer to the state of compaction and transcriptional potential of chromatin rather 
than higher order structures per se (Woodcock and Ghosh, 2010). Following the 
completion of mitosis, the compact chromosomal structure required for metaphase is 
no longer necessary.  Therefore, as the cell enters interphase, specific areas of the 
chromatin decondense yielding two distinct types of chromatin; euchromatin and 
heterochromatin. Euchromatin is characterised by chromatin domains containing 
transcriptionally active genes. These regions form chromatin loops that extend away 
from the compact chromosome territories, towards the interior of the interphase 
nucleus (Bartova et al., 2008b).  Active genes from different chromosome territories 
located on decondensed chromatin loops are transcribed by the same RNAP II in 
subnuclear compartments called transcription factories (Faro-Trindade and Cook, 
2006). Conversely, heterochromatin is a gene-poor, densely packaged domain 
localised to the nuclear periphery associated with trancriptional silencing (Bartova et 
al., 2008a). 
Higher order chromatin structures are of great importance for packaging all 
genetic information within cell nuclei. They also provide a dynamic platform that 
governs many fundamental nuclear processes, allowing stringent control over the 
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expression of an individual eukaryotic gene and further, more complex gene networks 
that require coordinate regulation.  
 
1.3. Histone Code Hypothesis 
As discussed in preceding sections, eukaryotic gene expression is regulated at 
the level of chromatin structure. We have discussed that input from gene regulatory 
sequences, the binding of sequence-specific activators and repressors and additional 
factors that modify, interact with and remodel chromatin are all required for the 
correct regulation of gene expression. At the turn of the 21st century it emerged that 
histones, once thought to be static structural elements, were indeed vital and dynamic 
entities of the machinery accountable for regulating gene transcription and other 
DNA-templated processes such as replication, repair, recombination and chromosome 
segregation. 
Numerous residues within the N-terminal tails and globular domains of 
histones are subjected to various post-translational modifications (PTMs); including 
acetylation, methylation and phosphorylation. These will be discussed in greater 
detail in a subsequent section (1.4). The huge diversity of modifications and the 
complex nature of their arrangement, both globally and on individual histone tails, led 
to the proposal of WKH FRQFHSW RI D µKLVWRQH FRGH¶ ZKHUH GLVWLQFW KLVWRQH
modifications act sequentially or in combination to generate signals that are read by 
other proteins to bring about specific downstream events including the transcriptional 
state of the gene (Strahl and Allis, 2000). Therefore, in addition to inducing extensive 
changes to nucleosomal structure, modifications can lead to the alteration of distinct 
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surfaces of the nucleosome. These amendments promote the binding of specific 
factors to the nucleosome, resulting in the dissociation or recruitment of proteins, 
dependent on the functional pathway activated.  
As research progresses however, it is evident that there are extra levels of 
intricacy involved in the chromatin signalling pathway, suggesting not a simple code 
but a complex language determining transcriptional readout. More complex scenarios 
are arising disclosing crosstalk between multiple modifications on the same or 
adjacent nucleosomes. In some cases, PTMs acting in combination in both a context 
and time-dependent manner is crucial for a particular transcriptional readout (Lee et 
al., 2010). Also, it is becoming clear in recent histone crosstalk research that the order 
and mechanism of the addition and removal of PTMs are essential for the readout of a 
gene (Lee et al., 2010). Thus, mapping histone modification trends, without the 
context of the recruitment, regulation, and interactions of the complexes executing 
these marks is not sufficient to understand the mechanisms regulating gene 
expression.  
 
1.4. Covalent Modification of Histones and Chromatin 
Remodeling 
Post-translational modifications are chemical alterations following translation, 
which ultimately regulate the stability and function of both histone and nonhistone 
proteins. A prominent attribute of histones is the large number and type of modified 
residues they possess (Figure 1.3). These modifications are known to function via two 
characterised mechanisms. The first is associated with the disruption of DNA-histone, 
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or histone-histone contacts, in order to decondense chromatin; and the second is to 
recruit a series of nonhistone cofactors. These proteins carry with them enzymatic 
activities, that are capable of further modifying chromatin and its structure 
(Kouzarides, 2007). Alterations in chromatin structure have been linked to functional 
outputs including cellular processes such as transcriptional regulation, DNA damage 
repair, and replication. Some of the extensively studied modifications will 
subsequently be discussed in detail. 
Figure 1.3. Overview of the different classes of modification identified on 
histones and their associated functional outputs. Figure adapted from 
Kouzarides, 2007. 
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 1.4.1. Acetylation 
Acetylation of histone lysine residues is one of the most thoroughly 
investigated covalent modifications influencing gene expression in eukaryotic cells.  
Acetylation is a reversible modification where lysines undergo an acetylation-
deacetylation switch governed by different physiological conditions. The transition 
between these modifications is controlled through the activities of two sets of 
enzymes named the lysine/histone acetyltransferases (KATs/HATs) and the 
lysine/histone deacetyltransferases (KDACs/HDACs). KATs function by catalysing 
the transfer of an acetyl group from acetyl-&R$PROHFXOHV WR WKHİ-amino group of 
lysine residues within the N-terminal tails of histones (Berndsen et al., 2007).  
Histone acetylation occurs throughout the whole eukaryotic genome and is 
generally associated with the activation of transcriptional events. Acetylation 
potentially neutralises electrostatic interactions between the histone lysines and 
phosphate groups of DNA, thereby preventing the compaction and folding of higher 
order chromatin structures, reducing internucleosomal contacts and promoting 
accessibility for the transcriptional machinery. Furthermore, lysine acetylation, 
similar to other PTMs, is significant as a direct signal and binding platform for trans-
acting factors (Verdone et al., 2006). Antagonistically, KDAC activity and 
deacetylation cause repression at specific genes. The effect of deacetylation is partly 
mediated by a direct compaction of chromatin structure and also in promoting the 
binding of proteins, generally repressors, which recognise unacetylated histones. For 
example, heterochromatic spreading requires the recruitment of the Sir silencing 
complex by the active deacetylation of H4K16. This, in turn, promotes a condensed 
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structure and repression of gene expression (Shahbazian and Grunstein, 2007). 
Another important function of histone acetylation patterns is in assembly of 
chromatin. Newly synthesised histones are transiently acetylated, a factor which is 
important for their recognition by chaperone proteins and their correct deposition into 
nucleosomes, compacting replicated or newly transcribed DNA. After deposition, 
histones are rapidly deacetylated and later, reacetylated with new patterns to enable a 
variety of functions such as those stated above (Shahbazian and Grunstein, 2007). 
As stated previously, PTMs function as an intricate language and it has been 
highly documented that the crosstalk between acetylation and other marks is 
fundamental in modulating chromatin-based transcriptional control and defining 
heritable epigenetic programs. This can be depicted by one of the first characterised 
examples of histone crosstalk between the histone H3 tail residues S10 
phosphorylation and K14 acetylation. It was found that several KAT enzymes, in 
particular GCN5, displayed an increased acetyltransferase activity on H3 peptides at 
K14, when already bearing the S10 phosphorylation (Lo et al., 2000). 
 
1.4.2. Phosphorylation 
Phosphorylation is the reversible addition of a phosphate group to a serine or 
threonine residue within a protein substrate. Protein kinases catalyse the addition of 
phosphate groups and protein phosphatases remove those groups to modulate the 
balance between substrate phosphorylation and dephosphorylation within the cell. 
This modification affixes a bulky and negatively charged phosphate moiety to the 
hydroxyl side chain, thus increasing the electrostatic ion-pairing and hydrogen-
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bonding capabilities of the serine, threonine and even tyrosine residues (Taverna et 
al., 2007). Alternatively, phosphorylation can induce protein interaction as it is read 
by specialised domains (Komander, 2009). Depending on the site of phosphorylation, 
this histone mark can function in the control of the cell-cycle, PTM-regulated signal 
transduction, DNA damage repair and transcriptional regulation. The phosphorylation 
of chromatin in cooperation with other histone marks has been shown in recent 
DUWLFOHV WR KDYH D GLUHFW HIIHFW RQ JHQH H[SUHVVLRQ 3URWHLQ .LQDVH &ȕ PHGLDWHG
phosphorylation of H3T6, for example, was shown to prevent LSD1 and JARID1B 
from demethylating H3K4 during androgen receptor gene activation (Metzger et al., 
2010). A second illustration of crosstalk is that between H3S10ph and H3K9me3. At 
the onset of mitosis H3S10ph impedes an interaction between Heterochromatin 
Protein 1 (HP1) and H3K9me3, emitting HP1 from its binding site and antagonising 
transcriptional repression (Fischle et al., 2005). 
 
1.4.3. Methylation 
Methylation is defined as the transfer of a methyl group from S-
DGHQRV\OPHWKLRQLQH $GR0HW WR WKH İ DPLQR JURXS RI D O\VLQH UHVLGXH RU WKH
guanidine nitrogen of an arginine residue (Bannister and Kouzarides, 2005). 
Methylation is generally more complex than acetylation as substrates can be mono-, 
di- or tri-methylated. These events are catalysed by three structurally defined types of 
lysine methyltransferase (KMT). The methylation of arginine residues is carried out 
by the Class I family of protein arginine N-methyltransferases (PRMT) and lysine 
methylation has been shown to be catalysed by the conserved SET domain family of 
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proteins. The stringent regulation of the activity and specificity of both sets of 
enzymes is, in part, carried out by different binding proteins and the complex in 
which it resides. The lysine methyltransferases will be discussed in more detail in 
section 1.12. 
Histone methylation plays a fundamental role in a wide range of nuclear 
processes, including heterochromatin formation, X-chromosome inactivation and 
transcriptional regulation (Martin and Zhang, 2005). There is a wealth of research 
carried out on the subject of transcriptional control trying to decipher the methylation 
code. It has been found that whereas acetylation is predominantly associated with 
transcriptional activation, methylation can result in either activation or repression. 
The overall effect depends on the sequence-specific methylation site in histones and 
the methylation state of the arginine or lysine residues (Qian and Zhou, 2006). For 
example, three methylation sites are recognised to recruit activator proteins: H3K4, 
H3K36 and H3K79 and three are connected to transcriptional repression: H3K9, 
H3K27 and H4K20. Of course, as described in previous sections much remains to be 
discovered regarding how these signals work in combination to impact on gene 
regulation and other processes. Currently, twenty-four methylation sites have been 
identified in histones (Bannister and Kouzarides, 2005) however, the understanding 
of the mechanistic and functional consequences of this modification is limited. 
Nevertheless it can be speculated that the ultimate function of the methyl group is a 
reflection of the type of protein it has evolved to recruit. 
Similar to acetylation, methylation is now known to be a reversible process. 
Work by Shi et al., (2004) eliminated controversy in the field with the discovery of 
LSD1, a nuclear homolog of the amine oxidases. LSD1 acts to demethylate H3K4 
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and consequently repress transcription. However, in complex with the androgen 
receptor LSD1 demethylates H3K9 and activates transcription (Metzger et al., 2005). 
Recently, proteins harbouring the JmjC catalytic domain have also been found to 
demethylate lysine residues but via a distinct catalytic reaction to LSD1 (Kouzarides, 
2007). 
As of yet, arginine demethylases have not been identified however, the 
presence of lysine demethylases suggest it is likely arginine demethylases do exist. 
The lysine demethylase LSD1 acts via an amine oxidase reaction, a reaction predicted 
to be compatible with arginine demethylation also. Although not established, 
members within this enzyme family may be able to demethylate arginine residues 
(Bedford and Richard, 2005). It has also been shown that adjacent, pre-existing PTMs 
close to a site of methylation can mask the recognition motif of protein 
methyltransferases (Bedford and Richard, 2005). In addition to the above 
mechanisms, an alternative pathway for the reversal of arginine demethylation has 
been proposed. This process is termed deimination and involves the conversion of 
unmodified or mono-methyl arginine residues into citrulline at specific sites on the 
tail of histone H3 and H4 (Bannister and Kouzarides, 2005). Deimination is mediated 
by the enzyme peptidyl arginine deiminase 4 (PADI4) and prevents arginine 
methylation by CARM1. This modification represents a novel mechanism for 
antagonising the transcriptional induction mediated by arginine methylation (Cuthbert 
et al., 2004). 
 




Protein ubiquitination involves the modification of lysine residues with the 
small protein ubiquitin, a polypeptide composed of 76 amino acids. Ubiquitin is 
covalently attached to lysine residues via a three-step enzymatic series. In an ATP-
dependent reaction, ubiquitin activating enzymes (E1) append ubiquitin to an E2 
conjugating enzyme which acts in ubiquitin transfer. Finally E3 ligases function as 
adaptors by binding both the substrate and E2-ubiquitin substrate; in this manner they 
function in the recognition of substrates and the facilitation of isopeptide bond 
formation between the substrate and ubiquitin (Komander, 2009). Within its own 
primary sequence ubiquitin contains seven lysines, rendering it also a substrate for 
ubiquitination.  This gives rise to various combinations of mono- and poly-
ubiquitination that can occur on a single substrate. Poly-ubiquitination adds greater 
FRPSOH[LW\ WR WKH µFRGH¶ WKHUHE\ LQFUHDVLQJ LWV IXQFWLRQDO YHUVDWLOLW\  3URWHLQ
ubiquitination is a reversible modification, in which the removal and editing of 
ubiquitin chains is carried out by specialised proteases named deubiquitinating 
enzymes (Sowa et al., 2009). Initially this ubiquitin tag was found to serve as a signal 
for protein turnover as an ubiquitinated protein would undergo rapid degradation 
mediated by the proteasome. However, ubiquitination has since been shown to 
function in several other processes quite distinct from the regulation of protein half-
life. Such processes include transcriptional control, DNA repair (Kouzarides, 2007), 
the DNA-damage response, endocytosis, cell signalling and trafficking and the 
mediation of protein-protein interactions (Komander, 2009). 




Small ubiquitin-related modifier (SUMO) is an 11kDa protein that can be 
coupled to other proteins to control their function. This modification has been shown 
to take place on all four histones, and specific sites have been identified on H2A, 
H2B and H4 (Nathan et al., 2006). SUMO resembles ubiquitin structurally but not 
functionally. Whereas ubiquitin tags proteins for degradation, SUMO has been shown 
to influence the targets function by affecting its intracellular localisation, interactions, 
stability and activity (Meulmeester and Melchior, 2008). The SUMOylation process 
has been implicated in the regulation of an array of fundamental cellular processes; 
including cell cycle regulation, gene transcription and cellular differentiation, and is 
essential for the well-being and survival of most organisms. Mammals express at 
least four SUMO proteins SUMO 1,2,3 and 4, which can be distinguished by their 
different target proteins and consequent differential functions (Meulmeester and 
Melchior, 2008). The reversible SUMOylation process begins with the activation of 
mature SUMO by the E1 activating enzyme Aos1-Uba2. SUMO is subsequently 
transferred to the E2 conjugating enzyme Ubc9. Ubc9 can make contact with SUMO 
interacting motifs (SIM) within target proteins and, facilitated by E3 ligases, SUMO 
finally forms an isopeptide bond with the amino group of a lysine residue in its target 
protein. Several E3 ligases have been identified, however, interestingly the PHD 
domain of the KAP1 corepressor has been shown to possess intramolecular E3 ligase 
activity. This activity is required for Ubc9 binding and the succeeding direction of 
SUMOylation to site-specific lysine residues within its adjacent bromodomain. 
SUMOylation is required for KAP1-mediated gene silencing (Ivanov et al., 2007). 
Chapter One: Introduction 
26 
 
Dynamic interplay has been shown between SUMOylation, acetylation and 
ubiquitylation which occur on the same lysine residue. SUMO therefore antagonises 
and acts as a potential block to activating modifications, coupling the modifiction 
with transcriptional repression (Nathan et al., 2006). SUMOylation can be reversed 
by SUMO-specific proteases, which cleave the isopeptide bond between SUMO and 
its target protein. 
 
1.4.6. ADP Ribosylation 
ADP ribosylation involves the transfer of the ADP-ribose moiety of ADP-
ribosyl nicotinamide (NAD+) precursor to an arginine/ glutamic acid residue on an 
acceptor protein, also releasing the bi-product nicotinamide. This modification is 
reversible and exists in mono- and poly- forms. The enzymes that mediate it are the 
Mono-ADP-ribosyltransferases (MARTs) or the Poly-ADP-ribose polymerases 
(PARPs) respectively. In addition to these two classes of enzymes, the Sir family of 
NAD+ dependent histone deacetylases have been shown to possess low levels of 
MART activity, so possibly represent a novel family of intracellular MARTs (Hassa 
et al., 2006). There are many reports of ADP-ribosylation of histones, however this 
modification remains ill-defined with respect to function. It has been linked to many 
fundamental physiological processes including signalling, transcription, DNA repair 
and apoptosis, whether these functional outputs result from MART/PARP enzymatic 
activity or the actual histone modification itself remains elusive. In terms of 
chromatin structure, it has been shown that poly-ADP ribosylation results in a 
relaxation at the site of modification, leading to an opening for factors involved in 
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DNA-mediated processes (Hassa et al., 2006). Evidence that catalytic activity is 
involved in such processes is prevalent for the role of PARP-1 in DNA repair. The 
presence of double strand breaks leads to an induction of 10-500 fold in the activity 




Evidence exists that lysine residues within histones are also modified by the 
covalent attachment of the vitamin biotin, catalysed by biotinidase and 
holocarboxylase synthetase (HCS). Eleven biotinylation sites have been identified in 
histones H2A, H3 and H4 and linked to biological functions such as cell proliferation, 
gene silencing and the cellular response to DNA damage. Specifically, H4K12 
biotinylation is enriched in heterochromatic regions and plays a role in gene 
repression (Hassan and Zempleni, 2008). Observations have also shown that crosstalk 
exists between the biotinylation of histones and other modifications such as 
methylation and phosphorylation. For example, the dimethylation of R2, R8 and R17 
lead to an increase of biotinidase-mediated biotinylation of K4, K9 and K18 (Kobza 
et al., 2005). Biotinylation is a reversible process; however the enzymes or 
mechanisms required for debiotinylation remain uncertain. Yet, the abundance of 
biotinylated histones at specific genomic loci does depend on the exogenous biotin 
supply and availability (Hassan and Zempleni, 2008). Recent doubt has been cast 
over this modification with regards to its in vivo occurrence. Healy and colleagues 
have accumulated data suggesting biotin is absent in native histones, suggesting that 
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the regulatory function of biotin on gene repression must be through alternate 
mechanisms (Healy et al., 2009).  
 
1.4.8. Proline Isomerisation 
Peptidyl proline exists in either a cis or trans conformation and 
conformational changes between the two states results in severe distortion of the 
polypeptide backbone. Proline isomerisation is a non-covalent modification that can 
occur both in histone and non-histone proteins, acting as a regulatory switch in 
signalling pathways. Isomerisation occurs spontaneously, however enzymes have 
evolved to accelerate the interconversion of the proline isomers. The enzyme, FPR4 a 
member of the FK506 binding proteins, has been identified in budding yeast and can 
bind the amino terminal tails of H3 and H4, specifically proline residues P30/38 of 
histone H3. Isomerisation of P38 antagonises the methylation of H3K36 by SET2 
providing evidence for the crosstalk between lysine methylation and proline 
isomerisation in the regulation of transcription (Nelson et al., 2006). The parvulin 
(Pin1) family of enzymes catalyse the isomerisation of peptidyl-prolyl bonds in 
numerous transcription factors in a phosphorylation-dependent manner. In this case, 
isomerisation allows the control of the conformation, stability and activity of 
numerous proteins involved in transcriptional and cell cycle regulation (Shaw, 2007). 
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1.4.9. Histone Tail Clipping 
Recently, a novel Histone H3 endopeptidase activity has been identified in S. 
cerevisiae. This led to the finding of a new type of histone modification, named 
µFOLSSLQJ¶LQYROYHGLQWKHUHJXODWLRQRIJHQHH[SUHVVLRQ7KHHQ]\PHFOHDYHVKLVtone 
H3 N-terminal tails after alanine residue 21 showing a bias for those tails carrying 
repressive signals; for instance those tails harbouring the activatory PTM H3K4me3 
resist clipping (Santos-Rosa et al., 2009). Clipping has been implicated to function at 
promoter-bound nucleosomes therefore, suggesting a localised expulsion of 
repressive marks and proteins at promoters during the induction of expression. H3 tail 
clipping has also been shown to precede histone eviction, signifying the importance 
of this modification in marking which nucleosomes are to be displaced during 
transcriptional events (Santos-Rosa et al., 2009).  
 
1.4.10. Chromatin Remodelling 
As described previously, the above modifications serve as a code signalling 
for changes in the chromatin architecture and allowing the progress of fundamental 
nuclear processes. The dynamic properties of nucleosomes and consequent structural 
alterations are governed by the histone tails themselves and through the action of 
ATP-dependent chromatin-remodelling complexes. Alterations to histone proteins, 
especially the histone tails, were found to affect processes such as nucleosome 
sliding, histone dimer exchange and DNA wrapping (Ferreira et al., 2007).  For 
example, truncation of the different histone tails yielded distinct observations for 
nucleosome mobility. Truncation of the H2A tail promotes nucleosome mobility, 
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whereas deletion of the H4 and H2B tails reduces it (Ferreira et al., 2007). In 
addition, despite having no effect on nucleosome mobility, the deletion of the H3 tail 
had the most prominent influence on nucleosome structure. Truncation of the H3 tail, 
ZLWKHPSKDVLVRQUHVLGXHVFRPSULVLQJWKHĮ-N helix, was found to alter the wrapping 
of nucleosomal DNA through a reduction in the stability of histone-DNA contacts 
within the nucleosome core. As a consequence, the removal of DNA from the 
octamer structure results in the destabilisation of H2A/H2B histone dimers within 
nucleosomes, facilitating access to the underlying genetic information (Ferreira et al., 
2007). Chromatin remodelers utilise the energy of ATP-hydrolysis to shift, 
destabilise, expel or restructure nucleosomes in order to aid the creation of a dynamic 
chromatin environment (Clapier and Cairns, 2009). Distinctive targeting and tasks 
require specialisation and thus, remodelers are specific multi-protein complexes that 
can be defined, by their domain composition and their main functions, into four 
families; the Switching defective/Sucrose Nonfermenting (SWI/SNF), Imitation SWI 
(ISWI), Chromodomain, Helicase, DNA binding (CHD) and Inositol requiring 80 
(INO80) remodelers. The families share a common catalytic subunit, the ATPase 
domain, which has been shown to use ATP-dependent DNA translocation to break 
histone-DNA contacts in order to redefine promoter architecture (Clapier and Cairns, 
2009). 
The ISWI family of remodelers aid in the organisation and assembly of 
chromatin, allowing the uniform spacing of nucleosomes at gene promoters. 
Generally, ISWI remodelling occurs at nucleosomes that lack acetylation, localising 
their activity to nucleosomes at transcriptionally inactive regions. ISWI complexes 
function by either disrupting nucleosome periodicity and generating disordered 
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nucleosome arrays, such as by the Nucleosome Remodelling Factor (NURF), or by 
creating regularly spaced, ordered nucleosome arrays, such as the function of the 
ATP-dependent Chromatin assembly and remodelling Factor (ACF), to uphold 
repressed or basal chromatin states (Cairns, 2009). In contrast the SWI/SNF 
complexes provide access to nucleosomal DNA and the exposure of DNA elements 
transiently on the surface. SWI/SNF family members can both slide and eject 
nucleosomes, correlating their functions with nucleosome disorganisation and 
promoter activation (Cairns, 2009). SWI/SNF complexes contain modular domains 
that recognise histone acetylation marks, increasing their targeting to and affinity for 
promoters undergoing activation. Furthermore, the mechanisms by which different 
remodelling enzymes act are sensitive to multiple aspects of nucleosome structure. 
)RUH[DPSOHPXWDWLRQV WR WKHKLVWRQH+Į1UHJLRQVHOHFWLYHO\DIIHFWHG the rate of 
nucleosome repositioning and the products generated following ATP-dependent 
remodelling by Chromatin Structure Remodelling (RSC) complex, compared to a 
lesser effect with the Chd1 and SWI/SNF remodelers (Somers and Owen-Hughes, 
2009). 
Both these examples highlight the importance of PTM recognition by non-
catalytic subunits of the remodeler complexes. These reader domains of the histone 
code are involved in the regulation of catalytic ATPase activity and the remodelling 
reactions and products by stabilising contacts with the nucleosome core surface, 
enhancing nucleosome sliding and dictating the directionality of nucleosome 
movement (Clapier and Cairns, 2009).  
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1.5. Lysine Acetyltransferase Enzymes 
The importance of histone acetylation by HATs has long been recognised in 
chromatin biology; especially with respect to its correlation with transcriptional 
regulation, whereby hyperacetylation of histones is prominent in euchromatin. 
Dozens of proteins have been discovered which possess intrinsic acetyltransferase 
activity and of late, it has emerged that the activity of some of these enzymes is 
directed towards non-histone lysine residues. Studies on a global scale, including 
high-resolution mass spectrometry and the genome wide ChIP-Sequencing mapping 
of chromatin, have demonstrated how abundant protein acetylation is and how broad 
the regulatory effect is upon cellular processes (Choudhary et al., 2009). Due to this a 
new field of research is underway, exploring the entire set of acetylated proteins in a 
cell RU RWKHUZLVH UHIHUUHG WR DV WKH µDFHW\ORPH¶ (Smith and Workman, 2009). Such 
substrate diversity and rapid discovery of new chromatin modifying enzymes has 
founded a new coherent nomenclature system, where the more generic term of lysine 
acetyltransferases (KATs) is now used (Allis et al., 2007). KATs are a diverse 
superfamily of enzymes evolutionary conserved from yeast to humans and are 
characterised into different groups based upon sequence comparisons. Three main 
groups including the Gcn5-related N-acetyltransferase (GNAT), p300/CBP and 
MYST families are among those most intensely studied because of their broad 
conservation, varied functions and links with disease. These proteins function as 
transcriptional coactivators and in a diverse array of other nuclear and cytoplasmic 
processes.  
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KATs catalyse the addition of an acetyl moiety from an acetyl-CoA molecule 
WRWKHİ-amino group of a protein lysine residue. Enzyme acetyltransferase activity is 
regulated in a variety of ways including post-translational modification, degradation 
or altering the subcellular localisation of the KAT (Yang, 2004). In addition, most 
KATs physiologically exist as part of a multisubunit complex, in which different 
combinations of subunits contribute to the distinctive characteristics of each KAT 
complex (Lee and Workman, 2007).  KAT complexes are generally more active than 
their counterpart enzymes and demonstrate distinctive substrate targeting, implicating 
the non-catalytic proteins in the regulation of activity and substrate specificity (Yang, 
2004). 
The specificity of KAT action still remains an elusive topic despite intensive 
characterisation of the different complexes. Biochemical and genetic analyses 
advocate that KATs exert a high degree of specificity towards target acetylation and 
in the processes they regulate. However, with the advancement of genome-wide 
mapping techniques such as ChIP combined with microarray (ChIP-chip) or with 
high-throughput sequencing (ChIP-Seq), it has been shown that KATs co-occur 
simultaneously to a similar set of loci in the genome, suggesting a low degree of 
specificity in their function (Anamika et al., 2010). Recently, a model has been 
proposed combining all data sets, in which KATs have a dual mode of action. This 
FRQVLVWVRIDQ µLQLWLDWLRQ¶ VWDJHRI WUDQVFULSWLRQDODFWLYDWLRQZKLFK LVGHILQHGE\ WKH
specific recruitment of one particular KAT to a given gene promoter. The sequential 
WUDQVLWLRQ LQWR µPDLQWHQDQFH¶ SKDVH UHSUHVHQWV WKH VWDELOLVDWLRQ RI DQ DFWLYH
transcription stage where recruitment of multiple KATs bind in a less-specific 
manner to the gene promoter (Anamika et al., 2010). The development of novel 
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ChIP-grade antibodies against KATs and complex-specific subunits will allow further 
investigation into the functional role and specificity of acetyltransferases in vivo. 
 
1.5.1. MYST family 
The MYST (MOZ, Ybf2/Sas3, Sas2, TIP60) family was originally named for 
its four founding members in yeast and mammals and at present consists of five 
human KATs: TIP60 (KAT5), MOZ (KAT6A), MORF (KAT6B), HBO1 (KAT7) 
and MOF (KAT8). This family of KATs are highly conserved in higher eukaryotes 
and in addition, orthologues have been identified in many lower eukaryotes. 
Sequence and structural comparisons depict their defining MYST catalytic domain 
which is composed of a zinc finger and an acetyl-CoA binding motif.  
Obtaining consistent details of the catalytic mechanism for the MYST family 
of KATs has proven problematic. Different groups have carried out meticulous 
kinetic and structural analyses to unravel the mode of catalysis; however, 
discrepancies lie amid their individual findings. Essential Sas2-related 
acetyltransferase 1 (Esa1), the yeast homologue of TIP60, is used as the prototypical 
enzyme for understanding the structure and mechanism of the MYST family 
(Berndsen et al., 2007). Originally, based primarily on the structural similarity to the 
catalytic core of the GCN5 / p300-CBP associated factor (PCAF) subfamily, initial 
structural determination of Esa1 suggested a sequential mechanism of acetyl transfer 
(Yan et al., 2002). Subsequently, after additional structural and functional studies, 
Yan and colleagues re-assessed the mechanism, and put forward the new double-
displacement model (ping-pong catalysis). This proceeds through the transfer of the 
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acetyl group of the acetyl-CoA cofactor to a cysteine shown to be strictly conserved 
among MYST family members. The acetyl group is then transferred from this acetyl-
cysteine enzyme intermediate to a histone lysine substrate (Yan et al., 2002). The İ-
amino group (1İ+2) of the target lysine is known to be deprotonated, prior to acetyl 
transfer by a glutamate residue conserved among all KATs, despite their differing 
catalytic mechanisms. In recent years, this mechanism was challenged by Bernsden 
and colleagues, whose data represents results yielded from the minimal core complex 
piccolo NuA4, and supports the original ternary complex mechanism involving a 
direct attack of a deprotonated N-İ-lysine on the bound acetyl-CoA (Berndsen et al., 
2007). Mutational analysis is casting doubt on the importance of the conserved 
cysteine residue for MYST acetyltransferase activity; however currently there is still 
active controversy in the field, highlighting the need for further research. Such 
understanding into the mode of action of KAT enzymes will be crucial to the design 
of inhibitors. Besides the MYST domain other common structural features of the 
MYST proteins include chromodomains, plant homeodomain-linked (PHD) zinc 
fingers and regions defined by a high quantity of a particular amino acid residue 
(Figure 1.4).  
MYST family enzymes conduct a considerable proportion of all nuclear 
acetylation and have a well-established role in histone acetylation. MYST-dependent 
regulation of chromatin impacts processes including gene regulation, DNA repair, 
development, cell cycle and stem cell homeostasis. However, recent studies show a 
broader substrate spectrum exists for MYST KATs and novel non-chromatin targets 
under their regulation are continually being discovered (Sapountzi and Cote, 2010). 
Of the five human KATs, TIP60 has the most known non-histone targets. With 
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respect to chromatin-based targets the NuA4 complex, containing TIP60, is a key 
regulator of the transcription of genes involved in cell cycle control and embryonic 
stem cell identity, and also modifies chromatin surrounding DNA double strand 
breaks to aid repair (Squatrito et al., 2006). The majority of non-histone proteins 
acetylated by TIP60 are transcription factors, most of which are directly linked to 
transcriptional control. Acetylation by TIP60 exerts its effects through the alteration 
of protein substrate stability or activity (Sapountzi and Cote, 2010). TIP60 acts by the 
acetylation and activation of components of the DNA repair pathway, including p53 
and ATM, modulating the decision between cell-cycle arrest and apoptosis upon p53 
activation (Sykes et al., 2006). In contrast, the stability of the oncoprotein c-Myc is 
regulated by TIP60 acetylation, where a dramatic decrease in the rate of protein 
degradation is seen upon acetylation (Patel et al., 2004).  
 
1.5.2. CBP/p300 family 
The nuclear CREB-Binding Protein (CBP) was first identified as an 
interacting partner of the activated phosphorylated form of the CREB (cAMP 
response element binding protein) transcription factor (Chrivia et al., 1993). Its 
paralogue p300 was alternatively isolated as a cellular factor bound by the adenovirus 
E1A protein (Eckner et al., 1994). Both proteins are ubiquitously expressed in all 
higher eukaryotes, including flies, worms and plants, but not in lower eukaryotes 
such as yeast (Yuan and Giordano, 2002). CBP and p300 are similar proteins which 
exhibit several regions of close homology within their amino acid sequences (Figure 
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1.4). These include the cysteine-histidine-rich regions (CH1, -2 and -3), 
bromodomain, and the acetyltransferase domain.   
CBP and p300 have been implicated in a host of cellular processes; both 
chromatin related such as transcription, DNA replication and repair and those not 
directly linked to chromatin, such as the regulation of p53 turnover in cycling cells 
(Grossman et al., 1998) and nuclear import (Ryan et al., 2006). Two important 
aspects, related to their modular structure, render CBP and p300 as effective global 
coactivators. By simultaneously interacting with the basal transcription machinery 
and other specific transcription factors, both proteins function as physical bridges 
which stabilise the transcription complex (Kalkhoven, 2004). Secondly, the ability of 
CBP/p300 to acetylate promoter proximal nucleosomal histones, results in the 
decompaction of local chromatin structure, allowing the access of other essential 
regulators (Kundu et al., 2000). 
  









Figure 1.4. Modular structure of Lysine AcetylTransferases (KATs). Domain organisation 
of lysine acetyltransferase enzyme families (A) MYST (B) CBP/p300 (C) GCN5/ PCAF from 
humans, indicating highly conserved regions and functional domains. Domains are labelled as 
follows: H1/5, histones H1- and H5-like domain; PHD, plant homeodomain; DPF, double PHD 
finger; Zn, C2HC zinc finger; MYST, (MOZ, Ybf2/Sas3, Sas2, TIP60) homologous 
acetyltransferase region; acidic, glutamate/aspartate-rich region; S/M, serine/ methionine-rich 
region; PQ, proline/glutamine-stretch; CD, chromodomain; CH, cysteine/histidine rich motif; 
KIX, CREB binding region; BD, bromodomain; SID, steroid receptor coactivator 1 interaction 
domain; P/CAF HD, P/CAF homology domain; E3, E3 ligase domain. 
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The p300/CBP HAT domain is comprised of two important functional 
entities; the coenzyme A (CoA) binding and catalytic site, and zinc finger (Figure 
1.4). Recently, ambiguity concerning the distinct catalytic mechanism of CBP/p300-
mediated acetylation has been resolved, in part, by the production and analyses of 
high resolution crystal structures of semi-synthetic p300 in complex with its inhibitor 
Lys-CoA. When compared to other KATs, Liu and colleagues identified structural 
conservation within the central core region associated with CoA binding. However, 
several novel features separate these two coactivators from the other KAT families, 
and begin to provide reasoning for their characteristic broad substrate specificity. 
Here structural, kinetic and mutagenesis data proposes that two substrate binding 
pockets, connected via a narrow electronegative groove exist; one responsible for 
CoA binding and a second highly electronegative pocket required for protein 
substrate binding. It is suggested that catalysis occurs through the Theorell-Chance 
mechanism, where substrates weakly associate with the p300 surface, allowing the 
lysyl residue to advance through the groove and react with the acetyl group (Liu et 
al., 2008). It has been shown that regulation of the p300 HAT domain occurs via an 
activation loop. This loop, rich in basic residues, is thought to associate with the 
secondary binding pocket until extensive autoacetylation occurs on constituent poly-
lysine residues (Liu et al., 2008). Autoacetylation induces specific structural changes 
in the acetyltransferase domain (Arif et al., 2007). These conformational changes, 
accordingly act as a master switch to expose the substrate binding site and enhance 
the catalytic activity of p300 (Thompson et al., 2004). 
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1.5.3. GNAT family 
Homologues of GCN5 have been identified in a host of different organisms 
including both higher and lower eukaryotes. In mammals, two related GCN5 
acetyltransferase subclasses were described: GCN5 and PCAF (Verdone et al., 2006). 
Both KATs are considered as global coactivators, and are indispensable for normal 
cellular function. Vertebrate GCN5 is approximately 73% identical to the vertebrate 
PCAF protein, with most identity focused into three highly homologous domain 
structures (figure 1.4). The N-terminal half contains the PCAF homology domain, 
and the C-terminal consists of the bromo- and acetyltransferase domains.  
GCN5 and PCAF have been implicated in a host of processes including 
transcriptional activation, cell-cycle, differentiation and apoptosis. Further, PCAF 
acts as a co-activator in myogenesis (Puri et al., 1997), nuclear-receptor-mediated 
activation (Blanco et al., 1998) and growth-factor-signalled activation (Xu et al., 
1998). Numerous substrates are known for GCN5 and PCAF, out of which their 
major targets are histones and nucleosomes. These enzymes exist as part of 
multisubunit complexes, such as the GCN5 complex containing ySAGA, hTFTC, 
hSTAGA and the PCAF complex containing hPCAF. Residence within the protein 
complexes has been shown to alter their nucleosomal substrate specificity; for 
instance when incorporated into a complex, the acetylation target of GCN5 changes 
from H3K14 to H3K9, K18, K23, and to a lesser extent H2B and H4 (Guelman et al., 
2006). As well as possessing locus-specific coactivator functions GCN5 and PCAF 
are able to acetylate non-histone substrates including p53 (Poux and Marmorstein, 
2003), TFIIE/F (Imhof et al., 1997) and MyoD (Dilworth et al., 2004).  
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Recently, it was shown that along with acetyltransferase activity, PCAF 
possesses intrinsic ubiquitin E3 ligase potential within its PCAF homology domain. 
Such activity was demonstrated to control the stability of the oncoprotein Hdm2, a 
protein that promotes p53 degradation, and thus plays a role in regulating cellular p53 
levels (Linares et al., 2007). Whether GCN5 also harbours this activity is yet to be 
determined. 
The acetyltransferase domain of various GNAT family members has been 
extensively studied. This domain can be divided into two distinct regions; the 
structurally conserved central protein core associated with AcCoA binding, and a 
pronounced cleft flanked by N- and C-terminal regions. These N- and C-terminal 
segments show structural divergence from other family members, and are implicated 
for histone substrate binding and catalysis (Trievel et al., 1999). The catalytic 
mechanism of the GNAT superfamily was one of those first to be documented. 
Results from detailed bi-substrate kinetic analysis and product inhibition studies 
supported a sequential ternary complex (ordered Bi-Bi) kinetic mechanism (Tanner et 
al., 2000a; Tanner et al., 2000b). Acetyl-CoA binds first with a high affinity for the 
free form of the enzyme, followed successively by the H3 histone substrate. Within 
WKH WHUQDU\ FRPSOH[ WKH İ-amino group of the lysine substrate directly attacks the 
carbonyl carbon of AcCoA, transferring the acetyl group to the acceptor peptide. 
Preceding catalysis, a conserved glutamate residue (hPCAF-E570, yGCN5-E173) 
DFWV DV D JHQHUDO EDVH FDWDO\VW GHSURWRQDWLQJ WKH İ-amino group and facilitating 
nucleophilic attack. The resulting products are then released sequentially, with the 
CoA following the ejection of the acetylated H3 product. The regulation of PCAF 
function proceeds through its own post-translation modification. Human PCAF is 
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acetylated, in vivo, by itself or p300 through intra- or intermolecular events, resulting 
in the augmentation of its acetyltransferase activity (Santos-Rosa et al., 2003).  
The diverse superfamily of lysine acetyltransferases executes an acetylation 
spectrum that is essential for a diverse range of cellular processes. Therefore, 
disruption of such enzymes and their consequent acetylation patterns may lead to the 
development of cancer and other diseases. 
 
1.6. Structure and Function of MOZ / MYST3 
The monocytic leukaemia zinc finger protein (MOZ), also called MYST3 or 
KAT6A, is a histone acetyltransferase belonging to the MYST family of KATs. MOZ 
was first identified in recurrent chromosomal translocations which involve the fusion 
of MOZ to the gene encoding CBP; an event associated with an aggressive form of 
acute myeloid leukaemia (AML) (Borrow et al., 1996). 
 
1.6.1. MOZ is a modular protein 
 The modular structure of MOZ consists of several discrete domains (Figure 
1.5(A)). The central MYST histone acetyltransferase domain, which it shares with the 
other four mammalian MYST family members, is thought to perform the catalytic 
function of the enzyme. Recently, novel results suggest that enzymatic catalysis and 
DNA targeting activities are both contained in the MYST regulatory domain; a 
feature not conserved among other histone acetyltransferases. Probing by Holbert and 
colleagues into the MOZ MYST domain, by means of structural and biochemical 
studies, revealed a conserved central core associated with the binding of acetyl-CoA 
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and catalysis. This core is flanked by evolutionary divergent N- and C-terminal 
regions harbouring a TFIIIA-type zinc finger and helix-turn-helix DNA-binding 
motifs respectively. MOZ was shown to bind to DNA through these motifs and 
furthermore, kinetic data indicated a distinct surface for DNA binding separate from 
that of catalysis; implying the two MYST domain properties are not mutually 
exclusive (Holbert et al., 2007). 
Amino-terminal of this are a H1/5 like domain (also named N-terminal part of 
ENOK- NEMM) and tandem plant homeodomain zinc fingers (PHD). The H1/5 
domain shows a weak sequence homology to motifs seen in the linker histones H1 
and H5, although its function still remains somewhat ambiguous. Yet, through 
deletion analyses, the Kitabayshi group has implicated the H1/5 domain in nuclear 
localisation and emphasises its essential function in transcriptional coactivation 
(Yoshida and Kitabayashi, 2008). Since this domain has also been associated with a 
function in nucleosome binding (Ramakrishnan et al., 1993), it is thought that MOZ 
may be able to directly alter chromatin compaction by interaction with the 
nucleosome. The functional importance of the double PHD fingers (DPF) is unclear, 
yet it is speculated that they recognise methyl-lysine-containing motifs of histones 
(Kouzarides, 2007). More recently however, the characterisation of a tandem PHD 
domain in the recognition of acetylated histone H3 shows the importance of two PHD 
fingers acting as one integrated functional unit (Zeng et al., 2010). The carboxy-
terminal region of MOZ contains serine-, proline- and methionine-rich areas which 
have been reported to possess transcriptional activation properties in vitro 
(Champagne et al., 2001).  
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 Attributable to the MYST domain, MOZ has been reported to possess 
intrinsic KAT activity towards all four core histones in vitro (Champagne et al., 2001; 
Holbert et al., 2007). MOZ can also acetylate histone H4 lysine residues 5, 8, 12 and 
16 and histone H3 lysine 14 in vitro (Kitabayashi et al., 2001a). Separate studies have 
also highlighted histone H3K14 in Hela cells (Doyon et al., 2006), histone H4K16 
when comparing normal lymphocytes to leukaemia cells (Fraga et al., 2005), and 
histone H3K9 at Hox gene loci (Voss et al., 2009) as preferential targets of MOZ 
acetylation. Such studies reveal a broad range of MOZ-specific acetylation targets, 
causing controversy as to the actual identity of lysine residues MOZ may show 
preference to acetylate. Further, functional data linking the HAT activity of MOZ at 
specific lysine residues to the regulation of transcription in vivo is limited. More 
recently, MOZ has been shown not to restrict its acetylation to only histone substrates 
but also to non-histone protein lysine residues. New acetylation targets include the 
complex component BRPF1 (Ullah et al., 2008) and the tumour suppressor p53 
(Collins and Heery, unpublished data), however the regulation exerted by or the 
function of these PTMs is yet to be unveiled. 
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Figure 1.5. Modular structure of MOZ and its interacting partners. (A) 
Schematic representation of MOZ Domain organisation, indicating highly conserved 
regions and functional domains. Domains are labelled as follows: H1/5, histones H1- 
and H5-like domain; PHD, plant homeodomain; DPF, double PHD finger; Zn, C2HC 
zinc finger; MYST homologous acetyltransferase region; acidic, glutamate/aspartate-
rich region; S/M, serine/ methionine-rich region; PQ, proline/glutamine-stretch. The 
mapped binding sites of published interacting partners are also detailed on the 
schematic. (B) MOZ functions as the catalytic subunit of a variety of multi-subunit 
complexes. 
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1.6.2. MOZ resides in multi-subunit complexes 
MOZ resides as a catalytic subunit in several stable, nuclear multi-subunit 
complexes (Figure 1.5(B)). Kitabayashi et al, first isolated MOZ as part of the 
AML1-&%)ȕ WUDQVFULSWLRQ IDFWRU FRPSOH[ ZKHUHE\ 02= IXQFWLRQV WR VWimulate 
AML1-mediated transcripition (Kitabayashi et al., 2001a). Since then, a number of 
interacting partners have been identified and shown to function in complex with 
MOZ. These complexes will be discussed in subsequent sections related to their 
function.  
The most recently discovered multi-subunit complex containing MOZ, also 
consists of the homolog of Esa1-associated factor 6 (EAF6) and Bromodomain- and 
PHD finger-containing (BRPF) proteins 1/2/3; BRPF are a family of proteins rich in 
modules commonly found in chromatin-associated factors including PHD fingers, 
bromodomain and the chromo/Tudor-related PWWP domain. The presence of such 
domains suggests that the BRPF protein is accountable for recruiting the MOZ 
complex to its site of action and consequently in chromatin regulation (Yang and 
Ullah, 2007). The inhibitor of growth 5 (ING5) member of the ING family of putative 
tumour suppressors is also co-purified as part of the MOZ complex in vivo. The ING 
family of tumour suppressors are known to be involved in many critical processes, 
however as they do not possess intrinsic enzymatic activity they are thought to 
function as adaptors, providing a powerful link between chromatin-modifying 
activities and their genomic sites. More specifically, ING subunits have been shown 
to be crucial for the KAT acetylation of chromatin substrates, where they are possibly 
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responsible for the initial binding to the chromatin through their PHD fingers (Doyon 
et al., 2006). 
Further insight into the molecular architecture of the quartet MOZ KAT 
complex has recently been provided, revealing that the associated subunits regulate 
both the acetyltransferase and other functions of MOZ. BRPF1 has been shown to 
bind the MOZ MYST domain, which in turn acts as a scaffold for the association of 
ING5 and EAF6 subunits and the overall assembly of the complex (Ullah et al., 
2008). At the functional level, complex formation significantly stimulated the 
acetyltransferase activity of the MOZ MYST domain and further influenced its 
preferred target. The native complexes differ in substrate specificity to their enzyme 
counterpart, primarily acetylating H3 and H4 free histones and nucleosomal histone 
H3 (Ullah et al., 2008). In addition, interaction with BRPF1 was also seen to augment 
the transcriptional activation potential of MOZ towards Runx2. Complex 
reconstitution studies are proving imperative to our understanding of the molecular 
mechanisms underlying MOZ function; where it is evident that under physiological 
conditions non-catalytic subunits act to regulate acetyltransferase and coactivator 
activities and refine substrate specificity. 
 
1.6.3. MOZ functions as a transcriptional activator in hematopoietic 
processes 
 MOZ interacts with many transcription factors in particular with 
hematopoietic specificity, such as Runx1 (AML1) (Kitabayashi et al., 2001a; Pelletier 
et al., 2002) and the ETS family factor PU.1 (Katsumoto et al., 2006); but also Runx2 
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(Pelletier et al., 2002), p53 (Rokudai et al., 2009) and NF-ț% (Chan et al., 2007) 
functioning as a modest transcriptional coactivator (Figure 1.5). MOZ cooperatively 
activates transcription factor-dependent expression of genes (Collins et al., 2006), 
such as AML1-dependent transcription of myeloperoxidase (MPO) (Kitabayashi et 
al., 2001a); however the role of HAT activity in MOZ coactivator function remains 
unclear. As an example, the MYST domain is required for NF-ț%-dependent 
transcription (Chan et al., 2007) but not for AML1-dependent transcription 
(Kitabayashi et al., 2001a), indicating that the role of HAT activity in gene regulation 
is dependent on the promoter context.  
 AML1 and PU.1 play fundamental roles in the establishment of definitive 
hematopoiesis, therefore as a coactivator of these transcription factors the role of 
MOZ in normal and leukaemic blood formation has been extensively studied. Gene 
targeting in mice demonstrated that MOZ-deficient mice are embryonic lethal at E15 
with an undersized liver, the organ responsible for the production of hematopoietic 
cells during this developmental stage (Katsumoto et al., 2006). Flow cytometry was 
carried out on cells prepared from E14.5 fetal liver to observe the effect of the MOZ 
null mutation (MOZ-/-) on different populations of cells. Firstly, reductions were seen 
in the number of short-term hematopoietic stem cells (HSCs) and lineage-committed 
progenitors, implicating MOZ in the generation and maintenance of these early 
populations (Katsumoto et al., 2006). More specifically, in lineage-committed cells 
the number of B-lineage cells was severely reduced, maturation arrest was observed 
in erythroid lineage cells by an accumulation of erythroblasts and finally, an 
increased population of myeloid lineage cells was seen (Katsumoto et al., 2006). 
Increases in the committed myeloid cells suggest that differentiation is stalled at the 
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progenitor stage in the MOZ-/- fetal livers. Altogether, these observations highlight 
that MOZ plays a key role for appropriate development and differentiation of 
lymphoid and myeloid cells (Katsumoto et al., 2008).  
 An attribute of HSCs is their capability to reconstitute hematopoiesis of a 
lethally irradiated mouse. Competitive reconstitution assays were performed in order 
to establish whether MOZ-/- embryos possess functional HSCs, where these embryos 
were injected into irradiated normal recipient mice. Survival was therefore dependent 
on the ability of the donor cells to restore hematopoiesis. Their findings showed that 
no mice receiving cells from MOZ-deficient embryos survived past 28 days, 
indicating that MOZ is essential for sustaining the long-term repopulation of stem 
cells. MOZ therefore, regulates HSC self-renewal activity to reconstitute the 
hematopoietic system in recipients after transplantation (Katsumoto et al., 2006; 
Thomas et al., 2006).  
As mentioned previously, the biological function of the well-established MOZ 
acetyltransferase activity is still ambiguous. Functional analyses investigating the role 
of MOZ in normal hematopoiesis was carried out in mice deficient of the entire MOZ 
protein. Defects observed in these studies are therefore likely to be a reflection of the 
cumulative effects of the loss of AML1 transcriptional coactivator function and HAT 
activity. Perez-Campo and colleagues used a mouse strain carrying a single amino 
acid mutation that inactivates HAT activity (HAT-/-), to explore the specific 
significance of MOZ-driven acetylation in the regulation of hematopoiesis (Perez-
Campo et al., 2009). This study showed that mice exclusively lacking MOZ HAT 
activity exhibit a reduction in the number of HSCs and lineage-committed precursors, 
as well as a B-cell development defect. Additionally, hematopoietic precursors had a 
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profound deficit in their proliferative capacity, explaining the failure to maintain a 
normal number of precursors in HAT-/- cells (Perez-Campo et al., 2009). Taken 
together, this study demonstrates a crucial role for MOZ HAT activity in the 
proliferation and maintenance of hematopoietic precursors at all stages of 
development. 
 
1.6.4. MOZ functions as a transcriptional activator in developmental 
processes 
 In addition to MOZ mRNA being detected in all hematopoietic progenitors, 
the gene is also extensively expressed throughout embryonic development and in 
adult tissues (Thomas et al., 2006). This implies that MOZ can regulate many 
biological processes both within hematopoiesis and in other cell types. In fact, MOZ 
has been implicated in developmental processes via the regulation of Homeobox gene 
expression, the gene clusters responsible for body segment identity during 
development. A zebrafish MOZ mutant phenotype was shown to exhibit 
developmental defects in the head region, where the mutation of MOZ results in the 
abolition of Hox gene expression specifically in skeletogenic cranial neural crest cells 
(CNC). This MOZ-dependent Hox gene expression in CNC determines the normal 
facial support skeleton in Zebrafish (Crump et al., 2006). In contrast, in MOZ-
deficient mice, an extensive anterior homeotic transformation of the axial skeleton 
(neck and trunk region) and nervous system is observed (Voss et al., 2009). The 
severity of the developmental defect implicates MOZ as a regulator for a large 
number of HOX proteins. Results from Voss and colleagues confirmed that MOZ 
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deletion leads to a global decrease of Hox gene expression and further, effects the 
specification of the anterior expression boundary of Hox genes (Voss et al., 2009). 
ChIP using antibodies against specific histone PTMs, followed by quantitive genomic 
PCR revealed a reduction of H3K9 acetylation at the TSS of Hox loci in MOZ-
deficient mice. Contradictory to previous in vitro studies, no effect on H3K14 
acetylation levels was shown and H4K16 acetylation and H3K9 trimethylation were 
seen to increase in the MOZ-/- mutant compared to wild-type controls. MOZ is 
therefore required to maintain normal levels of H3K9 acetylation at Hox loci in vivo 
(Voss et al., 2009). Further novel findings disclose that H3K9 hypoacetylation, Hox 
gene repression and the anterior homeotic transformation caused by a lack of MOZ 
are all rescued by Retinoic acid (RA) signalling, a known potent activator of Hox 
gene expression. RA and MOZ are thus defined to act in parallel to define body 
segment identity (Voss et al., 2009). 
The role of Hox gene expression in embryogenesis and development is well 
documented however, the homeobox genes have also been demonstrated to exert a 
critical function in normal hematopoiesis (van Oostveen et al., 1999). The abnormal 
expression of HOX transcription factors has been linked to both (Mixed Lineage 
Leukaemia) MLL-rearranged (Ayton and Cleary, 2003) and MOZ/CBP-associated 
leukemogenesis (Camos et al., 2006). A recent study explores the molecular crosstalk 
involved at the Hox gene promoters in order to regulate their expression in human 
cord blood CD34+ cells (Paggetti et al., 2010). MOZ was found to colocalise and 
interact with the histone methyltransferase MLL and the adaptor protein essential for 
MLL-mediated H3K4 trimethylation, WDR5. Moreover, both modifying enzymes are 
recruited to multiple Hox promoters where they were found to synergistically 
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stimulate promoter activity (Paggetti et al., 2010). MOZ/MLL-targeted knockdown in 
multipotent CD34+ cells was seen to alter the recruitment of the enzymes to Hox 
promoters, thereby decreasing the levels of H3K4me2/3 epigenetic modifications and 
consequently leading to Hox gene repression and an impaired ability to differentiate 
into myeloid progenitors (Paggetti et al., 2010). Dissecting the molecular mechanisms 
behind the regulation of MOZ-target genes is important for our understanding of 
MOZ function and further emphasises new ways by which MOZ/MLL crosstalk 
deregulation can lead to leukemogenic abnormalities in hematopoietic cells.  
 
1.6.5. MOZ functions as a transcriptional activator in the DNA damage 
response 
 MOZ interacts with p53, functioning as a coactivator for p53-mediated 
transactivation of specific target genes. The p53 protein is an essential regulator of 
the cellular response to different forms of stress, where it can trigger apoptosis to 
eradicate the damaged cell or initiate G1 cell-cycle arrest to allow for damage repair. 
KitabayaVKL¶VJURXSLQYHVWLJDWHGWKHUROHRIWKH02=-p53 interaction in response to 
genotoxic stress (Rokudai et al., 2009). Flow cytometry experiments showed an 
impaired G1 arrest of MOZ deficient cells following adriamycin (ADR)-induced 
DNA damage compared to wild-type, indicating that MOZ regulates this cell-cycle 
block. Further, an increase in the level of the p53-MOZ complex was observed in 
response to this genotoxic treatment. When examining the effect of MOZ-/- on the 
expression of different p53 target genes it was seen that only p21 expression was 
abolished. The p53-MOZ interaction is therefore required for the recruitment to and 
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activation of the p21-gene promoter in response to DNA damage and the consequent 
p21 expression leads to G1 cell-cycle arrest (Rokudai et al., 2009). Interestingly, a 
recognised oncogenic mutation of p53, G279E, was seen to disrupt the p53-MOZ 
interaction but maintain the DNA binding activity of p53. This provides possible 
reasoning for the lack of ability of the p53 G279E mutant to activate transcription, 
where MOZ is required as its coactivator (Rokudai et al., 2009). The importance of 
p53/MOZ-mediated transcription is reinforced in this study, where its inhibition is 
involved in carcinogenesis.  
The vital transcriptional coactivator function of MOZ is described above 
where MOZ-regulated genes are involved in processes including hematopoiesis, 
development, the DNA damage response (DDR) and carcinogenesis. Whereas our 
knowledge is constantly expanding, research into defining the relevance of all the 
MOZ modular domains and physiological complex components is required. Further, 
the refinement of both histone and non-histone lysine substrates and the mechanisms 
behind the control of MOZ-target genes is essential to establish a complete picture of 
MOZ function and its ultimate role in disease. 
 
1.7. The Role of MOZ & Other KATs in Disease 
The activities of KAT and KDAC enzymes are vital for normal gene 
regulation and cellular homeostasis. Dysfunction of KATs has been linked to 
malignant transformation and many other diseases including cancer, diabetes, AIDS 
and neurodegeneration. More specifically, the MYST and CBP/p300 family members 
have been shown to play a causative role in leukaemogenesis. Acute myeloid 
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leukaemia is associated with frequent, reciprocal chromosomal translocations in 
hematopoietic progenitor cells. MOZ was first identified in recurrent chromosomal 
translocations which involve the fusion of MOZ to the gene encoding CBP (Borrow 
et al., 1996) and since then MOZ fusions incorporating the nuclear coactivators p300 
(Kitabayashi et al., 2001b), TIF2 (transcriptional intermediary factor)(Carapeti et al., 
1998) and NCOA3 (Esteyries et al., 2008) have been identified. AML that express 
MOZ-related translocations are generally monocytic leukaemias classified under the 
M4/M5 French-American-British subtypes (Yang and Ullah, 2007) and these MOZ 
fusions are found in approximately 6.5% of such AML subtypes (Esteyries et al., 
2008). 
In all MOZ translocations identified to date, the breakpoint of MOZ is located 
within or around its acidic region (Figure 1.6). The N-terminal region of MOZ, 
containing the H1/5 like-, DPF-, MYST- and basic-domains is therefore retained and 
the C-terminus is replaced with one of the fusion partners listed above (Katsumoto et 
al., 2008). At the molecular level, the resulting creation of such chimeric products 
allows the catalytic subunits of one fusion partner to become mistargeted by the 
binding domains within the other. This can lead to a reduction of enzymatic activity 
at intended genomic loci, aberrant global and promoter-specific acetylation, 
sequestration of essential nuclear regulators (Avvakumov and Cote, 2007) or the 
instability of co-regulator complexes (Kindle et al., 2005), thus, perturbing gene 
expression programs necessary for normal myeloid differentiation. 
MOZ-TIF2 and MOZ-CBP have been shown to exert their oncogenic effects 
by altering cofactor recruitment and chromatin modification at target promoters. 
Specifically, MOZ-TIF2 acts as a dominant inhibitor of the transcriptional activities 
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of CBP-dependent activators such as nuclear receptors and p53. This effect is caused 
by the direct binding of CBP to the C-terminal activation domain (AD1) of MOZ-
TIF2 and as a consequence of this interaction, intracellular levels of CBP are strongly 
reduced and more specifically, CBP is depleted from PML bodies (Kindle et al., 
2005). In addition, it has been shown that MOZ-TIF2 associates with the 5$5ȕ 
promoter perturbing the ligand-dependent recruitment of CBP and resulting in the 
down-regulation of the 5$5ȕ gene. In contrast, MOZ-TIF2 enhanced AML1/Runx1 
reporter activation (Collins et al., 2006). The MOZ-CBP fusion protein shows similar 
WUDQVFULSWLRQDOUHJXODWLRQIXQFWLRQVDWWKH5$5ȕDQG$0/SURPRWHUV as compared 
to MOZ-TIF2 (Collins et al., 2006), but has also been implicated in the stimulation of 
NF-ț%- dependent transcription (Chan et al., 2007). MOZ fusion proteins are 
therefore seen to differentially regulate the transcription of their targets, with 
transcription effects being possibly dependent on the promoter context. 
The mechanism by which MOZ-TIF2 depletes intracellular levels of CBP and 
p300 is still ambiguous, however recently it has been shown to act via a proteasome-
independent mechanism. Treatment of cells with a cell permeant calpain/cathepsin 
inhibitor (CPI-2) blocks the effect of MOZ-TIF2-mediated destruction of CBP/p300, 
restoring CBP expression to normal levels and rescuing MOZ-TIF2 mediated gene 
repression (Kindle et al., 2010). These results indicate a role for calpain and cathepsin 
proteases in the oncogenic action of MOZ-TIF2. 
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Evidence has shown that the binding of MOZ-TIF2 to the CBP cofactor also acts in 
extending the proliferative capacity of hematopoietic progenitors in vitro and induces 
AML in vivo (Kindle et al., 2005). When introduced into irradiated mice, MOZ-TIF2 
is able to immortalise committed myeloid progenitor cells and cause AML (Huntly et 
al., 2004). Furthermore, it was shown that the C2HC nucleosome recognition motif of 
MOZ (Figure 1.6 (Zn)) is essential for the transforming properties of MOZ-TIF2, 
whereas the HAT activity of the MYST domain is dispensable (Deguchi et al., 2003). 
As well as interacting with CBP, it has most recently been shown that both MOZ-
TIF2/CBP fusion proteins can interact with the PU.1 transcription factor to stimulate 
the expression of macrophage colony-stimulating factor receptor (CSF1R). Cells 
containing elevated levels of CSF1R showed potent leukaemia-initiating activity and 
ablation of such stem cells suppressed the progression of MOZ-TIF2 induced AML 
(Aikawa et al., 2010).  
The role of KATs in cancer is complex, as, for example, it appears that the 
genes encoding CBP and p300 have both tumour-suppressor and tumour-promoter 
properties. A causative role for p300 and CBP in cancer has been implicated via 
many mechanisms. Firstly, both coactivators and in addition PCAF, are targeted by 
viral oncoproteins such as E1A. E1A binds and sequesters the KATs, inhibiting their 
acetyltransferase activities and preventing the binding of certain transcription factors. 
This represses transcriptional activation by transcription factors that require these 
KATs as coactivators (Frisch and Mymryk, 2002). Secondly, via the formation of 
chimeric fusion proteins, including those described above and also translocation with 
the mixed lineage leukaemia (MLL) gene, leads to the development of disease. The 
MLL-CBP/p300 fusion proteins are almost exclusively associated with 
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myeloproliferative diseases and have been proposed to lead to leukaemia by 
increasing histone acetylation of genomic regions targeted by MLL (Daser and 
Rabbitts, 2005).  
Finally, a variety of p300 and CBP sequence alterations have been identified 
in malignancies. A loss of heterozygosity of p300 is frequently coupled with 
glioblastomas, colon, breast and ovarian cancers (Bryan et al., 2002). p300 mutations 
have also been described which predict a truncated protein present in epithelial and 
colorectal cancers. In addition, a somatic in-frame insertion of 6 amino acids into the 
p300 HAT domain was found in a primary breast cancer and missense alterations 
found in a primary colorectal cancer (Gayther et al., 2000). Studies using CBP 
knockout mice show an increased incidence of some cancers including leukaemia, but 
also defects in cell proliferation (Kung et al., 2000). Dysfunctional CBP has also been 
implicated in the developmental disorder Rubinstein-Taybi syndrome. Monoallelic 
mutation of the human CBP locus is sufficient to induce the on-set of this disease and 
patients with this syndrome exhibit an elevated risk of developing malignant tumours. 
Mutational analyses of patients reveal heterozygous mutations in the PHD finger and 
HAT domain of CBP, leading consequently to reduced acetyltransferase activity for 
its substrates and coactivator function for CREB (Kalkhoven et al., 2003). More 
recently, inactivating mutations of CBP and p300 have been linked to relapsed acute 
lymphoblastic leukaemia (ALL) (Mullighan et al., 2011) and multiple forms of B-cell 
non-+RGJNLQ¶V O\PSKRPD (Pasqualucci et al., 2011). In both cases, deleterious 
substitutions or genomic deletions in the conserved residues of the HAT domain 
render it inactive, causing impaired histone acetylation and transcriptional regulation 
of CBP/p300 target genes. 
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With KATs playing a fundamental role in multiple cellular processes it is 
inevitable that their dysregulation will lead to the development of cancer and other 
diseases. Yet promisingly, our expanding understanding of KAT functional 
mechanisms is highlighting the curative value of these enzymes for the design of 
therapeutic interventions. 
 
1.8. Epigenetic Modulation: Potential Anticancer Therapy 
As described previously, there is a wealth of evidence indicating an aberrant 
acetylation status in cancer, whereby the complex interplay of KATs and KDACs is 
in some way perturbed. For this reason epigenetic drugs targeting KDAC chromatin 
modifying enzymes have been extensively studied and several are currently in 
clinical trials. Yet, it is important to appreciate that there are cancer cases involving 
the hyperacetylation of targets and the consequent use of KDACi in such situations 
could prove to be detrimental. At present, comparatively there is little information 
available on the anti-tumour effects of KAT inhibitors (KATi). This is most likely a 
result of i) KDAC inhibitors are still more efficient than KAT inhibitors; ii) 
information on the molecular basis of KAT inhibition is still vague; iii) the doses 
required for inhibition are high, causing difficulty in applying the inhibitors to 
cellular and biological systems (Manzo et al., 2009). However, with ever advancing 
knowledge of their structure, function and regulation KATs are emerging as 
promising pharmacological targets (Heery and Fischer, 2007). 
 The first reported KAT chemical inhibitors are bisubstrate analogues, in 
which a histone substrate peptide is covalently linked to a CoA motif at the lysine site 
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(figure 1.7A) (Zheng et al., 2008). Due to differential substrate specificities and 
catalytic mechanisms utilised by KATs, selectivity can be achieved through the 
alteration of the lysyl moiety in the conjugates. Lys-CoA was found to be a p300-
specific inhibitor and H3-CoA- VKRZVȝ0SRWHQF\ IRU3&$) (Lau et al., 2000). 
Despite their high potency for specific KATs these inhibitors exhibit low cell 
permeability and metabolic instability, which reduces their suitability for in vivo 
characterisation. To address this issue, the peptide CoA inhibitor was fused with a Tat 
peptide to yield a cell-permeable molecule and facilitate cell entry (Zheng et al., 
2005). It remains to be seen if these constructs are pharmacologically useful, however 
these inhibitors have proven valuable in the elucidation of KAT biological function. 
KATs such as p300 have been co-crystallised with lysyl-CoA inhibitors and such 
experiments have provided mechanistic data and implicated p300 in novel regulatory 
functions (Liu et al., 2008). With respect to its therapeutic potential, this structural 
information could also inspire structure-based inhibitor design. 
Enzymatic screens with natural products have yielded another category of 
small-molecule natural enzyme inhibitors. These include anacardic acid, curcumin 
and garcinol (figure 1.7B). Anacardic acid is a major component of cashew nutshell 
liquid and was identified as a non-specific p300/PCAF inhibitor (Balasubramanyam 
et al., 2003). However, again due to poor membrane permeability its in vivo effects 
could not be observed. Progressively, the scaffold of anacardic acid has been 
efficiently utilised by researchers to synthesise several KATi (Selvi and Kundu, 
2009). 
Curcumin is a yellow pigment extracted from the root of the turmeric herb 
Curcuma longa and has long been recognised for its medicinal properties. With 
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regards to its effects on KATs, curcumin has been shown to be a non-competitive 
inhibitor of p300 activity in vitro (Dekker and Haisma, 2009). It is cell-permeable 
allowing the use of the KATi in an in vivo context to specifically modulate KAT 
activity (Balasubramanyam et al., 2004). Previously, Balasubramanyam and 
colleagues have demonstrated that curcumin has no effect on other histone-substrate 
enzymes such as PCAF, HDAC1 and methyltransferases (Balasubramanyam et al., 
2004). However, unpublished data shows that the HAT activities of MYST family 
members, MOZ and TIP60, are also inhibited by curcumin (Collins, Heery -
unpublished). A promising observation of curcumin activity is that it is capable of 
inducing apoptosis in cancer cells without cytotoxic effects on healthy cells 
(Tourkina et al., 2004). In addition, curcumin has been found to possess antioxidative 
and anti-inflammatory properties (Selvi and Kundu, 2009) and it is due to these 
pharmacological properties that curcumin is under clinical study for many human 
pathologies (Manzo et al., 2009). In terms of searching for an exclusive KAT-specific 
inhibitor new products are still being actively pursued; as curcumin is a well-known 
antioxidant, it is therefore likely to interfere with other cellular pathways. The 
bioavailability of curcumin is also very low and further research needs to be carried 
out in order to improve this factor. Yet, the simple structure of this molecule allows 
the easy access to derivatives and the potential to overcome this shortcoming. 
Garcinol is an isoprenylated benzophenone isolated from Garcinia indica fruit 
rind. It was shown to be a highly potent competitive inhibitor of p300 and PCAF, 
which inhibits histone acetylation in vivo and induces apoptosis by binding to the 
acetyl-CoA ligand site (Arif et al., 2009). Favourably, garcinol is highly permeable to 
cultured cells however, its poor solubility and non-specific nature render it cytotoxic. 
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Conversely, this compound provides a foundation for medicinal chemists to 
synthesise more potent, selective and less toxic analogues. Indeed, optimisation of 
such leads has yielded some promising results. Mantelingu et al have modified 
garcinol to create isogarcinol (IG) and 14-methoxyIG (LTK-14) derivatives 
(Mantelingu et al., 2007). It was found that the LTK-14 compound specifically 
inhibited p300 activity by a noncompetitive mode of inhibition towards both the 
histone and acetyl-CoA substrates and additionally no longer affected the activity of 
PCAF (Arif et al., 2009). In the presence of 10 ȝ0 LTK-14, p300-mediated 
acetylation of histones H3 and H4 were equally inhibited up to 85-90 % compared to 
control. In addition, the garcinol derivative inhibited histone acetylation in HIV-
infected cells and further, impaired the multiplication of HIV (Mantelingu et al., 
2007). The revelation of highly specific inhibitors holds not only enormous 
therapeutic potential, but also provides exciting opportunities to probe into KAT 
function.  
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Figure 1.7. Chemical structures of known KAT inhibitors. (A) Bi-substrate 
analogues. (B) Natural compounds. (C) Small molecule synthetic inhibitors. 
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           High-throughput screening of synthetic libraries has also yielded candidate 
chemical probes for KATs (figure 1.7&LQFOXGLQJĮ-Methylene-Ȗ-butyrolactones, 
isothiazolones and quinolines (Manzo et al., 2009). Isothiazolones have been found to 
inhibit p300 and PCAF activity and also possess antiproliferative properties against 
FDQFHUFHOOOLQHV%RWKĮ-Methylene-Ȗ-butyrolactone and quinoline inhibitors have 
been shown to inhibit the catalytic mechanism of GCN5 (Dekker and Haisma, 2009) 
(Manzo et al., 2009).  
In a recent study by Buczek-Thomas a novel class of KAT inhibitors was 
introduced. They report that glycosaminoglycans (GAGs), with emphasis on heparin 
and heparan sulphate proteoglycans (HSPGs), are potent inhibitors of p300 and 
PCAF activities in vitro. The PCAF binding heparin was shown to act as a 
competitive-like inhibitor, causing an approximate 50-fold decrease in binding 
affinity of PCAF for its natural substrate histone H4 (Buczek-Thomas et al., 2008). 
This poses the theory that GAGs act as natural inhibitors of KAT enzymes, thus 
regulating histone acetylation and accordingly modulating cell function. 
Research into effective KATi is still in its infancy, especially with regards to 
searching for inhibitors with a high degree of enzyme specificity and potency towards 
their targets. However, promising results are emerging as some inhibitors are in the 
process of clinical trials. The main focus of inhibitor production is currently aimed at 
the p300/CBP and GCN5/PCAF family members, where the already characterised 
and available inhibitors can serve as the templates for enhancement by structure-
based and rational inhibitor design. Currently, inhibitors that target MYST family 
members are yet to be discovered; possibly due to their broad range of substrate 
specificities and functions. However, unpublished data from our group suggests that 
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both the previously characterised curcumin and garcinol inhibitors can also affect the 
activities of MYST proteins (Collins, Heery ± unpublished). Efforts to identify 
MYST-specific inhibitors are ongoing. 
 
1.9. Readers of the Histone Code 
Mechanistic understanding of how the plethora of histone PTMs are 
deciphered and translated into specific functional outputs, such as transcription, DNA 
repair and epigenetic silencing, has flourished over the last decade. At present, there 
are two non-mutually exclusive models dictating how histone PTMs may generate 
critical structural alterations in the chromatin polymer; the direct and effector-
mediated models. The direct model implicates histone PTMs in the direct alteration 
of chromatin compaction, whereby PTMs such as acetylation and phosphorylation 
serve to disrupt favourable histone-DNA and internucleosomal contacts. Conversely, 
the emerging effector-mediated concept SURSRVHV WKDW KLVWRQH 370V DUH µUHDG¶ E\
protein modules and their associated complexes, facilitating significant downstream 
events via the recruitment or stabilisation of non-histone binding effector proteins and 
machinery (Seet et al., 2006).  
Numerous conserved protein domains have been identified (Figure 1.8) and 
these modules have been shown to specifically bind covalent moieties depending on 
both their modification state and their position within a histone sequence (Taverna et 
al., 2007). Emerging research underscores the importance of the multivalency 
concept in chromatin biology, where PTMs are read combinatorially DVDµODQJXDJH¶
UDWKHUWKDQDVWULFWµFRGH¶(DUO\VWXGLHVIRFXVRQWKHFKDUDFWHULVDWLRQRIDQLQGLYLGXDO
Chapter One: Introduction 
66 
 
histone reader module binding to a single modification however more recently, 
research is advancing in order to define the readout of more complex epigenetic 
signatures. The coexistence of chromatin modifications on one or two tails of the 
same nucleosome, adjacent or discontinuous nucleosomes can be cooperatively or 
synchronously read by single binding modules or by the combinatorial engagement 
through effectors harbouring several putative interaction domains (Ruthenburg et al., 
2007b).  
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Figure 1.8. Chromatin-binding domains: readers and interpreters of the histone code. 
A number of chromatin-binding modules have been found associated with a wide array of 
effector proteins. Illustrated here are the various domains with their associated structures 
(Protein Data Bank accession numbers: bromo, 1F68; chromo, 2B2Y; PHD, 3C6W; SANT, 
2EQR; Tudor, 1G5V; SWIRM, 2COM; WD40, 2G9A; 14-3-3, 2C1J), as well as which 
PTMs the domain recognises. 
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1.9.1. Recognition of acetyl-lysine modifications 
Bromodomains (BD) are protein modules that interpret acetyl-lysine marks 
and are predominantly found in nuclear chromatin-associated proteins, such as KATs 
and subunits of remodelling complexes, in which they conduct crucial roles in 
transcriptional activation and chromatin remodelling. The majority of BDs utilise a 
similar method to recognise acetyl-lysine (Kac) residues and the BD residues 
engaged in Kac recognition are among the most highly conserved amino acid residues 
of the large BD family (Zeng et al., 2008b). Acetyl-lysine binding can be illustrated 
with the NMR-determined structure of Gcn5 BD as an example. The acetyl-lysine 
inserts into a deep and narrow binding pocket lined with aromatic and hydrophobic 
residues. The acetyl modification is specifically anchored through a hydrogen bond 
involving its acetyl carbonyl group and the amide nitrogen of a conserved asparagine 
residue. Further, a network of water-mediated intermolecular hydrogen bonds at the 
base of the cleft contributes to binding (Figure 1.9 (A))(Owen et al., 2000). 
Additional contacts are also made between peptide residues flanking the Kac and the 
amino acids residing at the entrance of the binding pocket. These interactions serve to 
reinforce the binding of the Kac of the target sequence. Structurally these residues 
compose highly flexible loop regions, which among BDs vary greatly in sequence 
and confer to their distinct histone-binding selectivity (Zeng et al., 2008b).  
In analyses of the ligand binding sites outside of the conserved scaffold, CBP 
and PCAF BDs were found to adopt two distinct consensus histone recognition 
patterns. PCAF was found to favour acetylation sites with a hydrophobic and 
positively charged or aromatic residue at position Kac+2 and Kac+3 respectively; 
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whereas CBP preferred a consensus of bulky hydrophobic residues at Kac+1 and 
Kac+2, a positively charged residue at Kac-1 and an aromatic residue at Kac-2 (Zeng 
et al., 2008b).  
The effector-mediated recognition of single PTMs is well characterised 
(Taverna et al., 2007), however how the cell conducts the combinatorial interpretation 
of histones or nucleosomes harbouring multiple modifications is still ambiguous. 
Recent progress, utilising structural and biophysical methods, have determined a 
number of distinct mechanisms involved in multivalent binding. Firstly, the mouse 
TAF1 homologue Brdt contains two bromodomains each with different PTM binding 
specificities. The single Brdt BD1 is responsible for selectively recognising 
hyperacetylated histone H4 harbouring two or more acetylation marks. The crystal 
structure of the BD1 in complex with a H4K5/8 di-acetlyated peptide illustrates how 
two acetyl-lysine residues cooperatively bind with a single binding pocket. Binding 
entails the prototypical recognition of H4K5ac as described previously for the GCN5 
BD, but conversely, a single amino acid substitution widens the Brdt BD1 binding 
pocket from the keyhole-like state of the GCN5 pocket (Moriniere et al., 2009). This 
wider pocket favourably accommodates both acetyl-lysines recognising the H4K8ac 
predominantly through hydrophobic interactions. Specificity for H4K8ac also arises 
structurally as the positive charge of an unmodified H4K8 residue would be adverse 
to the apolar environment (Moriniere et al., 2009). In addition, the BRD2-BD2 has 
been structurally characterised bound to the di-acetylated H4K5/12 peptide. In 
contrast to BD1, a single H4K5/12ac peptide interacts with two molecules of BRD2-
BD2 molecules simultaneously: the K5ac residue to one molecule and the K12ac 
residue binds to another (Umehara et al., 2010). These results provide a structural 
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basis for two distinct methods of bivalent histone PTM recognition by a single 
bromodomain.  
An alternative mechanism involves the multivalent PTM binding by linked 
binding modules. The tandem bromodomains of TAF1 exhibit stronger binding 
affinities to a di-acetylated histone H4 peptide in comparison to mono-acetylated 
histone H4 tails. Each BD engages one acetyl-lysine residue resulting in a 
cooperative binding effect between the tandem effector modules (Jacobson et al., 
2000). The majority of studies thus far have been conducted with peptide surrogate 
substrates, yet little is known about how combinations of PTMs are recognised in a 
more physiologically relevant nucleosomal context. Ruthenburg et al. characterised 
the multivalent interactions of the bromodomain and PHD domain transcription factor 
(BPTF) PHD-Bromodomain cassette using both peptide surrogates and semi-
synthetic histones reconstituted into mononuclesomes. The BPTF PHD domain is 
known to interact with H3K4me2/3 (Li et al., 2006) and via systemic screening with 
modified peptides, BPTF PHD-BD exhibited specificity for three acetyl-lysines 
H4K12/16/20ac (Ruthenburg et al., 2011). Biophysical and structural analysis 
revealed simultaneous bivalent binding by both modules, where binding was 
augmented for nucleosomes bearing both the H4K16ac and H3K4me3 modifications 
over mononucleosomes harbouring only H3K4me3. Furthermore, the bivalent nature 
of this interaction appears to enhance the selectivity of the BPTF PHD-BD cassette 
towards H4K16ac in combination with H3K4me3 binding at the mono-nucleosomal 
level, despite a lack of discrimination for the H4Kac peptide surrogates (Ruthenburg 
et al., 2011). These studies emphasise the importance in deciphering the nucleosomal 
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patterning of covalent marks, which dictate vital chromatin associations and 
downstream biological events. 
 
1.9.2. Recogntion of methyl-lysine/arginine modifications 
Two general classes of protein domains named the PHD fingers and Royal 
superfamily have evolutionary converged to bind methyl-lysine/arginine residues. 
The greater number of modules dedicated to methylation rather than acetylation 
interpretation is perhaps a result of the increased combinatorial complexity of the 
methylation modification. Additionally, whereas lysine charge is neutralised by 
acetylation all methylated states of lysine are predicted to carry a positive charge at 
physiological pH. With the addition of each methyl group, hydrophobicity and the 
cationic radius of the methylammonium group increases and consequently its ability 
to donate hydrogen bonds decreases (Taverna et al., 2007). The different methylation 
states thereby diversely alter the physiochemical properties of lysine residues, 
requiring state-specific readout by multiple effector domains. 
The recognition and interaction of methyl-lysine residues is mediated through 
contacts made between the methyl-ammonium moiety and aromatic residues as well 
as one or more acidic side chains within the binding module. Aromatic residues form 
D µFDJH¶ DURXQG WKH 370 FUHDWLQJ DQ DURPDWLF ʌ V\VWHP DQG D QHJDWLYH SRWHQWLDO
field, which promotes the engagement of the quaternary ammonium moiety with 
favourable electrostatic cation-ʌ LQWHUDFWLRQV )RU UHFRJQLWLRQ RI WKH ORZHU
methylation states, steric exclusion and hydrogen bonding are progressively more 
significant (Ruthenburg et al., 2007a).  
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The Royal superfamily members, encompassing chromo- and Tudor domains, 
Malignant Brain Tumour (MBT) and WD40 repeats utilise two recognition modes to 
engage methylated histone marks; a surface-groove mode for higher methylation 
states or cavity-insertion for complexes of lower methylation states. In the surface-
groove recognition mode, the binding pockets have less stringent preferences for 
specific methylation states and thereby tend to be wider and more accessible; 
allowing the bulky methyl-lysine side chain to extend along a protein surface groove 
(Taverna et al., 2007). Examples of such a recognition mode include the binding of 
H3K4me3 by the double tudor domain of the histone demethylase JMJD2A (Huang 
et al., 2006)(Figure 1.9(B)) and the recognition of H3K9me3 by the HP1 
chromodomain (CD) (Nielsen et al., 2002) (Figure 1.13). 
The MBT pocket of the tumour suppressor protein L3MBTL1 binds both 
mono- and di-methylated lysine residues within an aromatic cage via the cavity 
insertion method (Min et al., 2007). In this case the methyl-lysine is buried deep 
within the protein cleft, thereby discriminating against the higher degrees of histone 
lysine methylation by size exclusion. Furthermore, in addition to binding via a cage 
of aromatic residues, lower methylation state interpretation begins with the formation 
of a direct hydrogen bond and salt bridge between methylammonium group and the 
carboxylate of an acidic residue lining the aromatic pocket. Thus, trimethylation of 
lysine residues would be undesirable by a steric repulsion between the acidic side 
chain and the additional methyl group (Min et al., 2007). At present, knowledge of 
methyl-arginine effectors is sparse due to a lack of structural data and consequently, 
insights into the molecular mechanisms underlying the recognition pattern. However, 
recent studies show that arginine methylation antagonises the binding of other 
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effector modules. For example, structural characterisation reveals that the H3K4me3 
binding domains, including the ING2 PHD finger and WD40 repeats of WDR5, make 
critical contacts with the unmodified H3R2 residue. Results show that effector 
proteins are sensitive to H3R2 methylation, which disrupts complex interactions and 
antagonises binding to the N-terminal tail of histone H3 (Iberg et al., 2008). These 
findings underscore that it is the combinatorial readout of PTMs that govern the final 
outcomes dictated by the reader modules. 
 
1.9.3. Recognition of phospho-serine/threonine modifications 
Multiple serine, threonine and tyrosine histone residues can be modified by 
phosphorylation, however only a small number of phospho-histone effectors have 
been identified, despite the description of numerous phospho-binding modules for 
non-histone proteins. The mammalian 14-3-3 proteins represent an abundant and 
well-conserved family of phospho-specific binding proteins and structure-function 
studies have classified 14-3-3 isoforms that bind N-terminal H3 tails in a 
phosphorylation-dependent manner (Macdonald et al., 2005). Phosphorylation affixes 
a bulky and negatively charged phosphate group onto the hydroxyl group of a side 
chain, thus increasing the ion-pairing and hydrogen-bonding abilities of these 
residues (Taverna et al., 2007). The crystal structure of the 14-3-ȗLVRIRUPVKRZHG
that the phosphorylated (S10) peptide binds in an extended conformation spanning 
the entire 14-3-3 binding cleft. This extended conformation is stabilised by 
intermolecular hydrogen bonds between the side chains of 14-3-3 asparagine residues 
and the backbone carbonyl and amide groups of the H3 peptide (Macdonald et al., 
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2005). The S10ph group is bound in a pocket lined with highly basic amino acid 
residues, which act in neutralising the negatively charged phosphate moiety. Further, 
the expulsion of solvent and the presence of aromatic residues contribute to the 
charged character of the binding cleft (Figure 1.9(C)) (Macdonald et al., 2005). 
Regarding the crosstalk between and influence of PTMs on the same histone tail, it 
was found that acetylation of K9 or K14 had a minimal effect on binding of the 14-3-
ȗ PRtif with the phospho-serine residue. A H3K9ac/S10ph peptide binds in a 
partially extended conformation with a kink, causing the side chain of K9ac to fold 
back and form a hydrogen bond to the backbone amide of A7, thus not disturbing the 
14-3-3-S10ph interaction (Macdonald et al., 2005).  
 
1.9.4. Recognition of unmodified amino acid residues in histones 
An important concept is that complexes also interact with unmodified histone 
tails through SANT, WD40 repeats and PHD domains. This underscores the 
importance of the residue context, where the same residue in the absence or presence 
of a PTM, can be used to promote different chromatin associations or, in other 
instances weaken or block these interactions (Taverna et al., 2007). This thereby 
establishes the significance in the ability to also recognise residues in the absence of 
PTMs. Examples of the molecular recognition of unmodified residues by PHD 
fingers will be outlined in the subsequent section. In general, all effector binding 
modules form associations with unmodified histone residues. In addition to the 
primary recognition of the target PTM, an extensive network of interactions between 
the histone peptide backbone and binding pocket residues is required for the 
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stabilisation and efficient recognition of the histone PTM. This concept is perfectly 
illustrated by the previously described WDR5, a seven-WD40-repeat, H3K4me3 
binding protein that forms critical interactions with the peptide backbone residue 
H3R2. Indeed, crystal structures show H3R2, located on the exposed tail of histone 
+FRQWDFWVWKHFHQWUHRIWKH:'5ȕ-propeller structure. Once H3R2 is methylated 
by the PRMT6 HMT, binding and docking to its target H3K4me3 PTM is prohibited 
(Iberg et al., 2008).  
 
1.10. The PHD Finger: A Versatile Protein-Interaction Domain 
 Almost two decades ago, Schindler et al. first identified the PHD finger motif 
within an Arabidopsis homeodomain protein. The presence of eight regularly spaced 
cysteine/histidine residues was observed between two plant homeodomain proteins 
and such sequence similarity is concomitant with other metal-binding domains such 
as the RING (Really Interesting New Gene) finger. This novel motif was denoted 
PHD-finger (Plant HomeoDomain) (Schindler et al., 1993). Since then the PHD 
finger has been classified as a bona fide domain that is present in an array of 
eukaryotic proteins. PHD motifs tend to comprise between 50-80 amino acids and 
show D&+&VLJQDWXUHWKDWVWUXFWXUDOO\DGRSWVDµFURVV-EUDFH¶topology of the two 
Zn2+-coordinating residues (Bienz, 2006). PHD fingers are predominantly found in 
nuclear proteins that function in the regulation of chromatin, suggesting that they 
bind to a common nuclear ligand. However, due to low sequence similarity and 
structural flexibility among PHD finger domains, it is emerging that multiple 
biological ligands can be bound. 
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1.10.1. PHD fingers as chromatin binding modules 
 The original breakthrough of a function for PHD domains in gene 
transcription was assigned to the recognition of lysine-methylated histone H3 (Li et 
al., 2006). The PHD finger is now a well-established chromatin-binding module that 
recognises and interprets both methylated, acetylated or the unmodified states of 
histone lysine residues. Further, recent advancements in the structural and functional 
characterisation of PHD fingers underscore their functional versatility as epigenome 
readers and reveal a refined histone sequence reading capability that is governed by 
the cross-talk between different histone PTMs (Sanchez and Zhou, 2011). 
 The first solution structure of a PHD finger bound to a histone ligand was that 
of the human BPTF, the largest subunit of the ATP-dependent chromatin-remodelling 
complex, nucleosome remodelling factor (NURF) (Li et al., 2006). The BPTF C-
terminal PHD finger was shown to specifically bind the histone H3 tail when H3K4 is 
tri-methylated and H3R2 is unmodified, discriminating against the unmodified and 
mono-methylated H3K4 counterparts. The BPTF-PHD structure also set a precedent 
for the main characteristics required for the readout of H3K4me3 by PHD fingers. 
The binding of H3K4me3 occurs via an aromatic cage (Figure 1.10(A)), where the 
trimethyl ammonium moiety is stabilised by electrostatic cation-ʌ LQWHUDFWLRQV, like 
those observed in members of the Royal superfamily (section 1.9.2). Importantly, R2 
and H3K4me3 fit into two adjacent surface pockets divided by an invariant 
tryptophan group of the PHD finger (Figure 1.10(A)). The observed positioning of 
non-adjacent R2 and K4me3 side chains provides a molecular basis for H3K4me3 
site specificity (Li et al., 2006). Subsequently determined structures of other PHD 
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fingers bound to H3K4me3 peptides revealed that the aromatic cage varies, consisting 
of a combination of two to four aromatic and hydrophobic residues (Sanchez and 
Zhou, 2011). For instance the PHD finger of ING5, an integral subunit of active 
MOZ/MORF and HBO1 complexes, essentially utilises the same basis of recognition 
specificity as the BPTF PHD-H3K4me3 complex. However, the H3K4me3 binding 
pocket comprises only a partial aromatic cage, whereby the hydrophobic character of 
the two aromatic residues is supplemented by the side chains of serine and 
methionine residues (Figure 1.10(B)) (Champagne et al., 2008). 
A separate group of PHD fingers, including those of BRAF35-HDAC 
(BHC80) (Lan et al., 2007), autoimmune regulator (AIRE) (Org et al., 2008) and 
tripartite motif-containing protein 24 (TRIM24) (Tsai et al., 2010), have evolved to 
bind unmodified H3K4me0. The crystal structure of the BHC80 PHD finger, a 
component of the LSD1 corepressor complex, bound to an un-methylated peptide 
revealed the structural basis of the recognition of H3K4me0. Similar to its methylated 
counterparts, the N-terminus of the H3 peptide is recognised by a hydrogen bond 
cage formed by three backbone carbonyls (Figure 1.11). H3K4me0-binding PHD 
fingers lack an aromatic cage and binding to the free epsilon amino group is achieved 
by an arrangement of acidic and hydrophobic residues instead. The H3 peptide 
binding site is defined by a methionine, which is interposed between H3R2 and H3K4 
and a side chain of an aspartate residue, which inserts between the side chains of 
H3K4 and H3R8, forming an electrostatic bridge between the two (Figure 1.11) (Lan 
et al., 2007). 
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Figure 1.10. Recognition of the H3K4me3 modification by the PlantHomeo Domain.  
Schematic representation of the main interactions involved in the recognition of histone 
H3K4me3 by (A) an aromatic cage of BPTF PHD finger (PDB 2F6J) or (B) a partial 
aromatic cage of the ING5 PHD finger (PDB 3C6W). Blue circles and dashed lines indicate 
water-mediated hydrogen bonds. This figure was adapted from PDB structural information 
XVLQJWKH3\02/VRIWZDUH 
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             In addition, H3K4 forms a hydrogen bond with a main chain carbonyl oxygen 
of a glutamic acid residue (Figure 1.11) (Lan et al., 2007). The presence of these 
acidic side chains further confer binding specificity by creating an unfavourable 
environment for bulky cationic methyl groups, thus resulting in the steric exclusion of 
the equivalent H3K4me2/3 modifications (Lan et al., 2007). Recently, the PHD finger 
of AIRE has been shown to be sensitive to H3R2 methylation and therefore reads a 
completely unmodified H3 tail (H3R2me0 + H3K4me0); a property unique among 
the H3K4me0 histone readers. A salt bridge is formed between an aspartate residue 
and the unmodified H3R2, which is disrupted upon methylation of H3R2 (Chignola 
et al., 2009). This represents the readout of a histone PTM signature by a PHD finger 
and details the interpretation of negative cross-talk that exists between the 
unmethylated H3K4 and methylated H3R2 modifications. 
 Details from the few examples provided show that PHD fingers are capable of 
exerting such multifaceted functional flexibility as chromatin readers. However, 
reading of histone modification status is enhanced by the cooperative capacity 
achieved through the presence of two or more PHD fingers (or other reader modules) 
in the same protein or within a protein complex. The simultaneous bivalent 
interaction of the BPTF PHD-BD cassette to H3K4me3 and H4K16ac described 
above (section 1.9.1) (Ruthenburg et al., 2011) illustrates clearly an example of 
intramolecular cooperative histone PTM binding. It is also emerging that 
multisubunit complexes utilise multiple binding modules to guide the appropriate 
targeting and association of the complex to chromatin. The HBO1 HAT complex 
contains three PHD fingers in two different subunits; tumour suppressor proteins 
ING4/5 and JADE 1/2/3. Each of the PHD fingers was found to interact with the N-
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terminal tail of histone H3, but with different specificity towards its methylation 
status (Saksouk et al., 2009). In this example the combinatorial action of all three 
PHD fingers is required for the regulation of chromatin association and substrate 
specificity of HBO1 complexes (Saksouk et al., 2009). 
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1.10.2. Tandem PHD fingers as histone acetyl-lysine sensors 
Many proteins, especially those that function in the regulation of chromatin, 
have been shown to contain single or multiple PHD fingers. However, within the 
genome only five proteins harbour a double PHD finger domain where the PHD 
fingers are arranged in tandem; namely MOZ and MORF MYST family histone 
acetyltransferases and members of the d4-protein family, DPF1/2/3.  
DPF1 (Neuro-d4), DPF2 (ubi-d4/requiem) and DPF3 (Cerd4) are evolutionary 
conserved members of the D4, zinc and double PHD finger family characterised by 
an N-terminal 2/3 domain, a C2H2-type zinc finger and C-terminal tandem PHD 
fingers. Mouse Dpf1 expression is predominantly restricted to the brain and neuronal 
systems, where it is thought to function as a neurospecific transcription factor in 
neuronal development through the regulation of cell survival (Lessard et al., 2007). 
DPF2 is ubiquitously expressed and functions as a transcription factor necessary for 
the apoptotic response following the deprivation of survival factors (Gabig et al., 
1994). At a molecular level, DPF2 has recently been shown to act as a nuclear 
receptor-VHOHFWLYHFRUHSUHVVRUIRU(55ĮE\DVVRFLDWLQJZLWKERWKDFHW\ODWHG+DQG
HDAC1 in myeloblast cells (Matsuyama et al., 2010). DPF3 is a muscle expressed 
member of the d4-family. The human DPF3 gene gives rise to two splice variants; 
DPF3a and DPF3b. DPF3a encodes a truncated protein containing a single C-terminal 
PHD finger, while DPF3b harbours a C-terminal DPF (Lange et al., 2008). In vivo 
knockdown of dpf3 reveals the protein as a key regulator of heart and skeletal muscle 
development (Lange et al., 2008).  
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All three DPF proteins were found to act as novel components of the ATP-
dependent BAF chromatin remodelling complex, where their tandem PHD fingers 
function as novel readers of histone H3/ H4 acetylation and methylation (Lange et al., 
2008). Thus, remarkably the DPF family exhibit the first PHD domain that recognises 
acetylated lysine residues; a property originally assigned to the bromodomain only.     
The tandem PHD finger of DPF3b was shown to bind acetylated H3K14 
(Lange et al., 2008) and later, the three-dimensional structure of acetylated histone 
binding by DPF3b was solved using NMR methods (Zeng et al., 2010). The 
integrated tandem PHD finger functions as one functional unit in the sequence 
specific recognition of the acetyl-lysine residue, whereby PHD1 is responsible for the 
binding of the H3K14ac residue and PHD2 binds the H3R2-H3K4 region (Zeng et 
al., 2010). The H3K14ac hydrophobic pocket in DPF3b-PHD1 is completely novel. 
Acetylated H3K14 intercalates into a hydrophobic binding pocket and clustered at the 
rim of this pocket are aspartate, zinc-coordinating cysteine and arginine residues. The 
acetyl amide of H3K14ac is positioned within hydrogen bond distance to the side 
chains of the aspartate and cysteine residues, whereas the acyl chain of H3K14ac 
interacts with the arginine side chain (Zeng et al., 2010). DPF3b-PHD2 is similar to 
the H3K4me0 binding PHD fingers in that it shares the arrangement of acidic and 
hydrophobic residues in the binding pocket. Together they define the histone PTM 
recognition specificity, whereby the interaction of histone H3 is stimulated by 
acetylation of H3K14, but inhibited by tri-methylation of H3K4 (Zeng et al., 2010). 
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1.10.3. PHD fingers as protein-protein interaction domains 
 The PHD finger motif has also been shown to act as an independent protein 
interaction domain. Enhancer of Zeste (E(Z)) and Polycomblike (PCL) are both 
Drosophila Polycomb group (PcG) proteins required for the epigenetic suppression of 
multiple essential developmental regulatory genes including homeotic genes. Yeast 
two-hybrid and co-immunopreciptation experiments revealed a direct interaction 
between E(Z) and PCL both in vitro and in vivo. Subsequently, mutagenesis of the 
two PCL PHD fingers demonstrated that this protein-protein interaction was mediated 
by these conserved motifs (O'Connell et al., 2001). This interaction was observed to 
be evolutionarily conserved as the human homologues PHF1 (PCL) and EZH2 (E(Z)) 
were seen to associate. The interaction was also highly specific as no binding was 
observed between E(Z) and the PHD domains of Drosophila trithorax group (trxG) 
proteins; proteins which also function in the transcriptional regulation of homeotic 
genes (O'Connell et al., 2001).   
 As another example, the interaction between the BCL9 and Pygopus 
components of the Wnt signalling pathway is mediated via the Pygopus PHD finger. 
Mutation of a structural zinc-coordinating cysteine and also four conserved residues 
at the putative PHD domain surface abolishes the interaction with BCL9 (Townsley 
et al., 2004). Three of these surface residues are identical amid all known Pygopus 
proteins, but different in comparison to other PHD fingers, suggesting that these 
residues define the specificity of the BCL9-Pygopus interaction (Bienz, 2006). 
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1.10.4. PHD E3 ligase activity  
The closest structural relative to the PHD finger is the RING domain. The 
RING domain typically shows a C4HC3 signature and shares similarity with PHD 
domains in their structural cores and µFURVV-EUDFH¶topology of the Zn2+ coordinating 
residues (Bienz, 2006). RING fingers are motifs commonly found in E3 ligases 
functioning in the ubiquitin pathway, where they bind to E2 ligases to mediate protein 
ubiquitination (Joazeiro and Weissman, 2000). Hence, the similarity between the two 
domains prompted reasoning that PHD domains may also contain this intrinsic E3 
ligase activity. To date, few examples exist of PHD domains having been assigned 
with this function due to controversy amid the classification of specific types of zinc 
fingers. This controversy highlighted the need for better criteria and tools to delineate 
and distinguish between these motifs (Bienz, 2006). Despite this, one canonical PHD 
finger has now been implicated as a functional E3 ligase for SUMO molecules. 
Recent studies have shown that PHD and bromodomain modules located in 
close proximity in chromatin-associated proteins, functionally cooperate in the 
combinatorial recognition of histone modifications (Ruthenburg et al., 2011). In 
addition, work from Ivanov et al. demonstrates an alternative mechanism of synergy 
based on the enzymatic activity of a PHD finger, directing the modification of the 
bromodomain. The KAP1 (KRAB-associated protein 1) corepressor mediates gene 
silencing through the recruitment of nucleosome remodelling and deacetylation 
(NuRD) complex and the histone H3K9 methyltransferase SETDB1. Subsequent 
histone deacetylation and H3K9 methylation stabilises the interaction of HP1 with the 
target genes, formulating a silent gene expression state. SUMOylation was found to 
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be essential for KAP1-mediated repression (Li et al., 2007b) and the two SUMO 
acceptor sites, crucial for such repression, were mapped to within the bromodomain 
(Ivanov et al., 2007). Consequent SUMOylation of the KAP1 bromodomain regulates 
the recruitment of chromatin modifiers required for establishing silent-gene 
expression states at specific chromatin loci (Ivanov et al., 2007). Ivanov et al. 
demonstrate that the PHD domain is required for both E2 enzyme Ubc9 binding and 
directing SUMOylation to the specific lysine residues in the bromodomain. Thus, the 
PHD finger functions as a unique E3 ligase directing intramolecular SUMOylation of 
the adjacent bromodomain. Furthermore, the NMR structure of the PHD-BD has been 
solved revealing a completely unique unified tandem-domain architecture that is 
distinct to other PHD-BD structures (Zeng et al., 2008a). The KAP1 PHD finger and 
BD do not exhibit typical methyl- and acetyl-lysine binding activities, but instead 
function interdependently to bind Ubc9 at the tandem-domain interface and catalyse 
SUMOylation within this tandem module to stimulate co-repression activity (Zeng et 
al., 2008a). 
 
1.10.5. PHD fingers as nuclear phosphoinositide receptors 
 Phosphoinositides (PtdInsPs) are lipid signaling molecules which play critical 
roles in cytoplasmic signal transduction pathways. Biochemical studies have also 
detected PtdInsPs within the nucleus and additionally, evidence has emerged that 
these molecules can regulate several nuclear processes (Chen et al., 2002). However, 
their functions within the nucleus are ambiguous as very few binding modules for 
PtdInsPs have been identified. Gozani et al. have utilised screening techniques to 
identify the ING2 tumour suppressor protein as a candidate nuclear PtdInsP binding 
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partner. Specifically, the ING2 PHD finger motif was found to interact in vitro and in 
vivo with PtdIns(5)P and as a result, was observed to functionally modulate the 
subcellular localisation and aptitude of ING2 to stimulate p53 and p53-dependent 
apoptotic pathways (Gozani et al., 2003). 
 
1.11. PHD Fingers as Epigenetic Effectors and Potential Drug 
Targets 
Cancer initiation and development can arise from the inappropriate expression 
or silencing of gene programs, where the balance of underlying epigenetic marks are 
altered. Disease-related mutation or dysregulation has been identified in abundant 
modificatioQ µZULWHU¶ DQG µHUDVHU¶ HQ]\PHV KRZHYHU UHFHQWO\ DQ DUUD\ RI GLVHDVHV
have been associated with the dysfunction of proteins that contain chromatin 
UHFRJQLVLQJ µUHDGHUHIIHFWRU¶ PRGXOHV PDUNHGO\ 3+' ILQJHUV LQ QXPHURXV FDVHV
(Baker et al., 2008). This signifies a new category of diseases that stem from the 
misinterpreWDWLRQ RI WKH HSLJHQHWLF µFRGH¶ DQG H[DPSOHV RI VXFK GLVHDVHV DUH
consequently described. 
 Recent results have provided the first evidence showing that disruption of 
PTM recognition by PHD fingers can cause human disease. The Recombination 
Activating Gene 2 (RAG2) V(D)J recombinase mediates antigen receptor assembly, a 
process at the hub of the adaptive immune response. Mutation of RAG2 and 
consequent disruption of V(D)J recombination was found to cause Severe Combined 
Immunodeficiency (T-B-6&,'RU WKH OHVVVHYHUHµ2PHQQ6\QGURPH¶E\GLVUXSWLQJ
or impairing V(D)J recombination. T-B-SCID patients are vulnerable to infection due 
to a lack of functional B and T cells (Schwarz et al., 1996). Omenn Syndrome 
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patients suffer from autoimmune problems and chronic infections, a result of a lack of 
B cells and elevated levels of T cells (Marrella et al., 2008). RAG2 contains a C-
terminal PHD finger which has been shown to be critical for efficient V(D)J 
recombination in vivo. More specifically, evidence demonstrates that the PHD finger 
recognises and binds to the H3K4me3 modification enriched at V(D)J segments 
ready to undergo recombination (Matthews et al., 2007). Mutational analysis revealed 
that a quarter of known disease-causing mutations are located within the RAG2 PHD 
finger and the severity with which these mutations disrupt the PHD-H3K4me3 
interaction frequently correlates with the severity of the immunodeficiency disease 
(Schwarz et al., 1996)7KHVHUHVXOWVXQGHUVFRUHWKHLPSRUWDQFHRIWKHµUHDGHU¶3+'
module in targeting and stabilising the interaction of RAG recombinase enzymatic 
activity to the correct gene segments awaiting V(D)J recombination. 
In addition to immune diseases, mutations in the genes encoding PHD finger-
containing factors are strongly linked with neurological disorders. Haploinsufficiency 
of CBP leads to Rubinstein-Taybi syndrome (RTS), a congenital developmental 
disorder characterised by retarded growth, mental functions and facial abnormalities 
(Petrij et al., 1995). Mutational analysis of RTS-patients revealed two novel 
mutations within the PHD finger of CBP, which functionally resulted in the complete 
loss of acetyltransferase activity towards histones and CBP itself and demonstrated 
diminished coactivator function for the TF CREB (Kalkhoven et al., 2003). These 
findings emphasise the significance of the PHD finger for in vivo CBP function 
where a reduction in CBP HAT activity, as a result of PHD finger disruption, is 
sufficient for the development of RTS. ATR-X (Alpha-Thalassaemia mental 
Retardation, X-linked) syndrome is another example of a neurological disorder and is 
Chapter One: Introduction 
90 
 
characterised by severe mental and growth retardation, alpha thalassaemia and 
seizures. The ATRX protein harbours a PHD finger at its N-terminus and to date, 26 
disease-causing mutations have been identified within this domain (Argentaro et al., 
2007). The molecular effect of such mutations and their causative role in disease is 
currently still ambiguous and under investigation, however research focusing on the 
function of the ATRX PHD finger will provide valuable insights into the molecular 
pathogenesis of ATR-X syndrome. 
The mutation of PHD reader modules has also been intimately associated with 
the pathogenesis of solid and blood cancers, where recent results support a causal role 
for the deregulated PHD finger in oncogenesis. The mammalian ING family of 
putative tumour suppressors function at the molecular level as chromatin regulatory 
molecules, operating within distinct KAT and KDAC enzyme complexes. Reduced 
expression, somatic mutations and allelic loss of ING proteins are detected in breast 
cancer, gastric cancer, melanoma, glioma and head and neck squamous cell 
carcinoma (HNSCC) (Shi and Gozani, 2005). All ING proteins harbour an essential 
C-terminal PHD finger that specifically interacts with the H3K4me3 modification. 
Mutational screening revealed that specific mutations that abrogate H3K4me3-
binding are found in tumours (Shi and Gozani, 2005), implicating that ING PHD 
functional readout of H3K4 is directly involved during oncogenesis. 
More recent studies have reported a fundamental role for chromatin-binding 
PHD fingers in haematopoietic malignancies. Chromosomal translocations of the 
MLL gene and resultant fusion proteins, such as MLL-ENL, are frequently associated 
with leukaemia. In these translocations, MLL loses the highly conserved three PHD 
finger cassette, SET and activation domains and fuses with a partner protein (ENL) 
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with a transcription activation domain. The expression of the MLL-ENL fusion 
protein in mice leads to HSC immortalisation and the development of myeloid 
leukaemia; effects caused by the aberrant activation of MLL-dependent genes (Chen 
et al., 2008).  The third MLL PHD finger binds the nuclear Cyp33 ligand which 
sequentially recruits HDACs to the MLL repression domain and downregulates HOX 
gene expression. With the loss of PHD3 in MLL-ENL, this repression unit is 
eradicated and replaced with the ENL activation domain switching the fusion protein 
from a repressor to a constitutive activator of MLL-dependent HOX genes. 
Consequent overexpression of MLL target genes blocks HSC commitment and 
orchestrates MLL-related leukaemogenesis (Chen et al., 2008).  
In AML patients, chromosomal translocations fusing the transactivation 
activities of Nucleoporin 98 (NUP98) to a C-terminal PHD finger of JARID1A or 
PHF23 are clinically reported (Baker et al., 2008). These potent oncoproteins arrested 
haematopoietic differentiation where cells proliferate indefinitely as undifferentiated 
progenitors inducing AML. In this process the gain of PHD function was essential for 
malignancy and the minimal requirement for oncogenesis. The fusion NUP98-PHD 
finger specifically recognises and binds to the H3K4me2/3 modification and 
mutations that abolish this interaction also eradicate leukaemic transformation (Wang 
et al., 2009). NUP98-PHD fusions dominate over silencing factors and enforce and 
µORFN¶ GHYHORSPHQWDOO\ FULWLFDO ORFL LQWR DQ DFWLYH WUDQVFULSWLRQ VWDWH FKDUDFWHULVHG
epigenetically by H3K4me3 and induced histone acetylation. Upregulation of such 
developmental transcription factors defines leukaemic stem cells (Wang et al., 2009). 
This study represents a breakthrough in understanding the outcomes of 
Chapter One: Introduction 
92 
 
misinterpreting the histone code, where a direct cause-effect relationship is seen 
between a deregulated chromatin-binding PHD finger and oncogenesis. 
These studies underscore the importance of elucidating the physiological role 
RIHSLJHQHWLFµUHDGHU¶PRGXOHV)XQFWLRQDOLQIRUPDWLRQFRQYH\VYDOXDEOHLQVLJKWVLQWR
normal and pathological development and may accentuate chromatiQ µUHDGHUV¶ DV
potential therapeutic drug targets. 
 
1.12. Lysine Methyltransferases: Structure and Function of 
SUV39H1 
 Histone lysine methylation, with the exception of H3K79, has been shown to 
be catalysed exclusively by the conserved SET domain family of histone 
methyltransferases (Qian and Zhou, 2006). The evolutionary conserved SET domain 
was originally identified as a common motif in the Drosophila position effect 
variegation (PEV) modifier SU(VAR)3-9 (Supressor of variegation) (Tschiersch et 
al., 1994), enhancer of zeste (E(z)) (Jones and Gelbart, 1993) and trithorax (Stassen et 
al., 1995). Since then a large number of SET domain-containing proteins, which 
contain more than 700 members, have been characterised (Qian and Zhou, 2006).   
 The Drosophila Su(var) group of genes suppress PEV and their gene products 
are implicated in the formation of higher order repressive chromatin states. Su(var)3-
9 and the human homologue SUV39H1 encode heterochromatic proteins that harbour 
two of the most prominent evolutionarily conserved domains found in chromatin 
modulators; the chromodomain, implicated in directing the protein to distinct 
chromatin localisations, and the SET lysine methyltransferase domain (Figure 1.12). 
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SUV39H1 is a SET-domain-dependent, H3-specific methyltransferase which 
selectively methylates lysine 9 of the H3 N-terminus; a modification intimately 
correlated to the establishment of heterochromatic regions (Melcher et al., 2000).  
 A major function of the Su(var) genes determines the coregulation of higher-
order chromatin at centromeres and telomeres. More specifically, SUV39H1 was 
found to accumulate at centromeric positions during mitosis and structure-function 
analysis revealed that deregulated SUV39H1 interferes at multiple levels with 
mammalian higher-order chromatin organisation (Melcher et al., 2000). A 
+HWHURFKURPDWLQ 3URWHLQ  ȕ +3ȕ LQWHUDFWLRQ VXUIDFH ZDV PDSSHG WR WKH 1-
terminus of SUV39H1 and together with the adjacent chromodomain, directs the 
specific accumulation of the complex at heterochromatin and the successive 
modulation of a repressive chromatin structure. Further, deregulated SUV39H1 is 
itself redistributed and modulates the consequent localisation of HQGRJHQRXV +3ȕ
from heterochromatic foci to a uniform, broad-specificity distribution throughout the 
entire nucleus (Melcher et al., 2000). 
 Other nuclear processes were found to be sensitive to deregulated expression 
levels of SUV39H1, whereby cells over-expressing SUV39H1 displayed severe 
defects in mitotic progression and chromosome segregation. SUV39H1-
overexpressing cells displayed abnormal nuclear morphologies and severe growth 
retardation, characterised by a delayed progression through the G2/M cell cycle phase 
(Melcher et al., 2000). These cells additionally display compromised chromosome 
segregation potential, exhibiting an increase in the number of cells with polynuclei 
and mitoses with an elevated level of chromosomal bridges and lagging 
chromosomes (Melcher et al., 2000). Altogether, structure-function analysis has 
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revealed a dominant function for SUV39H1 in heterochromatin organisation, 
chromosome segregation and mitotic progression.  
 Alternative observations implicate a function for SUV39H1 in tumour 
suppressor pathways. A mouse knock-out experiment showed that SUV39H1 governs 
H3K9 methylation at pericentric heterochromatin regions and induces a specialised 
histone methylation pattern that differs from the expansive H3K9 methylation present 
at other chromosomal regions (Peters et al., 2001). Furthermore, Suv39h-deficient 
mice exhibit chromosomal instabilities that are correlated with an elevated tumour 
risk and aberrant chromosome interactions during meiosis; defining a crucial role for 
SUV39H1-mediated pericentric H3K9 methylation in protecting genome stability 
(Peters et al., 2001). More recently, a SUV39H1-dependent tumour suppressor 
mechanism has been shown to be induced by oncogenic Ras. In response to 
oncogenic Ras, SUV39H1 induces H3K9me-mediated heterochromatin formation 
and senescence of retinoblastoma (Rb) growth-promoting genes (Braig et al., 2005). 
SUV39H1 deficiency blocks ras-induced senescence and permits the formation of 
aggressive T cell lymphomas (Braig et al., 2005), emphasising the HMTs tumour 
suppressive potential.  
SUV39H1 has also been implicated in the epigenetic control of gene 
expression, where it acts as a corepressor at a number of gene promoters including 
AML1 and p21WAF1. AML1 forms a complex with SUV39H1 (Chakraborty et al., 
2003) and histone deacetylases (Reed-Inderbitzin et al., 2006) to repress transcription 
at AML1-dependent target genes. By binding to AML1, SUV39H1 abrogates 
promoter transactivation by AML1. SUV39H1 exerts its repressor functions by 
interacting with the DNA binding domain of AML1 and thereby, reducing the DNA-
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binding affinity of AML1. Further, coexpression of the two proteins dissociates the 
defined nuclear structure of AML1 from a net-like structure into a diffuse nuclear 
stain (Chakraborty et al., 2003). In addition, SUV39H1 acts in the negative regulation 
of p21, a major cell cycle regulator in the response to DNA damage, cellular 
senescence and tumour suppression. SUV39H1 and COUP-TF-interacting protein 2 
(CTIP2) are recruited to the p21 gene promoter, SUV39H1 induces the methylation 
of H3K9 at the promoter region and both functionally cooperate to silence p21 gene 
transcription (Cherrier et al., 2009).  
Sirtuin 1 (SIRT1) is an NAD+-dependent deacetylase that specifically 
deacetylates H4K16 which as a consequence, through an unknown mechanism leads 
to elevated levels of H3K9me3 (Vaquero et al., 2004). Vaquero et al., go on to 
demonstrate a functional link between the chromatin modifiers SIRT1 and 
SUV39H1, where SIRT1 positively regulates the activity of SUV39H1 during 
heterochromatin formation (Vaquero et al., 2007). SUV39H1 directly interacts with 
SIRT1 through its N-terminal chromodomain and is itself a target for SIRT1 
deacetylase activity. SUV39H1 activity is regulated by acetylation at residue K266 
positioned within its catalytic SET domain and deacetylation of this residue by SIRT1 
augments SUV39H1 activity, resulting in elevated levels of heterochromatin-related 
H3K9me3 (Figure 1.12(A)) (Vaquero et al., 2007). More recently, SUV39H1 activity 
has been shown to be negatively regulated through the interaction with the product of 
the deleted in breast cancer gene (DBC1) (Li et al., 2009). DBC1 disrupts the 
SUV39H1-SIRT1 regulatory complex by specifically interacting with both proteins. 
DBC1 uses the same N-terminal domain to bind SIRT1 and SUV39H1 concomitant 
with its ability to disrupt the complex interaction rather than forming a trimeric 
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complex (Li et al., 2009). Furthermore, DBC1 binds to the catalytic SET domain of 
SUV39H1 abrogating its activity and ability to methylate histone H3 (Figure 1.12(B)) 
(Li et al., 2009). 
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Figure 1.12. Schematic representation of the (A) positive and (B) negative regulation of 
SUV39H1 activity. (A) SIRT1 interacts with and deacetylates lysine 266 of SUV39H1, which 
in turn causes elevated levels of SUV39H1 activity and H3K9me3 modification. The active 
form of SUV39H1 acts as a transcription repressor at gene promoters including AML1 and 
p21. (B) SUV39H1 activity is impaired by acetylation at lysine 266 and the binding of DBC1 
to the SET domain, which both inhibit its ability to methylate histone H3.  
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 1.13. Structure and Function of HP1 
HP1 is a small chromosomal protein first discovered in Drosophila 
melanogaster as a major component of heterochromatin. Mutation of the fly gene 
Su(var)2-5, which encodes the HP1 protein, suppressed the silencing effect of 
heterochromatin in PEV. HP1 was therefore found to function as a dosage-dependent 
modifier of PEV in heterochromatic domains (Eissenberg et al., 1990). HP1 is 
phylogenetically highly conserved and present in almost all eukaryotes with the 
exception of budding yeast (Saccharomyces cerevisiae), but not prokaryotes. 
Generally, the HP1 family of proteins act in the repression of gene activity via the 
establishment and maintenance of higher-order chromatin structures. 
Multiple HP1 members can exist within the same species, for example there 
are three distinct isoforms in the Drosophila and mammalian HP1 families named 
+3DEF DQG +3ĮȕȖ UHVSHFWLYHO\ )LJXUH $ HP1 proteins possess a 
characteristic domain organisation containing two highly conserved domains: an N-
terminal CD and a C-terminal chromoshadow domain (CSD). These two domains are 
separated by a variable linker or hinge region containing a nuclear localisation 
sequence (NLS). The CD is a chromatin binding module that specifically recognises 
and binds to di- and tri-methylated lysine 9 of histone H3. The CD binds the 
methylammonium group of K9 via a cage of three aromatic residues that becomes 
ordered on binding. Other specific sites of the HP1 CD make contact with residues 
surrounding the K9 site of histone H3 and it is these interactions that appear to be the 
key determinant of recognition specificity of this reader module (Nielsen et al., 
2002). The interaction between the CD and the methyl K9 histone H3 mark is 
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important for the recruitment of HP1 to heterochromatic regions of the genome and 
its overall gene-silencing function (Kwon and Workman, 2011).  
The structure and globular conformation of the HP1 CSD is similar to that of 
the CD however, although the CD remains monomeric in solution the CSD has been 
shown to readily dimerise under the same conditions (Cowieson et al., 2000). Upon 
HP1 CSD dimerisation, a prominent non-polar groove is generated at the dimer 
interface that can accommodate HP1-interacting proteins containing the extended 
pentapeptide binding moWLI 3[9ȥȥ ZKHUH ȥ UHSUHVHQWV D K\GURSKRELF UHVLGXH 
(Cowieson et al., 2000). The CSD has been implicated in a wide array of protein-
protein interactions with factors that include transcriptional regulators, chromatin 
modifiers, replication and cell-cycle-related factors and nuclear architecture proteins. 
It is suggested that the CSD may be responsible for the targeting of HP1 to specific 
binding sites within chromatin (Kwon and Workman, 2011). 
The linker region separating the highly conserved CD and CSD is less 
conserved and contains the most variable primary sequence between HP1 proteins. 
Structurally, the hinge region has been proposed to be flexible and exposed to the 
surface (Singh and Georgatos, 2002) and is thereby highly susceptible to post-
translational modifications. Modifications have been shown to impact on the 
localisation, interactions and functions of HP1, highlighting the linker region as a 
possible central control region in the regulation of HP1 proteins (Lomberk et al., 
2006). 
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Figure 1.13. Schematic representation of HP1 paralogs in Drosophila. (A) The HP1 
protein contains an N-terminal chromodomain (CD) and a C-terminal chromoshadow 
domain (CSD), separated by a hinge region. The functional roles of the different domains are 
described. (B) Structural recognition of chromatin by the CD is depicted. The binding pocket 
for the N-methyl group is provided by three aromatic side chains.(PDB 1KNE). (C) The 
CSD is required for HP1 dimerisation and interaction with many proteins that possess a 
FRQVHUYHG 3[9ȥȥ SHQWD-peptide signature. Sequence alignments illustrate acknowledged 
HP1 binding proteins containing this consensus. 
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            The localisation and function of HP1 proteins at heterochromatic regions has 
been well documented. However, emerging studies show that they localise not only to 
heterochromatic domains but also to euchromatic domains (Lomberk et al., 2006). 
The localisation pattern appears to be isoform-VSHFLILFZLWKPDPPDOLDQ+3ĮDQGȕ
EHLQJSUHGRPLQDQWO\KHWHURFKURPDWLFDQG+3ȖEHLQJIRXQGLQHXFKURPDWLQ(Fanti et 
al., 2003). The localisation of HP1 is regulated by a number of distinct factors. 
Firstly, at an epigenetic level, the major mechanism localising HP1 within centric 
heterochromatin is via its CD interaction with methylated lysine 9 of histone H3. 
5HFHQWO\+3ĮKDVDOVREHHQVKRZQWRVSHFLILFDOO\ELQGWRWKH+<UHJLRQYLDLWV
CSD and JAK2-PHGLDWHG SKRVSKRU\ODWLRQ RI WKLV UHVLGXH GLVVRFLDWHV +3Į IURP
chromatin (Dawson et al., 2009). The revelation of novel HP1 recruitment factors 
demonstrates the complexity involved in targeting HP1 to distinct regions in different 
contexts. Alternative mechanisms defining the subnuclear localisation of HP1 involve 
post-translational modification of the HP1 protein itself, interactions between the 
CSD and other protein factors and at the genetic level, direct binding of HP1 to DNA 
(Badugu et al., 2003) and RNA transcripts (Piacentini et al., 2009).  
 The most common of HP1 functions is in the formation of heterochromatin. 
The underlying basis for heterochromatin formation and gene silencing revolves 
around interactions between the HMTase SU(VAR)3-9, HP1 and the H3K9me3 
modification. According to the model, SU(VAR)39 methylates histone H3 at lysine 9, 
creating a binding site for HP1 CD whilst interacting itself with the HP1 CSD. This 
three component complex then forms and allows the spreading of higher order 
chromatin states (Fanti and Pimpinelli, 2008). A recent study implicates HP1 at the 
hub of the spread and assembly of heterochromatin containing H3K9 methylation. 
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Canzio et al., have shown that the S. pombe HP1 homolog, Swi6, recognises the 
H3K9me3 mark at the interface of two CD. This interaction causes Swi6 to tetramise 
on a nucleosome, generating two CD sticky ends which can bridge nearby methylated 
nucleosomes (Canzio et al., 2011). HP1 CD oligomerisation therefore enhances the 
spread of heterochromatin in vivo. 
 In addition to functioning in the formation of heterochromatin and 
heterochromatic gene silencing, HP1 functions in the regulation of gene expression at 
multiple euchromatic sites. In general, HP1 proteins have been shown to decrease 
RNAP occupancy at gene promoters by recruiting silencing factors and creating less 
accessible localiseG FKURPDWLQ VWUXFWXUHV 0RUH VSHFLILFDOO\ +3Ȗ ZDV IRXQG WR
DVVRFLDWHZLWKWKHFRGLQJUHJLRQVRIWUDQVFULSWLRQDOO\DFWLYHJHQHV7HWKHULQJRI+3Ȗ
upstream of a gene promoter prompted silencing concurrent with localised chromatin 
condensation and an increase in H3K9 methylation (Maison and Almouzni, 2004). In 
depth analysis of such events implicated HP1-mediated silencing through the 
targeting of RNAP II coactivator complexes. HP1 was found to inhibit the assembly 
of the PIC in vitro, primarily blocking the addition of key subunits of the TFIID and 
Mediator complexes (Smallwood et al., 2008). 
 A growing body of evidence is also implicating HP1 as a positive regulator of 
gene expression at a subset of euchromatic loci. High resolution mapping 
experiments have shown that HP1 is associated with transcriptionally active 
chromatin in Drosophila (de Wit et al., 2007). Among its numerous euchromatic 
binding sites, detailed mapping has shown its enrichment at developmentally 
regulated chromosome puffs in polytene chromosomes; structures that represent sites 
of intense gene activity. HP1 binds to heat-shocked-induced puffs after induction and 
Chapter One: Introduction 
103 
 
is positively involved in Hsp70 gene activity (Piacentini et al., 2003).  Furthermore, 
HP1c has been shown to interact with the histone chaperone complex FACT. HP1 
guides the recruitment of FACT to active genes and links FACT to active forms of 
RNAP II. In the absence of HP1c the recruitment of FACT into heat shock loci is 
diminished, which subsequently causes a defect in heat shock gene expression (Kwon 
et al., 2010). Collectively, these studies implicate a role for HP1 in positive gene 
expression; however how HP1 proteins mediate this process still remains ambiguous. 
A number of recent studies highlight an emerging role for HP1 proteins in the 
DNA damage response (DDR). Several of these studies have established that 
heterochromatin is inhibitory to the repair process and that reducing levels of HP1 
results in the relaxation of heterochromatin, thus bypassing the requirement for ATM 
signalling and enhancing DNA repair (Ayoub et al., 2008). Ayoub et al. showed that 
DNA-damage induced phosSKRU\ODWLRQ RI WKH &' ORFDWHG 7 UHVLGXH LQ +3ȕ
triggers its dissociation from chromatin by inhibiting its interaction with H3K9me3. 
)ROORZLQJ WKLV WUDQVLHQW GLVSHUVDO RI +3ȕ IURP WKH +.PH PRGLILFDWLRQ +3ȕ
reaccumulates at damaged sites to restore the levels of bound HP1 to heterochromatic 
regions.  
In contrast, more recent studies reveal that HP1 proteins may be involved in 
facilitating the DNA repair pathways in response to different genotoxic stresses. All 
three isoforms of HP1 are recruited to UV-induced DNA lesions in both human and 
mouse cells (Dinant and Luijsterburg, 2009). Despite there being some HP1 
dissociation from H3K9me3 at damaged sites, recent results indicate a net 
accumulation of HP1 through its CSD at damaged chromatin. Moreover, the 
importance of HP1 in the response to UV damage is emphasised by the dramatic 
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sensitivity of nematodes, to UV, lacking functional HP1 proteins (Luijsterburg et al., 
2009). 
 
1.14. Project Aims and Objectives 
MOZ is an essential coactivator for genes that are involved in haematopoietic 
and developmental processes. However, the understanding of the mechanisms 
involved in MOZ function is vague. The dysregulation of MOZ is intimately 
associated with AML, where the oncogenic fusion proteins responsible for AML 
include the entire N terminus of MOZ. Within this segment are three functional 
domains, the H1/5, double PHD finger (DPF) and MYST domain, of which the latter 
is responsible for the proteins biochemical acetyltransferase function. The function of 
the MYST domain has been studied in some depth, however an anomaly still remains 
as to the specific target(s) of MOZ-acetylation; a result of conflicting in vitro and in 
vivo data. In comparison, little is currently known about the functions of the other two 
regions that are present in the fusion protein. Defining the role of the MOZ DPF 
module will shed light on its possible role in target specificity, how MOZ functions 
as a modular protein and consequently, give valuable insight into the mechanisms of 
carcinogenesis associated with MOZ fusion proteins. 
 At the outset of this project it was not known if MOZ could bind histone 
proteins. Thereby, the primary aim of this project was to establish the function of the 
MOZ DPF by carrying out a detailed biochemical characterisation of the interaction 
between the DPF and chromatin. Secondly, we aimed to investigate whether the DPF 
domain influences other biochemical functions of the MOZ protein, including its 
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HAT activity, transcriptional coactivator capabilities and subcellular localisation. The 
final objective was to explore a possible interaction of the MOZ protein with 
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2.1. Sources of Materials 
2.1.1. General suppliers 
 All general laboratory chemicals were of analytical grade and supplied by 
Fisher Chemicals or Sigma Aldrich unless otherwise stated. Phosphate Buffer Saline 
(PBS) was prepared using PBS tablets supplied by OXOID Ltd. Double deionised 
water was used to make all solutions, unless RNase free water was required and then 
deionised water was purified by passage through a Pur1te Neptune water purification 
system.  The pH of solutions was measured using a pH meter (Jenway 3510) against 
solutions of a known pH. Where appropriate, sterilisation was achieved by filtration 
through 0.2 micron filter or by autoclaving for 20 minutes at 120 °C. 
 
2.1.2. Bacterial reagents 
 The bacterial growth medium components, tryptone and yeast extract were 
purchased from OXOID Ltd. Escherichia. coli VWUDLQ '+Į +DQDKDQ  ZDV
purchased from Stratagene. 
 
2.1.3. Molecular biology reagents 
 All restriction enzymes and their respective buffers were purchased from 
Roche Applied Science or New England Biolabs (NEB).  Polymerase enzymes and 
their respective buffers and supplements were purchased from Finnzymes or 
Invitrogen Life Sciences. Molecular size markers and dATP, dCTP, dGTP and dTTP 
were purchased from Invitrogen Life Sciences. Gel extraction kits were obtained 
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from York Biosciences, Nucleospin® plasmid kits from Macherey-Nagel and maxi-
DNA kits from QIAGEN Ltd.  
 
2.1.4. Tissue culture reagents 
 All tissue culture supplements were purchased from Lonza Biowhittaker® and 
plastic-ware was obtained from Helena Biosciences.  
 
2.1.5. Biochemical reagents 
 30 % (w/v) acrylamide mix was purchased from National Diagnostics. SDS-
PAGE electrophoresis apparatus, Precision Protein Standards, wet transfer apparatus 
and Nitrocellulose transfer membrane were all purchased from Bio-rad. Complete 
Protease Inhibitor cocktail tablets were obtained from Roche. All primary antibodies, 
Horseradish peroxidise (HRP) conjugated secondary antibodies, Protein A or G 
sepharose beads were purchased from Abcam, Sigma-Aldrich, Roche and Millipore. 
Radioactive isotopes and Amplify solution were obtained from GE Healthcare. 
Biotinylated histone peptides were purchased from Millipore or custom made by 
Peptide Protein Research and fluoroscein-labelled histone peptides were also custom 
produced by Peptide Protein Research. 
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2.2. Bacterial preparation and culture 
2.2.1. Composition of solutions and media used in bacterial procedures 
Luria-Bertani (LB) medium: 1 % (w/v) tryptone, 0.5 % (w/v) yeast extract 1 % 
(w/v) NaCl (pH adjusted to 7.0). The medium was solidified by the addition of 2 % 
(w/v) bacteriological agar where required. 
Solid Growth Medium: For LB agar plates 1 L of LB medium was supplemented 
with 15 g bacto-agar prior to sterilisation. The appropriate antibiotic was added to the 
molten agar medium and 20-25 ml was poured into each petri-dish and allowed to 
solidify at room temperature. Plates were stored at 4 ºC for up to 1 month. 
Ampicillin: 1000x stock solution: 100 mg/ml in 50 % ethanol. 
Chloramphenicol: 1000x stock solution: 34 mg in 100 % ethanol. 
Kanamycin: 1000x stock solution:  50 mg/ml in H2O. 
 
2.2.2. Culture of Escherichia coli strains 
 The bacterial strain E. coli '+Į ZDV XVHG IRU DOO '1$ PDQLSXODWLRQV
Alternatively, various BL21 strains including the standard BL21(DE3), B834, 
Codon+ and Rosetta were used in optimised protein expression protocols. Single 
colonies of bacteria were obtained by streaking liquid culture onto LB agar plates 
containing the appropriate antibiotic and grown at 37 ºC. Liquid cultures were grown 
by inoculating LB (plus antibiotic) medium with a single bacterial colony. Cultures 
were then incubated in universal tubes (Bibby Sterilin, Staffordshire, UK) or conical 
flasks at 37 ºC with shaking at 220 rpm.  
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2.2.3. Preparation of Escherichia coli competent cells 
 E. coli '+ĮFHOOVZHUHPDGHFRPSHWHQW IRU'1$WUDQVIRUPDWLRQXVLQJ WKH
calcium chloride-magnesium chloride method. A single colony was used to inoculate 
a 2.5 ml LB medium and grown overnight at 37 ºC. The overnight culture was diluted 
1:100 in LB medium and grown at 37 ºC to an Optical Density (OD600 nm) of 0.3. 
The cells were chilled on ice for 20 minutes and consequently harvested by 
centrifugation at 4 ºC, 3500 rpm for 5 minutes. On ice, cell pellets were resuspended 
in 20 ml of ice cold 100 mM MgCl2 and incubated on ice for 5 minutes. After a 
second centrifugation, cells were resuspended in 10 ml ice cold 100 mM CaCl2 and 
incubated on ice for 30 minutes. The cells were harvested by centrifugation and 
finally resuspended in 5 ml CaCl2 solution (70 mM CaCl2, 15 % glycerol). Microfuge 
tubes were placed in liquid nitrogen to allow snap freezing of 200 µl cell suspension 
aliquots. Competent cells were stored at -80 ºC. The transformation efficiency of the 
cells was checked using pcDNA3.1+ vector and the transformation serially diluted to 
allow the determination of the number of transformants: 1 µg DNA should give 
~1x106 transformants. 
 
2.2.4. Transformation into Escherichia coli cells  
DNA products were transformed into competent '+ĮRU%/'( E. coli 
strains. The competent host cells were thawed on ice.  For each of the transformations 
0.5 µg of plasmid DNA was mixed gently with a 50 Pl cell suspension volume and 
incubated on ice for 30 minutes.  The cells were heat shocked at 42 qC for 2 minutes 
before returning to ice for 2 minutes.  After the addition of 500 Pl of LB medium the 
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reactions were incubated at 37 qC for 1 hour. Transformations were spun at 13,000 
rpm for 1 minute to pellet the cells and 350 Pl of supernatant was discarded. Cells 
were resuspended in the remaining LB medium and spread onto LB agar plates 
containing the appropriate antibiotic (ampicillin/ chloramphenicol/ kanamycin). The 
plates were incubated overnight at 37 qC. 
 
2.2.5. Long-term storage of bacterial cultures 
 To preserve transformed bacterial strains for long periods of time, glycerol 
stocks were prepared. Stocks consisted of a mixture of the bacteria in broth with 
sterile glycerol at an 80 % to 20 % ratio respectively. The contents were vortexed and 
stored at -80 ºC. 
 
2.3. Molecular biology techniques 
2.3.1. Composition of solutions used in molecular biology methods 
Gel loading buffer (5x): 15 g Ficoll400 dissolved in 10 ml 10 mM Tris-HCl-pH7.5 
and 50 mM EDTA-pH8.0, containing 0.4 % orange G, 0.03 % bromophenol blue and 
0.03 % xylene cyanol FF. 
Tris-borate-EDTA (TBE): 40 mM Tris-base, 40 mM Boric Acid, 0.5 mM EDTA 
(pH8.0). 
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2.3.2. Small-scale plasmid purification from bacterial cells  
E. coli cultures of 5 ml were grown overnight in an orbital shaker at 37 °C, 
220 rpm. Cells were harvested by centrifugation and the plasmid DNA was recovered 
from the pellet using the NucleoSpin® Plasmid kit (Macherey-Nagel), according to 
manufacturer¶s instructions. DNA was eluted from the NucleoSpin column with the 
supplied Elution Buffer (EB). 
 
2.3.3. Large-scale plasmid purification from bacterial cells 
To obtain a large-scale preparation of plasmid DNA, 250 ml LB media with 
appropriate antibiotic was inoculated with 1/100 fold dilution of suspended cells and 
left to grow overnight at 37 °C, 220 rpm. To isolate plasmid DNA from these cells 
the QIAGEN Plasmid Maxi Kit protocol was used, involving alkaline lysis of the 
cells, followed by immobilisation of the plasmid DNA onto a QIAGEN anion-
exchange resin. Elution and precipitation of the DNA was achieved in isopropanol, 
prior to being washed in 75 % ethanol and dried under vacuum. The resulting DNA 
pellet was resuspended in sterile water. Details of this protocol and the composition 
of buffers used can be found in the QIAGEN maxiprep handbook. 
 
2.3.4. Phenol/chloroform extraction and ethanol precipitation of DNA 
To separate nucleic acids from contaminating proteins, a phenol/chloroform 
extraction was carried out.  An equal volume of phenol:chloroform:isoamyl alcohol 
(25:24:1 saturated with 10 mM Tris pH8.0, 1 mM EDTA) solution was added to the 
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DNA sample to extract protein contaminants. The sample was vigorously mixed until 
an emulsion was formed and spun at 13,000 rpm for 2 minutes in a desk-top 
centrifuge (Heraeus Biofuge pico). The aqueous layer was transferred to a new 
microfuge tube and a further round of phenol:chloroform extraction carried out until 
all protein was removed from the interphase. Following the preceding protocol, 
several rounds of chloroform extraction were used to remove residual phenol. The 
DNA was then collected by ethanol precipitation. 
 
2.3.5. Ethanol precipitation 
DNA was precipitated using 0.1 volumes of 3 M NaOAc (pH5.2) and 2 
volumes of 100 % ethanol. The precipitate was recovered after vigorous mixing by 
centrifugation for 30 minutes at 13,000 rpm, 4 Û& (ALC PK131R, rotor T528).  To 
remove excess salt ions, the pellet was washed with 75 % ethanol and the 
centrifugation repeated. The pellet was dried under vacuum in a heated speed-vac 
(Savant DNA120 speed-vac) for 5 minutes before resuspension in sterile water. 
 
2.3.6. Spectrophotomeric quantification 
The quantification and quality of DNA was determined by optical density 
measurement at 260 nm using the NanoDrop® ND-1000 UV-Vis Spectrophotometer. 
These parameters were also clarified by restriction digest (section 2.3.13) or by 
comparison of DNA samples with molecular weight markers of known concentration 
following separation by agarose gel electrophoresis (section 2.3.8). OD260 nm 
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/OD280 nm values were also calculated and were useful indicators of protein sample 
purity. 
 
2.3.7. Sequencing of plasmid DNA  
Plasmid DNA for sequencing was sent to Geneservice Ltd (Source Bioscience 
Ltd Nottingham, UK) and was sequenced using Big Dye V3.1 chemistry and an 
AB13730xl Automated Sequencer. 
 
2.3.8. Agarose gel electrophoresis 
DNA was fractionated according to size on neutral agarose gels of between 
0.7 % and 2 % agarose (w/v) depending on the size of fragments being resolved. Gels 
containing 0.5 µg/ml ethidium bromide were set and run in 0.5x TBE buffer as 
described in standard protocols (Sambrook J, 1989). DNA samples were loaded in 5x 
gel-loading buffer, alongside Invitrogen standard 1kb DNA ladder (0.2 Pg/Pl).  Bands 
were then visualised using an ultraviolet transilluminator (BioRad Gel Doc 2000) and 
BioRad Quantity One computer software. The approximate size (kb) and 
concentration (ng) of DNA fragments were determined by comparison with standard 
molecular weight markers. 
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2.3.9. Isolation and purification of DNA from agarose gels  
DNA bands to be purified were visualized using an ultraviolet light box and 
excised from the gel after separation by electrophoresis. DNA was purified using the 
York Biosciences Gel/PCR purification kit DFFRUGLQJWRPDQXIDFWXUHU¶V instructions. 
 
2.3.10. Oligonucleotides 
Oligonucleotides were purchased from Sigma Genosys as lyophilised and 
desalted pellets. They were resuspended in sterile water to a 100 µM concentration 
and stored at -20 °C. Oligonucleotides used in this work are listed in appendix tables 
A.1 and A.2. 
 
2.2.11. Polymerase chain reaction (PCR) 
PCR was used to generate DNA fragments needed for the construction of 
recombinant plasmids. To synthesise DNA for cloning purposes, a DNA polymerase 
HQ]\PH ZLWK SURRIUHDGLQJ ¶ WR ¶ H[RQXFOHDVH DFWLYLW\ Phusion® High-Fidelity 
Polymerase (Finnzymes) was used. A typical reaction mixture consisted of 150 ng of 
DNA template and a final concentration of 1x Phusion HF reaction buffer, 0.5 µM of 
both the forward and reverse PCR primers, 0.2 mM of each dNTP, 2 % DMSO, 1.25 
units of Phusion® High-Fidelity DNA polymerase and made up to a final volume of 
50µl with nuclease-IUHHVWHULOHZDWHU5HDFWLRQVXQGHUZHQWDµKRWVWDUW¶3&5PHWKRG
in the Applied Biosystems 2720 thermal cycler. Samples were initially denatured by 
incubating at 98 qC for 30 seconds and then typical thermal cycling parameters were 
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as follows: denaturation, 98 qC for 10 seconds, annealing, 55 qC for 30s and 
extension, 72 qC for 30 seconds per kb of target DNA, for a total of 25-35 cycles.  
The temperature was maintained finally at 72 qC for 10 minutes. Once completed, 10 
% of the PCR reaction was separated by agarose gel electrophoresis to verify that 
correctly sized DNA fragment had been generated. 
 
2.3.12. Generation of mutations/deletions by recombinant PCR 
 To mutate/delete specific nucleotides within a DNA sequence two 
oligonucleotides were designed (Appendix table A.2) and used as primers for PCR as 
shown in Figure 2.1. Primers 1 and 2 were complimentary, except for the nucleotide 
mutations and spanned the region to be mutated. PCR reactions were carried out to 
extend and incorporate the mutagenic primers, resulting in nicked circular strands of 
mutated plasmid DNA. PCR reactions were carried out as described in section 2.3.11 
with the following amendments; 200 ng of DNA template was used and the thermal 
cycling extension time was increased to 20 minutes at 72 °C. PCR products were then 
treated with 0.5 µl Dpn1 restriction enzyme to digest the methylated, nonmutated 
parental DNA template for 2 hours at 37 °C. Control (no oligonucleotides used) and 
sample reactions were separated by agarose gel electrophoresis (section 2.3.8) to 
check for complete digestion of the parental template. The nicked, circular dsDNA 
ZDVWUDQVIRUPHGLQWR'+ĮVHFWLRQDQGWKHUHVXOWLQJVLQJOe colonies used to 
prepare small-scale plasmid DNA preparations (section 2.3.2), which were then sent 
for sequencing (section 2.3.7) to check for the incorporation of the mutated 
nucleotide sequence. 




Figure 2.1. Generation of mutations by recombinant PCR. Recombinant PCR 
can be used in order to create nucleotide mutations within a plasmid construct. Two 
complimentary primers are generated which contain the nucleotide mutation 
LOOXVWUDWHG E\ 9  ȁ DQG XWLOLVHG LQ WKH 3&5 UHDFWLRQ 'XULQJ 3&5 PXWDJHQLc 
primers are annealed to plasmid DNA and extended and incorporated by the action 
of the DNA polymerase, resulting in nicked circular DNA strands. This generates a 
full-length PCR product containing the mutation. Methylated, non-mutated parental 
DNA was then digested using the Dpn1 restriction enzyme and transformed into 
'+ĮE. coli in order to prepare the newly mutated plasmid DNA. 
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2.3.13. Restriction digests 
 Digests of plasmid DNA with restriction endonucleases were used to generate 
compatible ends for cloning and also to verify the insertion of a gene fragment into a 
newly created plasmid. The specific enzymes chosen were dictated by the primer set 
used in the cloning protocol and digests were carried out in the buffers and at the 
temperatures recommended by the manufacturer (Roche). Double digests were 
carried out together where the buffers and temperatures were compatible (both 
enzymatic activities > 75 %), otherwise the reactions were carried out sequentially.  
 Typically, digests were set up in a 20 ȝO UHDFWLRQ YROXPH FRQVLVWLQJ RI 1x 
SuRE/cut reaction buffer, 2 units restriction endonuclease (when a second enzyme 
was used, the total reaction volume was increased to prevent an excess glycerol 
concentration of 10 % that can interfere with the activity and specificity of 
endonuclease enzymes), template DNA (concentration depending on purpose) and 
sterile water up to a final volume of 20 ȝO'LJHVWVZHUHFRPPRQO\FDUULHGRXWDW 
°C for 2 hours unless advised otherwise by the manufacturer. 
 
2.3.14. Phosphatase treatment 
Digested vectors were prepared for ligation by treatment with 1.0 Pl of 
Thermosensitive Alkaline Phosphatase (Promega, 1 U/µl - TSAP) in 1x Promega 
0XOWLFRUH EXIIHU IRU  PLQXWHV at 37 °C.  TSAP catalyses the removal of the 
terminal phosphate groups of DNA, thus preventing reannealing and self ligation of 
linearised cloning vector DNA. Reactions were incubated at 74 °C for 20 minutes to 
irreversibly inactivate TSAP. 
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2.3.15. Ligation reactions 
Recombinant plasmids were generated by annealing cut fragments with T4 
DNA ligase (Promega).  Relative quantities of cut vector and digested inserts were 
determined by agarose gel electrophoresis (section 2.3.8) and spectrophotomeric 
quantification (section 2.3.6). Ligation reactions were set up incorporating a 
vector:insert ratio of 1:2. Typically, 30 ng of vector DNA and 60 ng of insert DNA 
was made up to 8 ȝOZLWKVWHULOHZDWHUDQGLQFXEDWHGDW °C for 5 minutes. T4 DNA 
ligase (1 ȝODQG[7'1$OLJDse reaction buffer (1 ȝOZDVDGGHGDQGWKHOLJDWLRQV
incubated for ~12 hours at 12 °C. Vector only control ligations were also set up as 
above except without the addition of insert DNA. The ligated DNA was transformed 
DQG H[SUHVVHG LQ '+Į E. coli (section 2.2.4), plasmid preparations made (section 
2.3.2) and verified for the correct integration of the gene fragment (2.3.13 & 2.3.16). 
 
2.3.16. Colony PCR screening 
Ligation colonies were picked from LB agar plates and used to inoculate 200 
ȝO of LB (+antibiotic) cultures. These cultures were grown at 37 °C for 2 hours or 
until the culture was turbid. The turbid culture was used as template, in place of DNA 
in proceeding PCR reactions. TaqTM (Thermus aquaticus) DNA polymerase 
(Invitrogen) was used to screen for bacterial cultures containing the appropriate DNA 
insert. Reactions consisted of the same reagents as previously stated with the 
following amendments: 1.25 units of Taq DNA polymerase and its corresponding 
buffer (1x), 1.5 mM MgCl2 and 2.5 µl of bacterial culture instead of DNA template. 
Positive clones were identified by running the entire PCR reaction on an agarose gel 
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(section 2.3.8). Correct insert integration was checked by diagnostic digests (section 
2.3.13). 
 
2.4 Cell culture 
2.4.1. Maintenance of adherent cell lines 
The human osteosarcoma, U2OS, and human embryonic kidney, HEK293 cell 
lines were routLQHO\ PDLQWDLQHG LQ 'XOEHFFR¶V 0RGLILHG (DJOH 0edium (DMEM) 
containing phenol red and supplemented with 1 % (v/v) 0.2 M L-glutamine, 1 % 
Penicillin/Streptomycin antibiotics and 10 % (v/v) heat inactivated fetal calf serum 
(FCS). Cultures were grown in sterile plasticware at 37 °C in a humidified 
atmosphere containing 5 % CO2. Adherent cells were passaged at 90 % confluency 
for a maximum of 30 passages, at which point the cells were discarded. To split cells, 
DMEM was aspirated and the cells washed twice with sterile 1x PBS. 1 ml 
trypsin/EDTA was added (except to HEK293 cell line) and the cells incubated for 2 
minutes at 37 ºC, 5 % CO2. Trypsin was aspirated and the cells were resuspended and 
subsequently diluted in fresh DMEM in 10 cm2 plates (for maintenance) or 6/12-well 
plates (for transient transfections). 
 
2.4.2. Maintenance of suspension cell lines 
The human promyelocytic leukaemia, HL-60 cell line were routinely 
maintained in Roswell Park Memorial Institute medium (RPMI) containing phenol 
red, supplemented with 1 % (v/v) 0.2 M L-glutamine, 1 % Penicillin/Streptomycin 
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antibiotics and 10 % (v/v) heat inactivated FCS. Cultures were grown in sterile plastic 
flasks at 37 °C in a humidified atmosphere containing 5 % CO2. Suspension cells 
were passaged every four days for a maximum of 30 passages, at which point the 
cells were discarded. To passage, cells were first counted. Cells were diluted in a 1:1 
ratio and mixed thoroughly with trypan blue (Autogen Bioclear), loaded onto a 
hepatocytometer (Hawksley, BS.748) and counted under a light microscope (Nikon 
eclipse TS100). Cells were then diluted in fresh RPMI media to a concentration of 
100,000 cells/ml in a sterile tissue culture flask and incubated at 37 ºC, 5 % CO2 (for 
maintenance). To harvest suspension cells for whole cell extract preparation, cells 
were collected at 1250 rpm for 10 minutes at room temperature and the RPMI media 
aspirated. 
 
2.4.3. Cryopreservation of cell lines 
 Cells were incubated with trypsin for 1 minute and after removal were 
returned to the incubator for 5 minutes. Cells were then resuspended in 2 ml of 
appropriate media (for a 10cm2 dish), counted (section 2.4.2) and diluted to the 
appropriate concentration. 400 µl (40 %) of cell suspension in complete media was 
transferred to labelled cryovials containing 100 µl (10 %) DMSO and a supplement 
of 500 µl (50 %) FCS.  The cell suspension was then gently pipetted to ensure even 
mixing of DMSO, FCS and media. The vials were then stored at -20 °C until 
suspensions were frozen solid. The cryovials were then placed at -80 °C overnight, 
after which the vials were stored in liquid nitrogen. 
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2.4.4. Resuscitation of cell lines 
 To recover cells from liquid nitrogen, cells were thawed at 37 °C and 
transferred into 10 ml of pre-warmed supplemented media. The suspension was 
mixed thoroughly and cells harvested by centrifugation at 1250 rpm, 5 minutes to 
remove residual DMSO that could hinder growth. Cells were then resuspended into 
10 ml of fresh media and incubated at 37 °C, 5 % CO2 with humidity. A few hours 
post cell plating the media was changed to remove dead and unattached cells. After 
24 hours the media was then changed one final time, to remove any dead cells. Cells 
were passaged at least three times (left approximately for 12 days) before 
experimental use. 
 
2.4.5. Calcium phosphate-mediated transfection of adherent cells 
Adherent cells were seeded at 20 % confluency in 10 cm plates 24 hours prior 
to transfection. The following day, DMEM was replaced with fresh media 3-4 hours 
prior to transfection. For transient transfections, 50-80 % subconfluent cells were 
transfected by using the calcium phosphate coprecipitation method. Cells were 
transfected with X µg of the appropriate plasmid DNA (quantity requires 
optimisation for each plasmid) and empty vector to standardise the quantity of DNA 
in each sample. To each sample 12.5 % (v/v) 2 M calcium chloride solution was 
added and made up to a final volume of 800 µl with sterile nuclease-free water 
pH7.0. This mixture was added dropwise to an equivalent volume of 2x Hepes 
Buffered Saline (HBS) solution whilst vortexing gently. After a 20 minute incubation 
at room temperature, 1.5 ml was added dropwise to the appropriate cell plate. 
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Following a 16 hour incubation at 37 °C, 5 % CO2, cells were washed thrice with 1x 
PBS and maintained in DMEM for a further 24 hours. Cells were lysed at the 
appropriate time post transfection (24-48 hours). 
 
2.5. Biochemical techniques 
2.5.1. Composition of solutions used in biochemical methods 
Lysis buffer: 20 mM sodium phosphate (pH7), 250 mM NaCl, 30 mM sodium 
pyrophosphate, 0.1 % NP-40, 10 mM NaF, 0.1 mM Na3VO4, 1 mM PMSF, 1x 
Complete protease inhibitors. 
Cytosol/Nuclear (C/N) Fractionation Buffer A: 10 mM HEPES pH7.9, 10 mM 
KCl, 0.1 mM EGTA, 1 mM PMSF, 1 mM DTT, 1x Complete protease inhibitors. 
C/N Fractionation Buffer B: 20 mM HEPES pH7.9, 400 mM NaCl, 1 mM EGTA, 1 
mM PMSF, 1 mM DTT, 1x Complete protease inhibitors, 10 % glycerol. 
RIPA Lysis Buffer: 10 mM Tris-HCl pH8, 0.5 mM EGTA, 140 mM NaCl, 1 % 
Trition X-100, 0.1 % sodium deoxycholate, 0.3 % SDS, 1 mM PMSF, 1x Complete 
protease inhibitors. 
Chro-IP  Lysis Buffer: 5 mM Tris-HCl pH8, 85 mM KCl, 0.5 % NP-40, 1 mM 
PMSF, 1x Complete protease inhibitors. 
Wash Nuclei Buffer: 10 mM Tris-HCl pH8, 0.5 mM EGTA, 200 mM NaCl, 1 mM 
PMSF, 1x Complete protease inhibitors. 
LOW Salt Buffer: 150 mM NaCl, 20 mM Tris-HCl pH8, 1 % Trition X-100, 0.1 % 
SDS. 
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HIGH Salt Buffer: 500 mM NaCl, 20 mM Tris-HCl pH8, 1 % Trition X-100, 0.1 % 
SDS. 
LiCl Buffer: 0.25 M LiCl, 10 mM Tris-HCl pH8, 1 % Sodium deoxycholate, 1 % 
NP-40. 
SDS-PAGE loading buffer (4x): 62.5 mM Tris-HCl pH6.8, 40 % glycerol, 2 % 
SDS, 14.5 mM 2-ȕ-Mercaptoethanol and a trace of bromophenol blue. 
Tris-glycine-SDS PAGE running buffer (10x): 250 mM Tris base, 2 M Glycine, 35 
mM SDS pH8.3. 
Tris-glycine-SDS transfer buffer (standard): 48 mM Tris base, 39 mM glycine, 
0.037 % (w/v) SDS, 20 % (v/v) methanol. 
Tris-glycine-SDS transfer buffer (for high molecular weight protein transfer): 48 
mM Tris base, 380 mM glycine, 0.037 % (w/v) SDS, 20 % (v/v) methanol. 
Brilliant Blue® staining solution: 0.25% brilliant blue® (w/v) in 45% methanol, 
10% acetic acid. 
Destaining solution: 45 % methanol, 10 % acetic acid. 
ECL developing solution: 1 ml Tris-HCl pH8.5, 6 µl H2O2, 22 µl solution A (90 
mM p-Coumari Acid in DMSO), 50 µl solution B (250 mM Luminol in DMSO) to a 
final volume of 10 ml with ddH2O. 
Fix solution: 45 % methanol, 10 % acetic acid. 
NTN buffer: 20 mM Tris-HCl pH8.0, 100-500 mM NaCl, 0.5 % NP-40, 1x 
Complete Protease Inhibitors (Roche). 
Glutathione Elution Buffer: Freshly prepared, 30 mM reduced glutathione, 50 mM 
Tris-HCl pH9, 150 mM NaCl, 0.1 % Triton X-100. 
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Binding buffer:, 50 mM Tris-HCl pH7.5, 300 mM NaCl, 0.1 % NP-40, 1 mM PMSF 
1x Complete Protease Inhibitors. 
Blocking solution (for western blotting): 5 % (w/v) milk powder in 1x PBS. 
Stripping buffer (for western blotting): 62.5 mM Tris-HCl pH6.8, 2 % SDS, 100 
mM 2-ȕ-Mercaptoethanol. 
10x HBS solution: 1.37 M NaCl, 50 mM KCl, 8 mM Na2HPO4, 55 mM D-glucose, 
210 mM HEPES. 
Mounting media: 90 % Glycerol, 10% PBS. 
2x HAT Buffer: 100 mM Tris-HCl pH8.0, 20 % glycerol, 20 mM butyric acid, 2 
mM PMSF, 2 mM DTT. 
 
2.5.2. Preparation of whole-cell extracts 
 Cells were harvested by aspirating the DMEM media and scraping the cell 
layer off in 1 ml sterile 1xPBS. Cells were collected by centrifugation at 13,000 rpm, 
the supernatant removed and washed twice in PBS. Cells were resuspended in cold 
lysis buffer (2x cell compact volume) and incubated for 30 minutes, 4 ºC with 
rotation. The cells were then snap frozen in liquid nitrogen, thawed in cold water and 
run over an eppendorf rack 10 times to ensure efficient lysis. Samples were again 
snap frozen in liquid nitrogen and thawed in water a further two times. If samples 
were viscous an optional sonication step was included (3x 20 sec on/30 sec off). 
Cellular debris was pelleted by centrifugation at 12,000 rpm at 4 ºC for 30 minutes. 
The cell-free extract (supernatant) was transferred to a fresh tube and stored at -80 ºC. 
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2.5.3. Preparation of cytoplasmic and nuclear extracts 
 Cells were harvested by aspirating the DMEM media and scraping the cell 
layer off in 1 ml sterile 1x PBS. Cells were collected by centrifugation at 13,000 rpm, 
the supernatant removed and washed twice in PBS. The cell pellet was resuspended 
in ice-cold C/N buffer A (approximately 3x cell compact volume) and incubated on 
ice for 10 minutes. A 0.5% final concentration of NP-40 was added to each sample, 
vortexed for 20 s, ice for 5 minutes and finally vortexed for a further 20 s. Samples 
were then spun at 13,000 rpm for 30 s and the supernatant (cytosolic fraction) was 
transferred to a fresh eppendorf tube. The resulting pellet was resuspended in C/N 
Buffer B and incubated on ice for 40 minutes. During this time period samples were 
vortexed for 15 s every 5 minutes. Again, samples were spun at 13,000 rpm for 20 
minutes at 4 °C and the supernatant (nuclear fraction, nucleic acid-binding fraction) 
transferred into an ice-cold eppendorf tube. In order to extract any remaining 
insoluble proteins from the cellular debris, the pellet was finally resuspended in RIPA 
buffer. Samples were sonicated for 8 minutes 15 s on/ 15 s off and the cellular debris 
pelleted by centrifugation at 13,000 rpm, 20 minutes, 4 °C. The supernatant (nuclear 
fraction, insoluble nuclear protein fraction) was transferred to a fresh tube and all 
fractions stored at -80 ºC. 
 
2.5.4. Protein concentration determination 
 Protein concentrations were determined using the Bradford assay method and 
the Bio-5DG G\H FRQFHQWUDWH DFFRUGLQJ WR PDQXIDFWXUHU¶V LQVWUXFWLRQV. Typically, 
reactions were set up consisting of 2 µl of sample and 1 ml 20 % dye in ddH2O. The 
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samples were mixed thoroughly and left to stand at RT for 20 minutes. Absorbancies 
were read at 595 nm and the concentration calculated relative to values of diluted 
Bovine Serum Albumin (BSA) standards of known concentrations. 
 
2.5.5. Sodium-dodecyl-sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Cell extracts, Immunoprecipitations (IP), purified and in vitro translated 
proteins were analysed by one-dimensional polyacrylamide gel electrophoresis. SDS-
PAGE gels were prepared with the appropriate percentage resolving and stacking gel 
(table 2.1), depending on the molecular weight of the protein being analysed. Protein 
extracts were denatured by boiling for 5 mins in 4x SDS-PAGE loading buffer prior 
to being resolved on an 8-15 % SDS-polyacrylamide gel. Gels were electrophoresised 
using a mini-gel system (Protean II, Bio-Rad) in 1x running buffer at a constant 
voltage. 
 
2.5.6. Staining of SDS-polyacrylamide gels 
Gels were incubated in 0.25 % Brilliant blue stain for 30 minutes, followed by 
two rounds of 30 minute incubation in destain solution. To completely destain the 
gel, a final overnight incubation in distilled water was necessary. In order to preserve 
the stained gels, they were placed on filter paper, covered with Saran wrap and dried 
(80 °C, 1 hr) under vacuum (Biorad Hydrotech Vacuum Pump and Gel Dryer). 
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 Resolving Gel Stacking Gel 
% Acrylamide 8 12 15  
ddH20 (ml) 2.3 1.6 1.1 1.4 
30% acrylamide mix (ml) 1.3 2.0 2.5 0.33 
1.5 M Tris (pH 8.8) (ml) 1.3 1.3 1.3 - 
1.0 M Tris (pH 6.8) (ml) - - - 0.25 
10 % (w/v) SDS (ml) 0.05 0.05 0.05 0.02 
10 % (w/v) ammonium persulphate (ml) 0.05 0.05 0.05 0.02 
TEMED (ml) 0.003 0.002 0.002 0.002 
 
Table 2.1. Solution compositions for resolving and stacking gels for SDS-
polyacrylamide gel electrophoresis. The volumes of the components stated are for 
the production of one 5 ml resolving gel and one 2 ml stacking gel.  
 
2.5.7. Western blotting and immunodetection 
Proteins separated on SDS-PAGE gels for western blotting were transferred to 
nitrocellulose membranes by electrophoresis in 1x transfer buffer using wet transfer 
apparatus. Membranes were stained in 1 % Ponceau S solution and then washed with 
sterile water to check the transfer efficiency. Ponceau S stained membranes were then 
photographed using the imager. 
Nitrocellulose membranes containing immobilised proteins were incubated in 
blocking buffer for 1 hour at room temperature to block non-specific antibody 
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binding sites. Membranes were consequently incubated with primary antibody at 4ºC 
overnight. Primary antibodies were prepared in blocking buffer at dilutions indicated 
in appendix table A.5. The nitrocellulose membrane was washed three times (3 x 5 
min) in 1x PBS containing 0.1 % Tween 20, before the addition of the appropriate 
secondary antibody for 90 minutes at room temperature. HRP-conjugated secondary 
antibodies were diluted 1:3000 in blocking buffer. Excess secondary antibody was 
removed by three more washes (3 x 5 min) in 1x PBS containing 0.1 % Tween 20. 
Protein:antibody complexes were detected by ECL chemiluminescence. Membranes 
were covered for 1 minute with 5ml of ECL developing solution, excess reagent was 
drained off and the membrane wrapped in saran wrap. The chemiluminescent signal 
was then read by the Luminescent image analyser (Fujifilm LAS-4000). For re-use 
with other primary antibodies, membranes were stripped by incubation in stripping 
buffer for 30 minutes at 55 ºC with occasional agitation. The membranes were then 
thoroughly washed and incubated in blocking solution as above and re-probed with a 
different primary antibody.  
 
2.5.8. In vitro transcription and translation (IVT) of expression vector-
encoded cDNA  
 cDNAs cloned into expression vectors under the control of the T7 or SP6 
promoter were transcribed and translated in vitro in a coupled reaction using the 
TNT® Coupled Reticulolysate System (Promega). Briefly, 1-2 µg of plasmid DNA 
(containing a T7/SP6 promoter) was mixed with 10 µl rabbit reticulolysate, 0.8 µl 
TNT reaction buffer, 0.4 µl T7/SP6 RNA polymerase, 0.4 µl amino acid mix (minus 
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Methionine), [35S]- Methionine (500 µCi/ 18.5 MBq, MP Biomedicals), 0.4 µl 
RNasin Ribonuclease inhibitor (Promega) and nuclease-free water to 20 µl. The 
mixture was incubated for 90 minutes at 30 ºC. 1 µl of each sample was then loaded 
onto an SDS-PAGE gel (section 2.5.5) to determine the efficiency of translation. The 
remaining IVT sample was stored at -80 ºC. 
 
2.5.9. Fixing and amplifying radioactive gels 
Radioactive gels were fixed in 10 % (v/v) glacial acetic acid, 45 % methanol 
(v/v) solution for 30 minutes at room temperature. The gels were then placed for a 
further 30 minutes in 15 ml Amplify solution (Amersham). The gels were then placed 
on Whatmann filter paper, covered in Saran wrap and dried under a vacuum at 80 ºC 
for 1 hour. 
 
2.5.10. Exposure of radioactive gels to X-ray film  
Dried gels were exposed to Kodak Biomax film in a Kodak Intensifying 
Screen (low energy) at -80 ºC for between 16 hours and 1 week depending on the 
intensity of the signal of the IVT sample.  The following day, the film was developed 
in the Curix 60 AGFA developer. 
 
2.5.11. Co-immunoprecipitation 
 Protein extraFWV  ȝJ REWDLQHG IURP PRFN DQG FR-transfected cells were 
GLOXWHGWRȝOZLWKO\VLVEXIIHU,QRUGHUWRSUH-clear and remove unspecific extract 
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ELQGLQJSURWHLQVȝORI3URWHLQ*$JDURVH (Roche) was added to each sample and 
incubated for 1 hour 4 °C with rotation. Samples were spun at 2,000 rpm for 2 
minutes to pellet Protein-G beads and the extracts transferred to a fresh tube. Next, 2 
ȝJRIDQWLERG\ZDVDGGHGDQGVDPSOHVZHUHLQFXEDWHGRYHUQLJKWDW&ZLWKURWDWLRQ
(a no antibody control was also carried out with the co-transfected sample). Protein-G 
beads were pre-ZDVKHGLQO\VLVEXIIHUȝODGGHGWRHDFK,3DQGVDPSOHVLQFXEDWHG
for a further 4 hours at 4 °C with rotation. Immunoprecipitations were washed thrice 
in lysis buffer and subsequently subjected to SDS-PAGE (section 2.5.5) and 
immunodetection (section 2.5.7) alongside a 10 % input as a control.  
 
2.5.12. Chromatin immunoprecipitation (ChIP) assays 
 Cells were counted using a hepatocytometer and aliquoted into 10.5x106 
cells/ml in 50 ml falcon tubes. Cells were harvested at 2,000 rpm, 5 minutes at RT 
and subsequently, washed twice in 10 ml 1xPBS. To crosslink cells, 1 % 
formaldehyde was added dropwise and incubated with agitation for 10 minutes. A 
final concentration of 0.125 M glycine was then added for 5 minutes to stop the 
crosslink reaction. Cells were pelleted by spinning at 2,000 rpm, 5 minutes at 4 °C 
and washed twice in ice cold 1x PBS. At this stage of the protocol crosslinked 
samples could be snap frozen in liquid nitrogen and stored at -80 °C until ready for 
use. 
 To prepare chromatin from cells, they were firstly resuspended in 1 ml Chro-
IP buffer and incubated on ice for 15 minutes. Cells were harvested by spinning at 
2,000 rpm, 5 minutes, 4 °C, resuspended in 1 ml wash nuclei buffer and left on ice for 
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5 minutes. After further spinning, the pelleted cells were resuspended in 600 ȝO5,3$
lysis buffer, incubated on ice for 15 minutes and sonicated (10s on/30s off) on ice for 
4 minutes. After sonication, cells were spun down at 14,000 rpm, 10 minutes, 4 °C 
and the supernatant (chromatin) transferred to a new tube. It was desirable for the 
chromatin to be chopped into DNA fragment sizes of 200-300 bp, so in order to 
check the size of the fragmented chromatin the following steps were carried out. 
Aliquots of 50 ȝORIFKURPDWLQZHUHLQFXEDWHGZLWK ȝORIGG+2O and NaCl (final 
concentration 0.3 M) at 65 °C overnight to reverse the crosslink. 20 ȝJRI51$VHZDV
then added per 100 ȝO VDPSOHDQG LQFXEDWHG for 10 minutes 37 °C. DNA was then 
purified with a PCR clean up kit (Macherey Nagle), eluted in 30 ȝOEB and run on a 
0.8 % agarose gel to check fragment size. 
 )ROORZLQJFKURPDWLQLVRODWLRQDQ,3DVVD\ZDVFDUULHGRXWȝOof Protein-G 
beads were used per IP reaction DQGȝOSHU,3IRUWKHSUHFOHDULQJVWHS3rior to IP, 
Protein-G beads were blocked with 1 mg/ml BSA and 0.25 mg/ml sheared salmon 
sperm DNA and incubated overnight at 4 °C with rotatiRQȝJRIFKURPDWLQZDV
diluted in RIPA buffer and SUHFOHDUHGZLWKȝOSUHEORFNHGProtein-G beads for 2 
hours, 4 °C. Beads were harvested, the supernatant transferred to a fresh tube and 
LQFXEDWHGRYHUQLJKWZLWKȝJRIDQWLERG\SHU,3DW&3UHEORFNHGEHDGVȝO
were then incubated with the IP samples for 2 hours at 4 °C. Beads were 
consequently washed once in RIPA, twice in LOW salt, twice in HIGH salt, twice in 
LiCl and twice in TE buffers. Following the stringent washing steps, ChIP samples 
were analysed by SDS-PAGE (section 2.5.5) and immunodetection (section 2.5.7).  
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2.5.13. Small-scale bacterial expression of GST-tagged proteins 
Freshly transformed colonies were inoculated into 2.5 ml of LB-Ampicillin 
media. After 2 hours growth at 37 °C, 1 ml was placed into 2 microcentrifuge tubes. 
As a control 25 µl of water was added to one and 25 µl of 20 mM IPTG inducer (final 
concentration 0.5 mM) to the other. The remaining 0.5 ml was kept at 4 °C for future 
inoculation of large-scale cultures. After a further 2 hours growth at 37 °C, cells were 
harvested by centrifugation at 13,000 rpm for 5 minutes and the pellets resuspended 
in 15 µl 4x SDS loading buffer. Samples were boiled for 5 minutes and loaded onto 
an SDS-PAGE gel. Induced cultures were run alongside the appropriate control 
culture, followed by brilliant blue staining to detect the presence of an induced band. 
 
2.5.14. Large-scale bacterial expression of GST-tagged proteins 
The remaining 0.5 ml from bacterial cultures that showed good protein 
induction was used to inoculate 50 ml LB(+antibiotic) medium and left to grow 
overnight at 37 °C with 220 rpm shaking. The following day 1 L LB(+antibiotic) 
media was inoculated with the overnight culture and grown at 37 ºC until cells 
reached exponential phase (OD600 0.8-0.9). A sample was transferred to a 
microcentrifuge tube (uninduced) and IPTG added to a final concentration of 0.3 
mM.  The cultures were incubated for a further 3-16 hours at 37-20 ºC (conditions 
optimised for each protein) and subsequently, a second sample was taken 
representing the induced fraction. Cells were harvested by centrifugation at 5,500 
rpm for 20 minutes at 4 °C (Sorvall Evolution RC rotor SLA-1500) and the pellet was 
frozen until ready for purification.  
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2.5.15. Purification of GST-tagged proteins 
Induced bacterial pellets from 1 L cultures were resuspended in NTN buffer 
and sonicated for 5 minutes (30 sec on/ 30 sec off, Jenway). Cell debris was cleared 
by centrifugation at 18,000 rpm for 1 hour at 4 °C (Sorvall Evolution RC rotor SS-
34), the supernatant transferred to a 15 ml falcon and a 20 µl sample removed. 200 µl 
of glutathione sepharose beads (GE Healthcare) were washed 4 times with an equal 
volume of 0.5 % milk in NTN buffer. On the last wash, beads were collected by 
centrifugation at 2,000 rpm for 2 minutes and resuspended in the NTN/milk buffer. 
200 µl of bead slurry was added to the cleared bacterial supernatant and placed on a 
rotating wheel overnight at 4 °C. The glutathione beads were collected by 
centrifugation and a sample of the aspirated supernatant kept for future analysis. The 
beads were washed 3 times with NTN (2x 300 mM, 1x 100 mM NaCl) and finally, 
resuspended in 1 ml of the buffer and stored at 4 ºC. SDS-PAGE was used to 
establish the level of Glutathione-S-Transferase (GST)-fusion protein induction and 
to monitor the success of purification at different stages of the procedure. 
 
2.5.16. Elution and preparation of GST-tagged protein 
To elute the GST-fusion proteins off the glutathione sepharose, beads were 
collected by centrifugation at 2,000 rpm for 2 minutes and the supernatant removed. 
600 µl glutathione buffer was added to beads and the samples were placed on the 
rotating wheel overnight at 4 °C. Samples were spun to collect the beads and the 
supernatant transferred to a fresh eppendorf tube. A second round of elution was 
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carried out as above for 4 hours to ensure the complete recovery of GST-tagged 
protein. 
The sample next underwent desalting and buffer exchange to remove low 
molecular weight compounds such as glutathione. This procedure was carried out 
using PD-10 desalting columns (containing SephadexTM G-25 medium, Amersham). 
The bottom cap of the column was cut off, excess fluid removed and then the column 
was secured in a clamp. The column was equilibrated with approximately 25 ml of 
coupling buffer which was allowed to pass through by gravity-flow. The flow-
through was discarded and a total volume of 2.5 ml protein sample (in binding buffer) 
was added to the column. Once again the flow-through was discarded and finally the 
GST-tagged protein was eluted with 3.5 ml of binding buffer and the flow-through 
collected. 
The GST-tagged protein was then concentrated to a total volume of 500 µl in 
a Vivaspin 2 ml concentrator (Vivascience). Samples were spun at 3,000 rpm, 4 ºC 
for 3-6 hours (eppendorf centrifuge) until the sample volume had reduced to 500 µl. 
The concentration of the protein was determined by Bradford assay and SDS-PAGE 
analysis against BSA standards of known concentration. Protein was next distributed 
into 20 µl aliquots and stored at -80 ºC. 
 
2.5.17. GST-pulldown of histone extracts 
Normalised levels of GST-tagged fusion protein were determined by SDS-
PAGE analysis. The desired amount of fusion protein (approximately 1.5 µg) was 
incubated with 10 µg calf thymus histone extracts (Sigma), overnight at 4 ºC with 
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rotation in 750 µl of NTN buffer. The beads were then washed three times in NTN 
buffer, dried under vacuum (Savant DNA120 Speedvac), boiled in 20 µl of SDS-
PAGE sample buffer and run on an SDS-PAGE gel to check for protein-histone 
interaction. 
 
2.5.18. GST-pulldown of mammalian expressed protein 
 Normalised levels of GST-tagged fusion protein were determined by SDS-
PAGE analysis. The desired amount of fusion protein (approximately 1.5 µg) was 
incubated with IVT protein (section 2.5.8) or 500 µg of whole cell extract (section 
2.5.2), overnight at 4 ºC with rotation in 750 µl of NTN buffer or cold lysis buffer 
respectively. The beads were then washed three times in the appropriate buffer, dried 
under vacuum (Savant DNA120 Speedvac), boiled in 20 µl of SDS-PAGE sample 
buffer and run on an SDS-PAGE gel to check for protein-protein interaction. Results 
were visualised via autoradiography (section 2.5.9-10) or western blotting (section 
2.5.7). 
 
2.5.19. Peptide binding assay 
 Normalised levels of in vitro translated protein or 1.5 ȝJ RI purified GST-
tagged fusion protein (molarity values: GST- 75 nM; GST-MOZ 1-321- 32 nM; GST-
MOZ DPF- 49 nM; GST-MOZ PHD1- 58 nM; GST-MOZ PHD2- 59 nM) was 
incubated with approximately 1.5 ȝJor 735 nM of biotin conjugated histone peptide 
(Millipore/Peptide Protein Research) or no peptide as control. Reactions were 
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incubated overnight with rotation at 4 °C in 750 µl Binding buffer (buffer 
composition section 2.5.1., p125). For simultaneous binding assays and titrations 
involving two peptides, a combined total of 735 nM peptide was used. A slurry of 15 
µl Dynabeads® (M-280 Streptavidin-Invitrogen) were prewashed twice in 1x PBS + 
0.1 % Tween and added to each reaction. The incubation with Dynabeads® took place 
for 1 hour at 4 °C. Dynabeads® were harvested using a magnet and consequently 
washed (3x10 minutes) in binding buffer. Samples were then subjected to SDS-
PAGE (section 2.5.5) and results either visualised by autoradiography (sections 2.5.9-
2.5.10) for IVT radio-labelled proteins or by immunodetection (section 2.5.7) with an 
Į-GST antibody (Sigma).  
 
2.5.20. Luciferase reporter assays 
Unless otherwise stated reporter assays were carried out in U2OS cells. 
Adherent cells were seeded at 3x105 cells/well in 12-well plates. Transfections were 
carried out using the calcium phosphate coprecipitation method (section 2.4.5). Per 
well, cells were transfected with 500-1000 ng of MOZ expression plasmid, 500 ng of 
reporter plasmid (pT109 - 3xAML1-luc) and 100 QJ RI ȕ-JDODFWRVLGDVH ȕ-GAL) 
internal control plasmid. The total amount of DNA per well was standardised with the 
addition of pcDNA3.1(+) empty vector plasmid DNA. Reporter assays were carried 
out in triplicate for each condition. Samples were briefly vortexed, added dropwise to 
2x HBS and incubated for 20 minutes prior to the addition to cells. Cells were washed 
in sterile PBS and fresh media added 16 hours post transfection. The cells were then 
O\VHGKRXUVDIWHU WUDQVIHFWLRQ/\VLVZDVFDUULHGRXWDFFRUGLQJWRPDQXIDFWXUHU¶V
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instructions (Applied Biosystems). Briefly, cells were washed twice in PBS and 100 
µl lysis solution added to each well. Plates were then placed at -80 °C to snap freeze 
the lysates and stored at this point until ready to conduct the reporter assay.  
Cells were then assayed using the Dual-OLJKW/XFLIHUDVHDQGȕ-GAL reporter 
gene assay system (Applied Biosystems). Plates were thawed and the remaining cells 
attached to the plates were scraped into the lysis solution and transferred to sterile 
eppendorf tubes. Lysates were spun at 12,000 rpm, 4 °C, 5 minutes to pellet any 
cellular debris. The reporter assays were carried out in white-walled 96 well plates 
(Nunc). Per well 5 µl of protein lysates was added, followed by 12.5 µl of Buffer A. 
The assay was carried out according to instructions from here on, utilising the 
provided Buffer B with the addition of 1:100 galactone and accelerator solution. 
Luminescence was detected on a Berthold Orion Microplate Luminometer.  
To analyse results, each Luciferase reading was cRUUHFWHGWRWKHȕ-GAL value. 
7KHȕ-GAL dependent luminescence served as both a transfection efficiency control 
and a loading control for the assay. Values were expressed as Relative Luciferase 
Units (RLU). MOZ dependent transactivation of the reporter constructs was then 
expressed as a fold change between cells expressing MOZ and those transfected with 
the appropriate empty vector. This was necessary as some cellular factors were able 
to stimulate a basal activity of the Luciferase reporter. Protein expression was 
confirmed for each of the reporter lysates by SDS-PAGE analysis and 
immunoblotting (sections 2.5.5, 2.5.7). 
 
Chapter Two: Materials and Methods 
139 
 
2.5.21. Indirect immunofluorescence 
3 x 105 cells were seeded onto 25 mm coverslips in 6 well tissue culture plates 
and when fully adherent, were transfected with the appropriate plasmid DNA via the 
calcium-phosphate mediated method (section 2.4.5). 48 hours post-transfection the 
following steps were performed at room temperature with the coverslip undisturbed 
in the well. Cells were gently washed twice with PBS and fixed by incubation for 10 
minutes with 4 % (w/v) paraformaldehyde. Cells were washed four times in PBS to 
remove excess fixative and permeabilised by incubation for 2 minutes with 0.2 % 
(v/v) Triton-x-100 (in PBS). Cells were washed as above, and non-specific binding 
sites blocked by incubation in 3 % (w/v) BSA (in PBS) for 30 minutes. Primary 
antibodies were prepared in 3 % (w/v) BSA (in PBS) blocking reagent at dilutions 
specified in appendix table A.5 to a final volume of 50 ȝO7RSUHYHQWWKHFRYHUVOLS
drying out, a large sheet of blue towel was soaked in water and placed in a sealed 
container. 50 ȝORISULPDU\DQWLERG\ was pipetted onto parafilm and coverslips were 
inverted (cell side down) onto the sample and incubated for 90 minutes in the sealed 
container creating a semi-humidified environment. The coverslips were replaced into 
the 6 well dish and washed as above. Alexa-488 or Alexa-594-conjugated secondary 
antibodies were prepared in blocking reagent at a 1:500 dilution and 500 ȝOXVHGWR
cover the cells. Cells were incubated for 30 minutes and covered with an aluminium 
foil box. Control cells were incubated in solely secondary antibody to determine the 
level of background fluorescence. The cells were washed again in PBS and finally 
incubated with 1:10,000 diluted Hoechst stain for 10 minutes. After a final set of 
washes in PBS the coverslips were removed from the wells, drained of excess 
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solution and placed cell side down onto 10 µl mounting media spotted onto a 
microscope slide. Coverslips were then secured to the slide by adding a thin layer of 
clear nail varnish around the perimeter and allowed to dry. Slides were stored at 4 °C, 
protected from light. Immunofluorescence images were captured using a Zeiss 
LSM510 Meta confocal microscope and images were processed in the LSM Zeiss 
Image Browser.  
 
2.2.22. Fluorescence polarisation 
Fluorescence polarisation assays were performed for MOZ DPF binding to N-
terminally fluoroscein labelled peptides of unmodified and modified histone H3 
(amino acids 1-21) and histone H4 (amino acids 2-24). Protein concentrations were 
determined by SDS-PAGE analysis relative to the BSA protein standard. 
Fluorescence polarisation assays were performed in black polypropylene 384-well 
plates (Fisher) with 1 nM fluoroscein-labelled peptide and varying concentrations of 
MOZ DPF protein in binding buffer. Measurements were obtained after a 20 minute 
incubation at 25 °C using a fluorescence polarisation reader (Perkin Elmer).  
 
2.5.23. In vitro histone acetyltransferase (HAT) assay 
Approximately 1.5 µg of purified HAT protein (molarity values: GST-MOZ 
DPF, 905 nM; GST-MOZ MYST, 620 nM; GST-MOZ DPF+MYST, 395 nM) was 
mixed with 1 µl of a histone mixture (10 mg/ml) RUȝJKLVWRQHSHSWLGH, ȝO
%6$  PJPO ȝO [+$7EXIIHU DQG PDGHXS WR D ILQDO 0 µl volume with 
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double-distilled water.  The following control reactions were set up; Acetyl-CoA 
only, no HAT, and HAT without histones, in order to obtain background readings. 
Samples were then incubated for 2 minutes at 30 ºC EHIRUH WKH DGGLWLRQ RI  ȝO
radio-labelled acetyl-CoA[3+@ ȝ0 Samples were incubated for a further 30 
minutes at 30 ºC. For kinetic assays samples were taken after the specified time at 30 
°C. 1H[WȝO WULSOLFDWHVZHUHDOLTXRWHG LQWRHSSHQGRUIVFRQWDLQLQJȝO[6'6
GLB and boiled to stop the reaction for 2 minutes. Each triplicate was spotted onto a 
filter (Whatman, 21mm) and allowed to dry for 1 hour. Filters were washed twice in 
50 mM sodium carbonate pH9.2 solution and dried for 20-30 minutes at 60 °C. Each 
filter was finally placed in a scintillation vial (Perkin Elmer) containing 10 ml 
scintillation fluid (EcoscintTM, National Diagnostics) to incubate overnight at room 
temperature. The radioactive decay (DPM) of tritium was counted using a Wallac 
1409 liquid scintillation counter. 
7KHUHPDLQLQJȝOIURPWKHDFHW\ODWLRQDVVD\ZDVORDGHGRQWRDQGUXQRQD
15% SDS-polyacrylamide gel. The gels were placed firstly in fixative, then in 
amplify and finally dried for one hour under vacuum. Gels were exposed to Kodak 
Biomax film in a Kodak Intensifying Screen (low energy) at -80 ºC for 48 hours and 
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The MOZ MYST domain has been reported to target both histone and non-
histone protein acetylation (Champagne et al., 2001; Ullah et al., 2008). In addition, 
the MYST module has been shown to possess DNA targeting activities, whereby the 
MYST domain binds to DNA via TFIIIA-type zinc finger and helix-turn-helix DNA-
binding motifs located at the N- and C-terminal regions of the module (Holbert et al., 
2007). However, how MOZ is recruited or targeted to chromatin substrates in order to 
direct its HAT activity is still unknown.  
Other modules within the MOZ protein have also been assigned functions 
including the C-terminal amino-acid rich regions, which are essential for its 
transcriptional coactivator properties (Champagne et al., 2001) and the N-terminal 
H1/5 domain, which has been implicated in nuclear localisation and shown to possess 
an essential function in transcriptional coactivation (Yoshida and Kitabayashi, 2008). 
However, MOZ also contains N-terminal tandem PHD fingers of which the 
functional importance of the DPF domain is yet to be established; although they 
appear to be important for leukaemogenecity of MOZ fusion proteins (Deguchi et al., 
2003). 
The dysregulation of MOZ is intimately associated with AML, whereby the 
oncogenic fusion proteins responsible for AML retain the entire N-terminal region of 
MOZ, encompassing the H1/5, DPF, MYST and basic domains (Katsumoto et al., 
2008). Furthermore, PHD fingers such as that in the NUP98-JARID1A fusion 
oncoprotein was found to be essential for leukaemic transformation and malignancy 
(Wang et al., 2009). These studies reveal a direct cause-effect relationship between a 
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deregulated PHD finger and oncogenesis. Thus, knowledge of DPF function is 
essential for our complete understanding of the molecular mechanisms involved in 
MOZ function in both a normal and malignant context. 
The effector-PHGLDWHG FRQFHSW SURSRVHV WKDW KLVWRQH 370V DUH µUHDG¶ DQG
interpreted by protein modules, facilitating downstream events via the recruitment of 
non-histone binding effector proteins (Seet et al., 2006). PHD fingers are motifs 
predominantly found in nuclear proteins that function in the regulation of chromatin 
and are now well-established as chromatin binding modules (Bienz, 2006). The PHD 
domain has been characterised as a functionally versatile epigenome reader that can 
recognise and interpret the methylated (Li et al., 2006), acetylated (Lange et al., 
2008) or the unmodified states (Lan et al., 2007) of histone lysine residues. In 
addition to MOZ and MORF, within the genome only three other proteins harbour a 
double PHD finger domain and they are the members of the d4-protein family, 
DPF1/2/3. The DPF3b tandem PHD fingers have been structurally and functionally 
characterised as a chromatin binding module, whereby the two PHD fingers function 
as an integrated unit that defines the histone PTM recognition specificity (Zeng et al., 
2010). 
Given a wealth of evidence showing that the PHD motif functions as an 
epigenome reader, this chapter describes work conducted in order investigate whether 
the MOZ DPF domain can function as a histone PTM sensor. Furthermore, numerous 
studies were carried out to extensively characterise the specific binding pattern of 
histone PTMs recognised and bound by the MOZ DPF. 
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3.2. Sequence alignments of MOZ and other PHD fingers 
PHD domains have been extensively studied both biochemically and 
structurally, resulting in the identification of distinct molecular mechanisms utilised 
for histone PTM recognition. Many PHD domains appear to have evolved to detect 
the modification status of H3K4. As discussed in the introduction, PHD domains that 
bind to unmodified H3K4 have been shown to make close contacts with residues in 
the vicinity of lysine 4, including hydrogen bonding and electrostatic interactions. In 
contrast, H3K4me3 binding PHD domains recognise the methyl groups via an 
aromatic cage and the consequent formation of favourable electrostatic cation-ʌ
interactions. The MOZ PHD finger sequences were therefore aligned with other 
single PHD domains to determine if any structural features would give a clue to MOZ 
DPF function (Figures 3.1-3.2). All multiple alignments were conducted using the 
MultAlin, Expasy based program (Multiple sequence alignment with hierarchical 
clustering. F. CORPET, 1988, Nucl. Acids Res., 16 (22), 10881-10890). Sequence 
alignments indicate that MOZ PHD2 is similar to many other PHD fingers, whereas 
PHD1 is quite different to PHD2 and has fewer and lower identity homologues within 
the human genome. When aligned with PHD fingers that recognise the H3K4me3 
PTM, such as ING family proteins or BPTF, it is evident that sequence similarity is 
very low (Figure 3.1). Sequences share 14 % similarity, of which 11 % are the 
structural cysteine and histidine residues that make up the universal PHD finger 
motif. None of the aromatic residues that configure the H3K4me3 binding cage are 
conserved in MOZ PHD finger 1 or 2 (Figure 3.1- X). Using this alignment we could 
predict that neither of the PHD fingers in the MOZ DPF unit function as H3K4me3 
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binding modules. Alignment with PHD fingers, such as BHC80 and AIRE1, that 
interact with the unmodified H3K4 residue show a greater sequence similarity 
compared to those detailed previously. Individually, the MOZ PHD1 shares a 27 % 
similarity with the other H3K4me0 binding PHD fingers, whereas MOZ PHD2 
displays a greater similarity (37 %) (Figure 3.2). The majority of identical/similar 
residues are representative of the PHD motif (C4HC3) and those involved in binding 
and stabilising the N-terminus of the histone peptide (C-terminal similar residues 
form a hydrophobic pocket). The acidic residues involved in forming direct hydrogen 
bonds with the unmodified histone residue and mediating electrostatic interactions 
between backbone histone peptide residues are however, not conserved (Figure 3.2- 
X).  
While most studies have focused on the functions of single PHD motifs, many 
proteins contain multiple copies of the PHD domain such as MLL, CHD4 and others. 
These can be clustered together or separated by other functional modules. MOZ and 
MORF are unusual in having tandem adjacent PHD fingers, however a protein NCBI 
BLAST search using MOZ DPF as an enquiry sequence presented the DPF2/3 
proteins as high homology hits. Thus, this arrangement is shared with one other 
protein family, the d4-family members DPF1/2/3. As discussed earlier the DPF 
proteins contain two adjacent PHD fingers, although it should be noted that at the 
outset of this project the function of the DPF PHD fingers was unknown. The DPF 
tandem PHD fingers were later discovered to function as one unit in the molecular 
recognition of histone PTMs, whereby residues from both modules are required to 
establish the binding specificity of the entire domain (Zeng et al., 2010). Sequence 
alignments of human DPF proteins are shown in Figure 3.3. Alignment of the human 
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MOZ and DPF tandem PHD fingers highlights a high degree of conservation between 
the two primary sequences (Figure 3.3). DPF shares 53% identity and 72% similarity 
with MOZ DPF, whereby conservation specifically includes the majority of residues 
involved in the recognition of the H3 peptide N-terminus and acetylated H3K14. 
DPF3 is associated with the BAF chromatin remodelling complex and was identified 
as a novel reader of histone H3/ H4 acetylation and methylation. DPF3 represents the 
first PHD domain that recognises acetylated lysine residues, a property originally 
assigned to the bromodomain only (Lange et al., 2008). 
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3.3. The N-terminal domains of MOZ bind to histone H3 
To study the biochemical function of MOZ, a series of recombinant MOZ 
constructs were generated including a FLAG- or GST- tag. Oligonucleotides were 
designed according to the boundary requisite and used in PCR reactions to generate 
the DNA fragments needed for the construction of recombinant plasmids (Figure 
3.4(A) - left panel). FLAG-tag and kozak sequences were also incorporated into 
oligonucleotide sequences used for cloning inserts into mammalian expression 
vectors. Next, a bacterial expression vector (pGEX) containing the sequence 
encoding a GST tag or a mammalian expression vector (pcDNA3.1+) were digested 
within their multiple cloning site with restriction endonucleases. Digested DNA 
fragments and vectors with compatible ends were then annealed together in a ligation 
reaction with T4 DNA ligase as described in the methods. Ligated DNA was 
transformed into '+ĮE.coli, plasmid preparations made and verified for the correct 
integration of the gene fragment by colony PCR (Figure 3.4(A) - right panel) and 
restriction digest (Figure 3.4(A) - bottom panel). 
Site directed mutagenesis by PCR was used to create mutations in template 
DNA. This generated a full-length PCR product containing the mutation (Figure 
3.4(B) ± left panel). Methylated, non-mutated parental DNA was then digested with 
the Dpn1 restriction enzyme (Figure 3.4(B) ± right panel, compare control lane to 
	'1$ WUDQVIRUPHG LQWR'+ĮE.coli, plasmid preparations made and verified 
for the correct mutation of the gene fragment by sequencing. 
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Figure 3.4. Creation of GST-fusion and FLAG-constructs used in this study. 
(A) Example of the standard cloning protocol, whereby desired products were 
amplified by PCR (top left panel) and inserted into a pre-digested vector. Newly 
synthesised clones were then screened for the correct insertion of product by colony 
PCR (bottom panel) and restriction digest (top right panel). Abbreviations; (M) 
marker, (C) control, (U) uncut, (S) single digest, (D) double digest. (B) Site-directed 
mutagenesis protocol was carried out as described in Materials and Methods.  
(A) 
(B) 
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           A bacterial expression system was used in order to produce the proteins 
required for testing in GST-pulldown assays. Firstly, plasmid DNA encoding the 
GST-fusion protein was transformed into the Rosetta strain of E. coli. Rosetta host 
strains are BL21 derivatives designed to enhance the expression of eukaryotic 
proteins that contain codons rarely used in E. coli. These strains supply tRNAs for 
these specific codons on a compatible chloramphenicol resistant plasmid. 
Recombinant proteins were expressed by the addition of the IPTG inducer (Figure 
3.6(A)) and subsequently, the host Rosetta cells were lysed to release the soluble 
protein. GST-fusion proteins were then purified via the high affinity of GST for 
glutathione using glutathione cross-linked sepharose beads. Protein levels were 
normalised to ensure equal loading in subsequent experiments (Figure 3.6(B)- top 
panel).  
Our previous studies using MOZ fusion proteins had shown that MOZ can 
associate with chromatin and alter the acetylation of histones (Collins et al., 2006; 
Kindle et al., 2005). We thus assumed that the DPF might have a role in chromatin 
targeting via histone interaction. To assess that MOZ can interact with histones an in 
vitro GST pulldown assay was performed using the purified N-terminus GST-MOZ 
1-321 or the DPF GST-MOZ 172-321 and core histones extracted from calf thymus. 
As a control, core histones were incubated with GST. Glutathione immobilised GST-
MOZ fusion proteins were incubated with core histones, samples washed stringently 
to remove non-specific binding proteins and tested for pulldown (interaction) of 
histones by SDS-PAGE or immunoblotting. 
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Figure 3.5. Establishing optimal conditions for the GST pulldown assay. 
Pulldown assays followed by western blotting and immunodetection of 
histone H3 using the GST protein and calf thymus histone extracts. Buffer salt 
and detergent compositions were altered until the background binding of the 
GST protein tag to the core histones was eliminated. 





Figure 3.6. The N-terminal domains of MOZ bind to Histone H3. (A) 
Schematic representation of GST-MOZ fusion constructs used in subsequent 
assays and the expression of constructs in Rosetta E. coli bacteria following 
IPTG induction. (B)  Pulldown assays followed by Coomassie staining or 
Western blotting and immunodetection of indicated histones using GST-MOZ 
fusion proteins and calf thymus histone extracts. 
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 In preliminary experiments it was seen that the control GST protein non-
specifically bound core histones when incubated in low salt buffers (Figure 3.5- lanes 
2&3 middle panel). Ponceau staining indicates equal loading of GST protein (Figure 
3.5- bottom panel). When salt was titrated into the buffer composition, binding of the 
GST protein to histones was lowered significantly (Figure 3.5- lanes 4-6 middle 
panel). Varying detergent concentrations in addition to this did not affect background 
binding further (Figure 3.5- lanes 3-6 top panel). Thus, optimal buffer conditions 
were established and set to high salt (500mM NaCl) and low detergent (0.5% NP-40) 
concentrations for all subsequent assays. 
 GST protein concentrations were normalised by SDS-PAGE and Coomassie 
staining to ensure equal amounts of protein was used throughout the assay (Figure 
3.6(B)- top panel). Pulldown assays resulted in no interaction between the control 
GST protein and core histones, showing the interaction does not occur through the 
GST tag fused onto MOZ (Figure 3.6(B)-lane 3 middle panel). When histones and 
GST-MOZ 1-321 were incubated together, histone H3 was retained on the GST-
conjugated beads suggesting that these two proteins interact directly in vitro (Figure 
3.6(B)-lane 4 middle panel). In contrast, using Coomassie staining as a protein 
detection method did not identify an interaction between the MOZ-DPF (172-321) 
and histones (Figure 3.6(B)-lane 5 middle panel), thus the increased sensitivity of 
immunodetection was used to test this result instead. Consequently, pulldown assays 
were followed by the immunodetection of histones H2A, H2B, H3 and H4 (Figure 
3.6(B)-bottom panel). Both MOZ 1-321 and MOZ DPF bind strongly to histone H3 
in these experiments, however we noted that MOZ 1-321 showed a more robust 
binding. This suggests that the MOZ 1-171 sequence might stabilise the binding of or 
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provide additional contacts to histone H3. Interestingly, this sequence contains a 
region showing weak homology with histone H1 and H5. Under these conditions we 
were unable to detect binding with histones H2A, H2B and H4. This may be 
explained by the presence of a mixed population of PTMs within the core histone 
extract and will be analysed in more detail in subsequent assays. 
 The interaction of both MOZ constructs with histone H3 was confirmed by 
titration of the GST-MOZ protein into pulldown assays. This led to dose-dependent 
binding of histone H3 for both the N-terminus and the DPF domain alone (Figure 
3.7). A weak interaction with histone H2B and H4 was also observed in the titration 
assays (Figure 3.7). Moreover, the binding to H4 was confirmed in subsequent 
experiments (See Figure 3.11)  
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Figure 3.7. Dose-dependent binding of MOZ N-terminal domains to Histone 
H3. Pulldown assays followed by Western blotting and immunodetection of 
indicated histones, using a titration of GST-MOZ fusion concentrations (0.75, 1.5 
and 3 µg) and 10 µg calf thymus histone extracts. 
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3.4. Binding of MOZ to histone H3 requires the integrity of the 
DPF 
 To investigate whether the integrity of the MOZ DPF is necessary for histone 
binding, point mutations were introduced into the DPF sequence by site-directed 
mutagenesis. Residues selected for mutation are depicted on the schematic cross-
brace structure, speculated to be adopted by a double PHD finger (Figure 3.8(A)). 
Firstly, two zinc-coordinating cysteine residues were mutated, one in each PHD 
finger (C233A & C307A). The cysteine residues do not interact with H3 directly but 
are required for the structural integrity of the PHD finger. Secondly, two conserved 
aromatic residues implicated in histone recognition and interactions in other PHD 
fingers, were mutated (W257E & W305E). All mutants were generated in the GST-
MOZ 1-321 construct, expressed in Rosetta cells and purified using glutathione cross-
linked sepharose beads as described in section 3.3. Protein concentrations were 
normalised by SDS-PAGE and Coomassie staining to ensure equal amounts of each 
protein were used in the assay. From this gel it is evident that slightly less GST-MOZ 
protein harbouring the W257E mutation was utilised in the subsequent assays, 
however this will be taken into consideration when interpreting latter results (Figure 
3.8(B)). Using optimal buffer conditions, each of the PHD mutants, WT and the GST 
control was incubated with core histones to investigate whether an intact PHD finger 
is required for an interaction with histones. Pulldowns were subsequently subjected to 
immunoblotting with the primary antibody raised against H3 (Figure 3.8(C)). No 
interaction is observed between the GST control and histones (Figure 3.8(C)-lanes 2 
& 8), but binding is evident between histone H3 and WT GST-MOZ 1-321, 
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validating results observed in section 3.3 (Figure 3.8(C)-lanes 3 & 9 top panel). 
Ponceau staining indicated equal loading of proteins in each assay reaction (Figure 
3.8(B) bottom panel).  
 Pulldown assay results with both the single cysteine and aromatic PHD finger 
mutants show a reduced interaction with histone H3 compared to wild-type (Figure 
3.8(B)-compare lanes 3 & 9 with 4-5 & 10-11). It appears that the single aromatic 
mutant in MOZ PHD1 (W257E) has a greater negative effect on binding to H3 than 
the MOZ PHD2 (W307E) aromatic mutant (Figure 3.8(C)- compare lanes 10 & 11). 
However, as stated previously, slightly less of the MOZ W257E protein was used in 
the assay (Figure 3.8(B) and (C)- bottom panel) making it difficult to draw 
conclusions from this result. Further, when both PHD fingers contain point mutations 
the impact on H3 binding is reduced to a greater extent compared to proteins 
harbouring a single PHD mutation (Figure 3.8(C)- compare lanes 4-5 with 6 and 10-
11 with 12). Thus, mutagenesis studies indicate that the binding of histone H3 by 
MOZ is mediated by the DPF domain and that the integrity of both PHD fingers is 
required for the interaction. 








Figure 3.8. Binding of MOZ to histone H3 requires the integrity of the DPF. 
(A) Schematic representation of the MOZ DPF cross-brace structure. Aromatic and 
zinc coordinating cysteine residues subjected to site-directed mutagenesis in GST-
MOZ 1-321 are highlighted. (B) Normalisation of GST-MOZ 1-321 protein 
concentrations by SDS-PAGE and Coomassie staining. (C) Pulldown assays using 
GST-MOZ mutants and calf thymus histone extracts were followed by western 
blotting and immunodetection of histone H3. 
(B) 
(C) 
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 3.5. Histone H3 and H4 PTMs alter the interaction with MOZ 
DPF  
 Having established that the MOZ DPF binds strongly to histone H3 and 
possibly to a lesser extent H4, we assessed how the histone modification status 
impacts on these interactions. As the H3K4 and H3K9 methylation status are major 
targets of other PHD domains, we reproduced the pulldown assays with the mutant 
GST-MOZ fusion proteins described in the previous sections, however this time 
blotting for the H3K4me3 and H3K9me3 modifications (Figure 3.9). Ponceau 
staining indicated equal loading of proteins in each assay reaction (Figure 3.9- bottom 
panel). As shown in Figure 3.9, WT MOZ 1-321 does not interact with the H3K4me3 
modification; a PTM strongly correlated with an active transcription state (Figure 3.9- 
second panel). In contrast, WT MOZ shows a strong interaction with H3K9me3; a 
PTM strongly associated with heterochromatic regions (Figure 3.9- third panel). This 
suggests a possible role of the DPF in targeting MOZ to repressive chromatin or 
releasing MOZ from sites of transcriptional activation. As with histone H3 binding, 
single cysteine and aromatic PHD mutations reduce binding of GST-MOZ 1-321 to 
the H3K9me3 modification (Figure 3.9-third panel, compare lane 3 with 4-5 and 9 
with 10-11). Further, to a greater extent, double PHD mutations completely abolish 
the interaction of MOZ 1-321 with histone H3 trimethylated at K9 (Figure 3.9- third 
panel, compare lane 3 & 9 with 6 & 12). These results indicate that the integrity of 
the MOZ DPF is required for histone PTM interaction and suggests that DPF binding 
is sensitive to the modification status of histone H3. 
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Figure 3.9. Binding of MOZ to Histone H3 PTMs requires the integrity of the 
DPF. Pulldown assays using GST-MOZ 1-321 mutants and calf thymus histone 
extracts were followed by western blotting and immunodetection of the indicated 
histone PTMs  
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          Core histones are purified from cell extracts and thus, contain a mixed 
population of PTMs. Therefore, to determine the specificity of MOZ DPF binding 
further, biotinylated histone peptides modified at specific lysine residues were used in 
a pulldown assay with GST-MOZ fusions. Sequences of biotinylated peptides used in 
subsequent assays are listed in Figure 3.10 and where possible the presence of 
modification was verified using the dot blot technique. Increasing amounts of 
peptides were spotted onto nitrocellulose membrane and immunodetection was 
carried out with the indicated histone modification antibodies (Figure 3.10). Where 
tested, all modified peptides were validated by their corresponding antibodies and 
unmodified peptides were checked for the absence of modification by those 
antibodies raised against acetylated or methylated H3/H4 epitopes.  
 GST-MOZ 1-321 and DPF proteins were eluted from the glutathione-
sepharose beads using the glutathione competitor and incubated overnight with the 
biotinylated histone peptides. Following this, biotinylated peptides were isolated via 
the high affinity of the biotin tag for Streptavidin using Streptavidin cross-linked 
sepharose beads. Samples were washed stringently as described in the materials and 
methods section and checked for the interacting GST-MOZ protein using SDS-PAGE 
and immunodetection with an antibody against the GST tag. 
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Figure 3.10. Validation of the modification status of biotinylated histone peptides 
used in binding studies. Dot blot analysis was carried out, where biotinylated peptides 
were spotted onto nitrocellulose membrane in increasing concentration increments (0.5,1 and 
ȝJ. Spotting was followed by immunodetection of the indicated histone post-translational 
modifications. N/A represents peptides not tested due to a lack of antibody against the 
specific modification. 
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 Initial experiments were performed to determine if the binding of MOZ DPF 
(194-323 - DPF boundaries were redefined) to histone H3 and H4 is mediated by the 
histone N-terminal tails. Firstly, to verify the results showing binding to core 
histones, this assay was carried out with peptides representing the N-terminus of each 
of the core histone tails and GST-MOZ DPF (Figure 3.11(A)). Results show that 
peptide H3 (1-21) interacts with the MOZ DPF, yet the internal H3 sequence (22-44) 
failed to bind (Figure 3.11(A) lanes 3 & 4). This suggests that the DPF binds the N-
terminal 21 amino acids of the histone H3 tail. The H2A and H2B unmodified N-
terminal tails also did not pulldown the MOZ DPF (Figure 3.11(A)-lanes 2 & 7), 
again reinforcing previous results. As shown more clearly in Figure 3.11, the MOZ 
DPF also strongly interacts with the N-terminal residues of histone H4 (2-24) (Figure 
3.11(A)- lane 5). Subsequently, the pulldown assay was carried out with a series of 
H3 and H4 peptides acetylated and methylated at specific lysine residues (Figure 
3.11(B(i))). Consistent with the absence of H3K4me3 binding in pulldown assays 
(Figure 3.9), both the MOZ 1-321 and DPF domains were unable to bind H3 1-21 
containing the H3K4me3 modification (Figure 3.11(B(i)) compare lanes 3 & 5). 
Remarkably, dimethlyation of H3K4 was bound equally as efficiently as the 
unmodified peptide (Figure 3.11(B(i)) compare lanes 3 & 4). This suggests that the 
DPF binding pocket can accommodate the size of dimethylated K4 but not with the 
added addition of a third methyl group. Alternatively, binding of H3K4me3 may be 
unfavourable as a consequence of steric repulsion, due to the increased cationic 
radius/charge of an additional methyl moiety. 
In contrast to H3K4, trimethylation of H3K9 did not affect binding to either 
MOZ 1-321 or the DPF domain (Figure 3.11(B(i))- compare lanes 3 & 6). However, 
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acetylation of K9 and K14 appeared to stimulate the interaction with MOZ 1-321 
(Figure 3.11(B(i))- top panel, compare lanes 3 & 7), although this was not apparent 
with the DPF domain under similar conditions (Figure 3.11(B(i))- middle panel, 
compare lanes 3 & 7 (ii) compare lanes 2 with 4, 5 and 6). This suggests that 
acetylation of H3K9 or K14 may induce additional interactions with MOZ via the 1-
171 sequence. Asymmetric dimethylation of H3R2 did not affect the binding of the 
DPF domain (Figure 3.11(B(ii))- compare lanes 2 & 3). Conversely, phosphorylation 
at H3S10 reduced the binding capacity of the MOZ DPF for the H3 N-terminal 
peptide (Figure 3.11(B(i))- compare lanes 2 & 7). This is possibly due to the 
appendage of a bulky, negatively charged phosphate group to the histone peptide, 
which can no longer be accommodated within the DPF binding cavity. Further, little 
or no interaction was observed with the internal histone H3 sequence (22-44) or the 
methyl PTMs in this region (Figure 3.11(B(i))-lanes11-13), consistent with MOZ 
DPF binding to N-terminal histone H3 (1-21) PTMs. 
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Figure 3.11. Binding preference of the MOZ DPF: An intolerance of H3K4me3 
and H4Ac. Western blot analysis of histone peptide pulldowns with indicated GST-
MOZ fusion proteins and biotinylated peptides (A) Pulldowns with core histone 
unmodified peptides. Densitometry readings were calculated, relative to the protein 
input, using the Image J software. (B)(i)(ii) Pulldowns with modified histone H3 and 
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          The 1-321 and DPF domains both showed strong binding to the histone H4 N-
terminus, however both proteins were unable to interact with hyperacetylated histone 
H4 (Figure 3.11(B(i)) compare lanes 8&9) or further, with any H4 peptide mono/di-
acetylated at each of the given target lysine residues (Figure 3.11(C) compare lanes 2 
with 3-7). This indicates that H4 hyper-acetylation is incompatible with MOZ 
recruitment to chromatin. The binding of MOZ DPF constructs to histone H4, but not 
hyperacetylated H4, may provide an explanation for the rather poor binding to H4 
observed with some preparations of core histones. Some commercial suppliers use 
sodium butyrate treatment (an inhibitor of HDAC activity) in their histone extraction 
protocol. This may mean that high levels of H4 are acetylated. To check for the 
presence of acetylated H4 in the histone preparations (Sigma), core histones were 
spotted onto nitrocellulose membrane and subjected to immunodetection with a pan-
acetyl-H4 antibody. As shown in Figure 3.12, H4Kac was readily detected. This 
suggests that a high proportion of H4 may be acetylated and therefore unable to bind 
MOZ DPF. In contrast H3Kac may stimulate binding to MOZ-DPF. 
Figure 3.12. Core histone extracts contain acetylated histone H4. Dot blot analysis. 
Core histones were spotted onto nitrocellulose membrane in increasing concentration 
increments (0.5, 1, 2 and 4 µg). Spotting was followed by the immunodetection of 
histone H4 and pan-acetylation of histone H4. 
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           MOZ is a modular protein consisting of several domains that could regulate or 
influence the binding specificity of the DPF domain (Figure 3.13(A)). Thus, to assess 
if the constructs used in our binding assays reflect the histone binding properties of 
the full-length protein, the full-length and breakpoint MOZ proteins were used in 
pulldown assays with the biotinylated peptides to investigate whether the binding 
patterns were similar. FLAG-MOZ and FLAG-MOZ N (which is truncated at the site 
of the oncogenic fusion protein breakpoint) were in vitro translated using a 35S-
methionine label, incubated with biotinylated peptides, immobilised onto Streptavidin 
beads and results visualised by SDS-PAGE and autoradiography. 35S-methionine 
labelled proteins were used in this case as the larger MOZ proteins do not express and 
purify efficiently as GST fusion proteins. Input loading shows efficient in vitro 
translation (Figure 3.13(B)-lane 1). Full-length MOZ and MOZ N were found to 
associate with both histones H3 and H4 and displayed similar histone binding 
properties as the DPF and N-terminus of MOZ. Briefly, this involved intolerance for 
the activatory H3K4me3 mark and hyperacetylated H4 (Figure 3.13(B)-compare 
lanes 2 & 7 with 4 & 8). 
Another protein expressed poorly as a GST-fusion was the GST-MOZ 1-171 
(H1/5) protein. This construct was also in vitro translated with a 35S-methionine label 
and used in peptide binding assays as described above. Input loading shows efficient 
in vitro translation of the protein (Figure 3.13(B)-lane 1). Interestingly, 
autoradiography shows no interaction of this module with any of the biotinylated 
peptides (Figure 3.13(B)- lanes 3-8). This further implements the MOZ DPF as the 
module responsible for histone recognition and suggests that the H1/5 domain may 
augment the DPF binding activity, rather than directly bind chromatin itself. 
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Figure 3.13. Binding specificity of the full-length MOZ protein: An intolerance 
of H3K4me3 and H4Ac. (A) Domain organisation of MOZ. (B) Autoradiograph 
analysis of histone peptide pulldowns with indicated in vitro translated 35S-
methionine labelled FLAG-MOZ, FLAG-MOZ N (oncogenic fusion protein 
breakpoint), FLAG-MOZ 1-171 and biotinylated histone peptides.  
(A) 
(B) 
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3.6. Both PHD1 and PHD2 are required to establish H3 PTM 
binding preference 
 The previous set of experiments established that MOZ can interact with H3 
and H4 termini and that this is regulated by PTM status. To determine whether the 
two MOZ PHD fingers can function as two separate entities and carry out specific 
roles in governing the DPF binding pattern, GST-MOZ 194-263 (PHD1) and GST-
MOZ 250-323 (PHD2) plasmid constructs were created (Figure 3.14(A)- left panel). 
These fusion proteins were expressed and purified as previously detailed. Both 
proteins were normalised to GST-MOZ DPF (194-323) using SDS-PAGE and 
Coomassie staining (Figure 3.14(A)- right panel) and subsequently used in binding 
assays with biotinylated histone peptides. Firstly, the binding specificity of the PHD 
fingers for the four histone peptides was investigated (Figure 3.14(B)). The MOZ 
DPF showed robust binding to histone H3 and H4 N termini, but not H2A, H2B or 
H3 (22-44) as in previous experiments (Figure 3.14 (B)- third panel). PHD2 showed a 
similar pattern binding unmodified H3 and H4 N-termini, but no binding to H2A or 
H2B (Figure 3.14 (B)- second panel). PHD1 was able to bind the H4 N-terminus but 
had a much reduced ability to bind the H3 N-terminus (Figure 3.14 (B)- first panel). 
This suggests that PHD1 contacts histone H4, whereas PHD2 can bind to both H3 
and H4.  
 Next, PHD1 and PHD2 were incubated with a range of biotinylated peptides 
containing selected histone modifications and the observed binding patterns 
compared to those of the MOZ N-terminus and DPF (Figure 3.15(A)). Interestingly, 
again PHD1 alone showed no binding to H3 N-terminal peptides whether modified or 
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not (Figure 3.15(A)-lanes 3-7). A similar level of binding was seen to unmodified 
histone H4 as with the DPF, however hyperacetylation of H4 prevented this 
interaction (Figure 3.15(A)-compare lanes 8 & 9). To determine whether this effect is 
seen only with hyperacetylation rather than mono-acetylation of H4, we performed 
similar studies with mono-acetylated peptides. These results show that acetylation of 
K5, K8, K12 or K16 completely block the interaction of the DPF with the N-terminus 
of histone H4 under these conditions (Figure 3.15(B)-compare lanes 2 with 3-7). 
Surprisingly, similar results were observed using the H4 selective module PHD1, 
although in isolation this domain showed some ability to bind H4K16ac but not 
others. This may indicate that PHD1 and PHD2 can have functionality that is distinct 
from the composite DPF. This may be important in multicomponent complexes or 
after post-translational modification of MOZ within the DPF. In addition, no 
interaction was observed with unmodified histone H3 (22-44) or methyl PTMs in this 
region (Figure 3.15(A)-lanes 11-13).   
PHD2 alone showed strong interactions with all N-terminal H3 peptides 
including the tri-methylated H3K4 mark (Figure 3.15(A)-lanes 3-7). Given the 
intolerance of the MOZ DPF protein for H3K4me3 binding, this result suggests that 
the PHD1 binding selection of H3K4me3 is dominant over that of PHD2 in the DPF 
composite. PHD2 also retained strong binding to histone H4, but like DPF and PHD1, 
H4 acetylation disrupted this interaction (Figure 3.15(A)-compare lanes 8 & 9). 
Again comparable to the DPF, a drastic reduction of binding was observed between 
PHD2 and any mono/di-acetylated H4 peptides (Figure 3.15(B)-compare lanes 2 with 
3-7). This underscores complete intolerance for the binding of H4 acetylation PTMs. 
No interaction was observed with unmodified histone H3 (22-44) or methyl PTMs in 
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this region (Figure 3.18(A)-lanes 11-13), emphasising the specific binding of PHD2 
and DPF to the very N-terminus (amino acids 1-21) of the histone H3 tail. These 
findings advocate that PHD1 and PHD2 functionally cooperate in an inter-dependent 
manner to determine the histone PTM binding selectivity of the DPF, in particular to 
the sensitivity to H3K4 trimethylation. 





Figure 3.14. Binding specificity of the individual PHD motifs of the MOZ DPF. 
(A) Schematic representation of the GST-MOZ split PHD finger fusions used in 
subsequent studies. SDS-PAGE followed by Coomassie staining was used to 
establish normalised input levels of each protein. (B) Western blot analysis of 
histone peptide pulldowns with GST-MOZ PHD split fusion proteins and core 
unmodified histone biotinylated peptides. Densitometry readings were calculated, 
relative to the protein input, using the Image J software.  





Figure 3.15. Both PHD1 and PHD2 are required to establish H3 PTM binding 
preference. Western blot analysis of histone peptide pulldowns with indicated 
GST-MOZ fusion proteins and biotinylated peptides. (A) Pulldowns with modified 
histone H3 and H4 modified peptides. (B) Pulldowns with histone H4 acetylated 
peptides. 
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3.7. MOZ is excluded from chromatin containing H3K4me3 
 The previous data indicated that in vitro the MOZ DPF can bind to both 
unmodified or acetylated histone H3 and unmodified histone H4, but is unable to 
interact with tri-methylated H3K4 and H4 that is mono- or hyperacetylated at the N-
terminus. In order to investigate whether these in vitro findings are true for in vivo 
systems, ChIP assays and immunofluorescence studies were conducted.  
 HEK-293 cells have been shown to express a detectable level of endogenous 
MOZ (Kindle et al., 2005) and were consequently used in the in vivo studies. HEK-
293 cells were cultured to confluency, the nuclear proteins and chromatin were cross-
linked using formaldehyde and finally the chromatin was isolated using standard 
ChIP techniques (see materials and methods section 2.5.12). Endogenous MOZ was 
then immunoprecipitated from chromatin preparations and subsequently subjected to 
western blot analysis and immunodetection using histone-PTM specific antibodies. 
MOZ was indeed found to associate with chromatin, compared to IgG control, in 
these ChIP assays (Figure 3.16- panel 1, compare lanes 2&3). Western blotting with 
histone PTM-specific antibodies revealed that chromatin associated with MOZ 
contained acetylated H3K14 and H4K9me3 (Figure 3.16- panel 3&4, compare lanes 
2&3), however MOZ did not coprecipitate with chromatin enriched in the H3K4me3 
modification (Figure 3.16- panel 4, compare lanes 2&3). Input (10 %) samples were 
loaded (Figure 3.16- lane 1) to ensure the chromatin preparations were enriched with 
the specific histone PTMs being tested. Thus, it is likely that MOZ may be excluded 
from chromatin that is enriched in H3K4me3, but may be associated with chromatin 
containing H3K9/14 acetylation. 
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Figure 3.16. MOZ is excluded from chromatin containing H3K4me3. HEK-293 
cells were crosslinked using formaldehyde and the chromatin isolated. Endogenous 
MOZ was immunoprecipitated from chromatin preparations and subsequently 
subjected to western blot analysis and immunodetection using histone PTM-specific 
antibodies. 
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3.8. MOZ colocalises with chromatin enriched in H3K9me3 
and acetylated histone H3 PTMs 
The previous data indicates that MOZ is associated with chromatin containing 
H3Kac PTMs, but is excluded from H3K4me3 enriched chromatin. To investigate 
this further, we next examined the subcellular localisation of exogenous full-length 
FLAG-MOZ proteins and their association with endogenous histone PTMs using 
immunofluorescence microscopy.  
To determine the subcellular localisation of MOZ, U2OS cells were seeded 
onto coverslips and transfected with the FLAG-MOZ expression plasmid. After 48 
hours post-transfection cells were fixed, permeabilised and incubated with anti-FLAG 
antibody and a mouse Alexa594-conjugated secondary antibody. The nucleus was 
visualised with Hoechst 33258 stain which intercalates with DNA. As shown in 
Figure 3.17, FLAG-MOZ displays a punctate nuclear expression pattern, whereby the 
protein is concentrated into subnuclear foci and excluded from the nucleoli (Figure 
3.17(A)). This localisation pattern is consistent with previous reports from our 
laboratory and is similar to that of the endogenous protein in cells that express MOZ 
(Kindle et al., 2005). 
Next, FLAG-MOZ transfected U2OS cells were incubated with both anti-
FLAG and anti-histone PTM antibodies and followed by incubation with a mixture of 
mouse Alexa594- and rabbit Alexa488-conjugated secondary antibodies. Both FLAG 
(red) and histone PTM (green) images were merged (yellow) to check for the nuclear 
localisation of the two markers. Cell nuclei were visualised with Hoechst 33258 stain 
(blue).   
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As shown in Figure 3.17, the FLAG-MOZ speckles do not overlap with 
H3K4me3 foci (Figure 3.17(B)- top panel), suggesting that MOZ is not localised to 
chromatic regions enriched with this modification. Indeed, the MOZ and H3K4me3 
stains appeared to be largely mutually exclusive within the nucleus. This corroborates 
previous in vitro and in vivo experimental findings in this study. Although H3K4me3 
is normally considered a marker of actively transcribed chromatin, it is not clear 
whether all transcribed genes contain this histone PTM. MOZ has been shown to 
activate certain genes, including Hox loci, so it does appear to have a function in gene 
activation. Our results may suggest that the function of MOZ in gene regulation either 
precedes or comes after the deposition of the H3K4 trimethylation. 
Staining of U2OS cells for H3K9me3 revealed a mesh-like pattern in the 
nucleus with a number of larger foci enriched in this PTM (Figure 3.17(B)- bottom 
panel). These foci have been previously described as heterochromatic regions. In 
contrast to its relationship to H3K4me3, the FLAG-MOZ protein showed partial 
colocalisation with H3K9me3 enriched foci (Figure 3.17(B)- bottom panel). 
However, MOZ did not stain all H3K9me3 foci and in the typical example shown can 
be seen to be excluded from some of the larger foci. Thus, MOZ and H3K9me3 
appear to be coincident in at least some regions of the genomes of interphase cells, 
consistent with our observation that this PTM does not displace MOZ from histone 
H3 in vitro. 
 Previous assays showed that the MOZ DPF was able to bind and associate 
with H3Kac PTMs and as a result we next checked whether FLAG-MOZ colocalises 
with these marks using the immunofluorescence method. Anti-pan acetyl-H3 and 
anti-H3K9ac antibodies were successfully used in the subsequent studies. Various 
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dilutions of the H3K14ac antibody were tested, however signal above secondary 
control background was unattainable; thus the antibody was unsuitable for use in the 
immunofluorescence application. As shown in Figure 3.18, staining of U2OS cells for 
acetylated H3 revealed foci enriched with these PTMs. These foci showed excellent 
colocalisation with the FLAG-MOZ foci and indicate that MOZ is associated with 
regions enriched in acetylated H3 (Figure 3.18- top and middle panels). This is 
consistent with our in vitro data and also, with in vivo studies by Voss and Thomas 
showing that MOZ is specifically required for the H3K9 acetylation mark of 
transcriptionally active Hox gene loci (Voss et al., 2009). Similarly, FLAG-MOZ 
speckles were also found to show a good colocalisation with H3K9ac, although using 
this antibody fewer clearer foci were detected in U2OS nuclei (Figure 3.18- bottom 
panel). Thus, in summary it is likely that MOZ colocalises to and associates with 
chromatin enriched in H3 lysine acetylation marks.  
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  Figure 3.17. Exclusion of MOZ from H3K4me3 enriched chromatin. U20S cells 
were seeded onto coverslips and transfected after 24 hours with expression plasmids 
encoding FLAG-MOZ. After 48 hours post-transfection, cells were fixed in 4 % 
paraformaldehyde, permeabilised and stained with antibodies raised against (A) mouse 
anti-FLAG (red) or (B) mouse anti-FLAG and the indicated rabbit anti-histone PTM 
(green). Staining was followed by incubation in (A) anti-mouse Alexa594 or (B) anti-
mouse Alexa594 and anti-rabbit Alexa488 secondary antibodies. Merged scans 
(yellow) highlight colocalisation or exclusion and Hoechst 33258 (blue) was used as a 
stain of DNA. 
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Figure 3.18. Colocalisation of MOZ with acetylated H3 enriched chromatin. U20S 
cells were seeded onto coverslips and transfected after 24 hours with expression 
plasmids encoding FLAG-MOZ. After 48 hours post-transfection, cells were fixed in 4 
% paraformaldehyde, permeabilised and stained with antibodies raised against mouse 
anti-FLAG (red) and the indicated rabbit anti-histone PTM (green). Staining was 
followed by incubation in anti-mouse Alexa594 and anti-rabbit Alexa488 secondary 
antibodies. Merged scans (yellow) highlight colocalisation or exclusion and Hoechst 
33258 (blue) was used as a stain of DNA. 
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3.9. The MOZ DPF facilitates simultaneous reading of H3 and 
H4 PTMs 
The coexistence of chromatin modifications on one or two tails of the same 
nucleosome suggests that it is likely that chromatin regulators can sense multiple 
PTMs cooperatively or simultaneously. To investigate how combinations of H3 and 
H4 PTMs influence MOZ DPF engagement, we devised an assay using equimolar 
mixtures of immobilised histone peptides. Schematic representation of the assay is 
depicted in Figure 3.19(A), where multiple peptides are immobilised onto 
Streptavidin-coupled Dynabeads®. Using single peptides, MOZ DPF showed similar 
binding patterns to H3/H4 PTMs as before, whereby strong binding was observed 
with H3 (1-21) (Figure 3.19(B) top panel- lane 7), H4 (top panel- lane 3 & 9), H3Kac 
(middle panel- lane 6) peptides and little or no binding was seen with H3 (21-44) (top 
panel- lane 8), H3K4me3 (top panel- lane 2) and H4Kac (top panel- lane 4). 
No increase in MOZ DPF binding was observed by providing a mixture of 
unmodified H3 and H4 peptides (Figure 3.19(B) middle panel- compare lanes 2&3 
with 4), suggesting that the binding is not cooperative or allosteric. Notably, the 
availability of unmodified H3 or H4 peptide rescued the lack of MOZ DPF binding to 
histone H3 (22-44) (Figure 3.19(B) top panel- compare lanes 7-9 with 10 & 11) and 
H3K4me3 (top panel- compare lanes 2 & 3 with 5). This suggests that despite tri-
methylation of histone H3K4 alone excluding MOZ DPF from histone H3, the 
modification acts as a recessive exit signal, which does not affect the simultaneous 
binding to PTM residues on neighbouring histone tails or nucleosomes. In contrast, 
the addition of an acetylated H4 peptide into these assays appeared to have a 
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dominant inhibitory effect, as it was observed to absolutely prevent binding of the 
MOZ DPF to unmodified H3 (middle panel- compare lanes 2 & 5), H3Kac (middle 
panel- compare lanes 6 & 7) and H3K9me3 (middle panel- compare lanes 8 & 9). 
Furthermore, this dominant inhibitory effect was also seen with histone H4 peptides 
harbouring individual acetylation marks, where binding of the DPF to unmodified 
histone H3 and H4 was prevented in the presence of any mono-acetylated H4 peptide 
(bottom panel- compare lanes 2 with 3-7 and 9 with 10-14 respectively). These 
results suggest that DPF can simultaneously engage PTMs on different histones, at 
least in the context of peptide surrogates. 
 To further confirm the inhibitory effect of H4 acetylation upon binding to 
other recognised PTMs, peptide binding assays were carried out using H3K9/14ac 
and H4Kac peptides mixed in differing molar ratios with the GST-MOZ DPF protein. 
Results show a dose-dependent disruption of MOZ DPF binding to H3Kac by 
H4Kac, but not by H4 (Figure 3.20). Densitometry values emphasise a 16% reduction 
in DPF-H3Kac binding at a low 90:10 percentile ratio of H3Kac:H4Kac and a 
dramatic 62% decrease at a 75:25 ratio. This underscores the potency of the H4Kac 
inhibitory effect, where even at low concentrations of H4Kac and an excess of 
H3Kac, MOZ DPF binding to PTMs is diminished. 
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Figure 3.19. The MOZ DPF facilitates simultaneous reading of H3 and H4 
PTMs. (A) Schematic representation of simultaneous peptide binding assays. (B) 
Peptide binding assays were conducted using either single biotinylated peptides or 
equimolar mixtures of two peptides and the GST-MOZ DPF protein. Western blot 
analysis and immunodetection using anti-GST followed. Densitometry values were 
calculated using the Image J software. 
(B) 
(A) 
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Figure 3.20. Dose-dependent disruption of MOZ-DPF binding to H3Kac by 
H4Kac. Peptide binding assays were conducted using H3K9/14 and H4 or H4 
acetylated peptides mixed in differing molar ratios (a total of 735 nM peptide(s) 
was used). Peptides were incubated with 50 nM GST-MOZ DPF protein in 750 µl 
binding buffer. Incubation with Dynabeads®, western blot analysis and 
immunodetection using anti-GST followed. Densitometry values were calculated, 
relative to the protein input, using the Image J software. 
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          This advocates a possible model where MOZ complexes are likely to induce 
acetylation of H4, which consequently acts as a dominant exit signal from chromatin, 
even in the presence of H3 PTMs that stimulate MOZ recruitment. Alternatively, 
H4Kac could function as a signal preventing MOZ from docking to chromatin 
enriched in this modification in the first instance. It is difficult to envisage how an 
acetyl-H4 mark can block the interaction of MOZ DPF with other PTMs when it 
LWVHOIFDQQRWELQG,WLVSRVVLEOHWKDWDQ+.DFJURXSPD\µUHVW¶LQWKe DPF binding 
site without forming covalent contacts with residues lining the pocket. This would 
suggest a transient and dynamic binding state, whereby the H4Kac group would 
temporarily block access to the reader module. Stringent washing steps in the in vitro 
assays may be rigorous enough to dislodge the H4Kac from the binding site; possible 
reasoning for a negative result for binding in these assays. Alternatively, every 
protein-ligand complex dissociates at a random time, causing a variable off-rate of 
the ligand dissociating from the protein. It is possible that the H4Kac peptide may 
bind briefly to the MOZ DPF protein and that complex dissociation exhibits rapid 
off-rate kinetics, causing the H4Kac peptide to swiftly dissociate from the DPF 
binding site. This could explain why little or no H4Kac modification was found in 
complex with the MOZ DPF in the peptide binding assays after stringent washing and 
further, how H4Kac was able to block the interaction of MOZ DPF with other PTMs. 
Dissociation binding experiments and structural crystallisation of the MOZ DPF in 
complex with an H4Kac peptide would aid the characterisation of the molecular 
mechanism by which H4Kac inhibits interaction with other PTMs. 
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3.10. The MORF DPF exhibits a similar binding pattern to MOZ 
DPF 
 MORF (MYST4) is another member of the MYST family of lysine 
acetyltransferases and is the most closely related member to MOZ in terms of its 
modular consistency and sequence homology. Alignment of the MOZ and MORF 
PHD fingers underscores the extent of this sequence similarity (Figure 3.21 (A)), 
where 87 % of amino acid residues are conserved (denoted with *) and 95 % are 
strongly similar (denoted with :). As only 5 % of residues among the two DPF 
sequences are weakly similar or different (indicated with . or ± respectively),  it was 
expected that these two highly homologous domains would exhibit a similar 
specificity and binding function towards histone PTMs.  
 In order to test this hypothesis, the MORF DPF (amino acids 201-330) DNA 
fragment was cloned into the GST-expression plasmid, the protein expressed, purified 
and utilised in binding assays with modified biotinylated histone peptides (Figure 
3.21 (B)). The binding pattern of MOZ DPF (Figure 3.11(B)- middle panel) in 
comparison to the MORF DPF (Figure 3.21(B)) is extremely similar. Like MOZ, 
MORF DPF interacts with both unmodified histone H3 and H4 peptides (Figure 
3.21(B)- lanes 3 & 8). However, the MORF DPF shows a robust preference for 
unmodified histone H4 (Figure 3.21(B)- compare lane densities 3 & 8). When tested 
with histone H3/4 peptides acetylated and methylated at specific lysine residues, the 
two distinctive findings obtained for MOZ DPF binding were observed. Firstly, the 
MORF DPF showed diminished binding to H3K4me3 compared with a tolerance for 
H3K4me2 (Figure 3.21(B)- compare lanes 4 & 5), suggesting that the MORF DPF 
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binding pocket was also unable to sterically accommodate a third methyl group. In 
addition, the MORF DPF was unable to interact with hyperacetylated histone H4 
(Figure 3.21(B)- compare lanes 8 & 9), implicating acetylation of H4 as an exit or 
prevention signal for MORF from chromatin. These results indicate that the 
homologous MOZ and MORF DPF domains exhibit very similar histone binding 
patterns, although MORF may display a particular preference for interaction with 
unmodified histone H4. This suggests that both enzymes are possibly targeted to or 
away from chromatin enriched in similar PTMs.  
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3.11. Quantitative analysis of MOZ DPF binding to unmodified 
or acetylated H3/H4 peptides 
 Biotinylated peptide binding assays are a useful tool to rapidly profile the 
interactions of MOZ DPF with histone PTMs. Densitometry readings yielded from 
such assays are useful in giving an indication of binding preferences. In order to 
measure binding preference for specific histone PTMs more quantitatively, 
fluorescence polarisation anisotropy was carried out as described in the Materials and 
Methods section. This method measures changes in the proportion of polarised light 
due to the reduced tumbling of a fluorescently labelled peptide upon interaction with 
a larger protein. Conditions for fluorescence polarisation were optimised to establish 
the background levels produced by different peptide concentrations. Optimal 
conditions were established by titration assays using different amounts of GST-MOZ 
DPF. Finally, assays were performed for GST-MOZ DPF binding to fluoroscein-
labelled H3 (1-21) and H4 (2-24) peptides. To obtain binding affinities, a constant 
concentration of each histone peptide substrate (1 nM) was incubated with increasing 
concentrations of GST-MOZ DPF (0.125 -  ȝ0. The fraction of peptide bound 
was then calculated relative to a background fluorescence reading. 
 As shown in Figure 3.22, polarised light due to reduced tumbling of the 
unmodified H3 and H4 peptides was increased upon the addition of increasing 
amounts of GST-MOZ DPF. The slope of the gradient for the histone H3 plot (pink) 
is steeper than that observed for the histone H4 peptide (blue). In addition, the overall 
fraction bound at high concentrations of MOZ-DPF is substantially higher for the H3 
peptide compared to the H4 peptide (Figure 3.22), emphasising that the MOZ DPF 
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binds unmodified histone H3 with a greater affinity than histone H4. Quantitative 
binding measurements lend support to the apparent specificity of the MOZ DPF for 
the unmodified H3 peptide compared to the H4 peptide; a result not established by 
peptide binding assays. Unfortunately, binding affinities (Kd-dissociation constant) 
could not be calculated accurately using these results, as binding saturation was not 
reached at the maximal possible concentration of GST-MOZ DPF. An alternative 
method that might require less protein is isothermal titration calorimetry, which may 
be performed in future studies.     
 The binding studies with biotinylated peptides suggested that acetylation of 
H3 and H4 had different affects on the binding of MOZ DPF. The acetylation of 
H3K9 and H3K14 resulted in increased binding to GST-MOZ 1-321, whereas this 
was less apparent with GST-MOZ DPF alone. Conversely, monoacetylation of K5, 
K8, K12, K16 or hyperacetylation of all four residues within the H4 peptide 
completely eradicated the interaction with MOZ 1-321 or the DPF (Figure 3.11). To 
further investigate this binding preference shown by the MOZ DPF, polarisation 
experiments were set up using fluoroscein-labelled H3K9ac (1-21) and H4K16ac (2-
24) peptides. As shown in Figure 3.22, binding of the DPF to H3K9ac (green) was 
increased in comparison to unmodified H3 (pink) (Figure 3.22). In contrast, 
acetylation of H4K16 (orange) reduced the level of binding observed in the 
polarisation assay, when compared to the H4 peptide (blue) (Figure 3.22). This result 
indicates that the MOZ DPF has a lower affinity for the H4K16ac peptide. Due to the 
high cost of fluoroscein-labelled peptides, we were unable to perform a control to 
establish whether this low level of increased polarised light is due to weak binding, or 
due to background. Background due to non-specific interactions could be established 
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by incubating the DPF with a negative control peptide, i.e a sequence for which the 
DPF has no affinity. However, on balance, it is likely that the acetylated H4 peptide 
has a weak affinity for DPF that is below the level of detection in the biotin-peptide 
pulldown assays. This could provide an explanation for the dominant inhibitory affect 
over the binding of other histone PTMs, whereby acetylated-H4 peptides block the 
ability of the DPF to bind H3. It will be necessary to generate a crystal structure for 
DPF/H4 complexes to establish whether H3 and H4 N-terminal tails dock at a similar 
or distinct site(s) on MOZ DPF. It is possible that even a weak affinity for acetylated-
H4 tail might induce a conformational change to displace the H3 tail. Given the 
apparent difference in binding strengths, displacement of H3 by H4Kac through 
competitive binding seems a less likely explanation. An alternative model could be 
that H3 and H4 tails interact, in particular following acetylation of H4. This might 
sterically hinder docking of MOZ with H3. However, preliminary binding studies did 
not detect any interaction between core histones and unmodified or acetylated H3 and 
H4 peptides (data not shown). 


























Figure 3.22. Quantitative analysis of MOZ DPF binding to site-specific 
histone H3 and H4 PTMs. Fluorescent polarisation assay measuring the affinity 
of MOZ DPF binding to N-terminal FITC-labelled peptides including H3 
unmodified peptide (1-21) (pink-circle), H4 unmodified peptide (2-24) (blue-
square), H3 (1-21) acetylated at K9 (green triangle) and H4 (2-24) acetylated at 
K16 (orange diamond). The data are presented as averages and standard error of 
the means from triplicate samples. 
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3.12. Comparison of MOZ DPF to DPF3 
Sequence alignments of the MOZ DPF domain revealed a high degree of 
sequence conservation (72% similarity) with the tandem PHD fingers of the human 
DPF family of proteins. Such high homologies suggest structural similarity and 
possible functional similarity with regard to binding preference for histone PTMs. 
The DPF3b PHD1&2 three-dimensional structure has recently been solved using 
NMR methods (Zeng et al., 2010). These structures were utilised to compare the 
conservation of surface exposed residues within the binding site. Protein Data Bank 
(PDB) NMR structures of DPF3b were manipulated in PyMOLTM (2006, DeLano 
Scientific LLC) by colour coding those amino acids conserved with the MOZ DPF. 
Light yellow and yellow coloured residues represent similar residues between DPF3b 
and MOZ PHD fingers 1 and 2 respectively and light orange and orange residues 
represent identical residues between DPF3b and MOZ PHD fingers 1 and 2 
respectively (Figure 3.23). By mapping conserved surface binding residues onto the 
DPF3b structure, it is evident that almost the entire binding surface is composed of 
residues that are identical in MOZ (Figure 3.23). This suggested that DPF3b and 
MOZ interact with their histone peptide substrates in a similar way and additionally, 
leads to the assumption that the overall structure of the tandem PHD fingers is highly 
analogous. The DPF3b tandem PHD fingers establish contacts with the entire length 
of the histone H3 peptide (1-20), including the recognition of and contact to H3K9. 
This differs from other PHD fingers like the cognate BHC80 PHD domain, which 
contacts the first 8 residues of the H3 peptide with H3 residues K9 and S10 making 
numerous non-specific contacts with a neighbouring molecule (Lan et al., 2007). The 
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histone H3 peptide forms an extended conformation bound in an elongated groove of 
the double PHD finger (Figure 3.23(A)). DPF3b interaction with histone H3 is 
enhanced by acetylation at lysine 14 and inhibited by trimethylation at lysine 4. In 
comparison, the MOZ DPF was also shown to bind acetylated lysine residues of 
histone H3 and further, the MOZ DPF interaction with H3 is inhibited by tri-
methylation at H3K4. The acetylated H3K14 intercalates into a hydrophobic pocket 
of DPF3b PHD1, of which the key hydrophobic amino acid residues lining this 
pocket are all conserved in the MOZ sequence. In addition, those amino acids that 
secure the binding of the N-terminal H3 residues, including unmodified H3K4, are 
conserved. Interestingly, those residues located at the rim of the acetyl-lysine binding 
pocket, which are responsible for anchoring the peptide within the module, are not 
conserved in the MOZ sequence. This suggests that the MOZ DPF may adopt a 
similar mode of histone H3 recognition to DPF3b, but may utilise a slightly different 
mechanism to bind the acetyl-lysine PTMs.  
The focal distinction between the two binding patterns is in the tolerance for 
H4 lysine acetylation. The DPF3b PHD1&2 preferentially binds acetylated H4 
peptides, however with a 15-fold reduction in affinity compared to H3K14ac. The H4 
peptide folds over itself extending the main chain peptide away from the binding site 
and allowing only the insertion of the K16ac group (Figure 3.23 (B)- side view). 
Therefore, a weaker interaction is seen compared to the H3K14ac peptide, due to 
fewer contacts being made with the entire length of the peptide. Thus, H4 acetylation 
enhances DPF3b binding to unmodified H4. In contrast, the acetylation of histone H4 
prevents the association of MOZ DPF with histone H4. Referring more meticulously 
back to the sequence alignment of DPF3b and MOZ (Figure 3.3) shows that, despite a 
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significantly high sequence homology, two residues in PHD1 and one residue in 
PHD2, which have been structurally implicated in DPF3b acetyl-H4 binding are not 
conserved in MOZ (Figure 3.3- ɏ). This suggests that MOZ DPF adopts different H4 
binding mechanisms, emphasising the importance of structural characterisation as 
small sequence differences may have a profound impact on functionality. 
 In addition to sequence alignments, structural homology modelling of the 
MOZ DPF was carried out using the Modbase web program designed by the Sali lab 
(University of California, San Francisco). The MOZ DPF sequence was entered into 
the database and two hits were returned; DPF3b (2KWJ) and MLL PHD3 (2KYU). 
Considering the previously observed high similarity to DPF3b, the predicted structure 
of MOZ DPF was modelled upon this databank entry (Figure 3.24- purple ribbon). In 
PyMOLTM, the predicted structure of MOZ DPF was superimposed with the structure 
of DPF3b in the presence of the H3K14ac (2KWJ) (Figure 3.24(A)- green ribbon) or 
H4K16ac (2KWN) (Figure 3.24(B)- orange ribbon) peptide. This figure predicts that 
the overall MOZ DPF structure favours the configuration of DPF3b in complex with 
an H3K14ac peptide and yet, in comparison, its consequent superposition onto the 
DPF3b-H4K16ac structure shows areas of misalignment especially within the loop 
secondary structure regions. These models are in agreement with the histone binding 
studies carried out in this chapter, suggesting that DPF3b and MOZ DPF may have 
differential abilities with regard to binding H4K16ac. 





Figure 3.23. Conservation of surface exposed residues based on the hDPF3 
NMR structure. (A) PDB; 2KWJ, DPF3b in complex with Histone H3K14ac 
peptide (green). (B) PDB; 2KWN, DPF3b in complex with Histone H4K16ac peptide 
(green). Light orange (PHD1) and orange (PHD2) colours represent residues that are 
identical between DPF3b and MOZ. Light yellow (PHD1) and yellow (PHD2) 
colours represent residues that constitute similar substitutions in both domains. The 
H3K14 and H4K16 residues are shown as stick representations. Models were created 
in PyMOLTM. 





Figure 3.24. Alignment of DPF3b and the structural homology model of 
MOZ DPF. Structural models were created by the Modbase web program designed 
by the Sali lab (University of California, San Francisco). Predicted structures of 
MOZ DPF (purple ribbons) superimposed on the DPF3b NMR structures; (A) the 
backbone structure of DPF3b (PDB 2KWJ) (green) from the DPF3b/H4K14ac 
peptide complex and (B) the structure of DPF3b (PDB 2KWN) (orange) from the 
DPF3b/ H4K16ac complex. Peptide structures are masked. 
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3.13. Structural characterisation of the MOZ DPF 
 Structural analysis is essential to determine the intricate details involved in the 
molecular recognition of specific histone PTMs by the MOZ DPF. To date, a 
collaboration has been set up with Dr. Ingrid Dreveny, a protein crystallographer with 
the Division of Medicinal Chemistry and Structural Biology at the University of 
Nottingham.  
In conjunction with Dr. Baigong Yue, the expression and purification of His-
tagged MOZ DPF recombinant protein was optimised to routinely yield a large 
quantity of soluble protein. Briefly, 5 L bacteria were cultured at 37 °C until the 
OD600nm reached 0.5-0.6. Protein production was initiated by the addition of 0.1 mM 
of the IPTG inducer and cultured for a further 16 hours at 22 °C. Cells were 
harvested, resuspended in binding buffer (0.02 M sodium phosphate, 0.5 M NaCl 
pH7.4), sonicated and the soluble protein was harvested by centrifugation. 
Supernatants were finally filtered through a 0.45 nm filter. Purification proceeded via 
a HiTrap Chelating column loaded with 50 mM NiSO4. The column was equilibrated 
with binding buffer, loaded with the protein sample and washed with binding buffer 
containing 5 mM imidazole. His-tagged MOZ DPF was then eluted from the column 
using binding buffer containing 300 mM imidazole and the His-tag cleaved from the 
protein by incubation with thrombin protease overnight at 22 °C. Approximately 60 
mg of protein was purified from a 5 L starting volume of bacterial culture.  
Recently, the structure of the MOZ DPF in complex with a histone H3 N-
terminal peptide was solved to a high resolution of 1.7 Å. Co-crystallisation trials 
were set up by Dr. Ingrid Dreveny using MOZ DPF and a histone H3 N-terminal 
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peptide substrate. This yielded large, single crystals (Figure 3.25) that have the 
symmetry of space group P412121. A high resolution dataset was collected at the 
European Synchrotron Radiation Facility, Grenoble, beam line ID23-2. The structure 
was solved by sulphur-SAD phasing using the anomalous signal from the zinc atoms. 
After density modification, model building was carried out and the structure was 





Figure 3.25. Crystallisation of the MOZ DPF domain. MOZ DPF was expressed in 
a bacterial system and purified via its His-tag. Purified protein was utilised in co-
crystallisation trials with an N-terminal histone H3 peptide. 
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The structure is of very high quality and provides mechanistic insight into 
how both PHD1 and PHD2 contribute to engage the first thirteen N-terminal residues 
of H3. Unexpectedly, the H3 peptide (residues T3-G12) in the complex structure 
adopts a two-turn alpha-helical conformation (Figure 3.26), which to our knowledge 
has not been observed previously for the H3 N-terminus in interactions with PHD 
domains and is likely to be an induced fold. Further, the structure shows that the 
interaction between unmodified H3 and MOZ DPF is characterised by an intricate 
network of hydrogen bonding interactions. The assignment of DPF interactions with 
the entire length of the H3 peptide is still ongoing, however an example of how H3K4 
is recognised is depicted in Figures 3.26-3.27. H3K4 appears to be embedded into a 
binding pocket constituted by amino acids from both PHD fingers 1 and 2 (3.26). 
Multiple hydrogen bonds are established between the free amino group of the H3K4 
side chain and DPF main chain carbonyls (Figure 3.27). The crystal structure also 
highlights the existence of water-mediated hydrogen bonds stabilising the H3K4 side 
chain; contacts which cannot be detected using NMR solution structures (Figure 
3.27). This is consistent with the biochemical data showing that PHD1 and PHD2 of 
the DPF composite functionally cooperate to sense the H3K4 modification status. 
Interestingly, H3KSURWUXGHV IURP WKH VHFRQGĮ-helical turn, away from the MOZ 
DPF binding site (Figure 3.26). Peptide binding assays showed binding of K9ac and 
K9me3 modified H3 peptides by MOZ DPF. The capture of this structure implies that 
modification at the H3K9 residue does not affect binding of the MOZ DPF to the H3 
peptide, rather than specifically recognising the modification itself. However, it is 
possible that modification of H3K9 by methylation or acetylation could induce a 
change in the histone peptide conformational structure, to place the K9ac/me3 into 
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the MOZ DPF binding site. This has been seen previously for the H3 peptide in 
complex with DPF3b whereby, when unmodified, the K14 residue extends away 
from the binding site. However, upon acetylation the conformation of the peptide 
changes, projecting H3K14ac into a hydrophobic pocket created by the DPF3b 
tandem PHD fingers (Zeng et al., 2010). Co-crystallisation trials are currently being 
set up with MOZ DPF and an H3K9ac peptide. 
Our MOZ DPF structure can be superimposed onto the DPF3b NMR structure 
(102 aligned residues, sequence identity of 52%) with a root mean square deviation 
value of 1.9 Å between the structures. The overall fold is conserved but differences 
are apparent in loop regions (Figure 3.28). However, the most striking difference 
between the complexes pertains to the conformation of the H3 peptides. In our 
structure the H3 peptide is Į-helical and more intimately embedded within the DPF 
binding site, whereas within the DPF3b complex the H3 peptide is unstructured 
(Figure 3.28). 
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Figure 3.26. Two-dimensional structure of the tandem PHD finger of human 
MOZ. Cartoon representation of the MOZ DPF domain (PHD1 in orange and 
PHD2 in yellow) in complex with the unmodified histone H3 N-terminal peptide 
(green ribbon). Histone H3 lysine side chains, K4 and K9 are shown protruding into 
or away from the DPF binding site respectively. Coordinated zinc atoms are 
depicted in spacefill format as grey spheres. 
Chapter Three: Results 
206 
 
Figure 3.27. Structural mechanism of H3K4 engagement by human MOZ 
DPF. A focussed view of the region surrounding H3 lysine 4 (red), detailing 
plausible hydrogen-bonding interactions (dashed lines) with DPF main chain 
carbonyls (blue) and a water molecule (red cross). 
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Figure 3.28. Comparison of MOZ and DPF3b tandem PHD fingers. 
Superposition of the MOZ DPF crystal structure (blue) with DPF3b (PDB 2KWK, 
(Zeng et al., 2010)) NMR tandem PHD finger structure (cyan) in complex with 
unmodified H3 N-terminal peptides (red and yellow respectively).  




 MOZ catalyses the acetylation of lysine residues within histone proteins 
(Champagne et al., 2001), however how MOZ is targeted to specific chromatin 
substrates in order to direct its HAT activity remains unclear. MOZ is a large modular 
protein and only the MYST domain has been functionally characterised, therefore at 
the outset of this work the functional importance of the N-terminal tandem PHD 
fingers was yet to be established. As the DPF domain is retained in oncogenic MOZ 
fusion proteins in AML (Katsumoto et al., 2008), it is likely to have important 
functions in both a normal and malignant context. 
 The PHD domain is a well-established versatile epigenome reader that can 
recognise and interpret the methylated (Li et al., 2006), acetylated (Lange et al., 
2008) or the unmodified states (Lan et al., 2007) of histone lysine residues. MOZ and 
MORF are unusual in that they contain a double PHD finger arranged in tandem, but 
other chromatin modulators have also EHHQ VKRZQ WR KDUERXU GRXEOH µUHDGHU¶
domains. These include the TAF1 double bromodomains that bind multiple 
acetylated H4 peptides (Jacobson et al., 2000) and the two tudor domains of 
JMJD2A, that together cooperate to recognise the H3K4me3 modification  (Huang et 
al., 2006). More recently, the structural and functional characterisation of histone 
recognition by the double PHD finger protein, DPF3b, has been established. The 
tandem PHD fingers were shown to function as an integrated unit that determines its 
recognition specificity for the histone PTMs (Zeng et al., 2010). Sequence alignments 
of the MOZ DPF domain with DPF3b revealed a high degree of sequence 
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conservation (53%) between the two sequences. Thus, we first asked whether the 
MOZ DPF domain could also function as a histone PTM sensor.  
 Using GST pulldown assays it was demonstrated that the N-terminus of MOZ 
(1-321) and the DPF alone bound strongly to histone H3 in a dose-dependent manner. 
However, only a very weak interaction was observed with histones H2B and H4. 
Mutagenesis of the DPF indicated that MOZ binding of histone H3 was indeed 
mediated by the DPF domain and that the integrity of both PHD fingers was required 
for the interaction.  
Commercial core histones are purified from cell extracts and hence, exhibit a 
mixed population of PTMs. In order to define the specificity of MOZ DPF binding, 
we assessed how selected histone PTMs impact on these interactions. Using GST 
pulldown assays with biotinylated histone peptides as substrates, revealed that 
binding of MOZ DPF to histone H3 and H4 was mediated by the histone N-terminal 
tail sequences. Conversely, no interaction between the N-termini of H2A or H2B was 
observed. Further, pulldowns carried out with a series of modified H3 and H4 
peptides, showed that both the MOZ N-terminus and DPF domain were unable to 
bind H3 containing trimethylation at K4. This result was also consistent with a low 
sequence similarity observed by the alignment of MOZ DPF with other H3K4me3-
binding PHD fingers. Interestingly, MOZ 1-321 and the DPF alone were able to 
accommodate the dimethylation of H3K4, suggesting that the increased size and 
cationic radius of an additional methyl moiety is unfavourable for binding within the 
DPF binding pocket. Of course, to establish the actual effect of the third methyl group 
on binding requires the structural characterisation of the MOZ DPF in complex with 
the H3 peptide. Indeed, the latter cocrystallisation of MOZ DPF with an H3 peptide 
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rationalises the in vitro exclusion of H3K4me3 from the DPF binding site. In contrast 
to H3K4, trimethylation of H3K9 did not affect binding to either the MOZ N-
terminus or the DPF domain. However, H3K9/14 acetylation was seen to have 
differential effects on the MOZ 1-321 and DPF constructs. H3Kac stimulated the 
interaction with MOZ 1-321, but appeared not to have an affect on the binding of 
DPF alone. This suggested that a H3 acetylated peptide may induce additional 
contacts with the MOZ 1-171 sequence. The MOZ 1-321 and DPF constructs both 
showed strong binding to histone H4, however no interaction was observed for both 
proteins to any acetylated form of the histone H4 peptide. This suggested that H4 
acetylation was incompatible with MOZ recruitment to chromatin. Similar histone 
binding properties, namely the intolerance for H3K4me3 and acetylated H4, were 
also observed for the full-length MOZ protein and the closely related homolog 
MORF (87% identity). This implied that both enzymes are targeted to or released 
from chromatin enriched with similar PTMs. 
 Future work would entail an extensive profiling of the interactions between 
the MOZ DPF domain and other histone PTMs, not only to include individual PTM 
sites but also, to examine the effects of neighbouring modifications on recognition 
and binding. Recently, this has been made possible by the availability of commercial 
arrays such as MODifiedTM Histone Peptide Arrays (Active Motif). Each array 
contains 384 different histone modification combinations for the acetylation, 
methylation, phosphorylation and citrullination on the N-terminal tails of all four core 
histones; and thus would allow the rapid profiling of MOZ DPF interaction with 
multiple histone PTMs. In addition, recent data from our group shows that, like 
TIP60, MOZ expression is upregulated during DNA damage (unpublished). For this 
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reason, we would also like to investigate whether the MOZ DPF can function in 
sensing damage-DVVRFLDWHG370VVXFKDVȖ+$;RU+.DF 
 We next assessed whether the individual PHD fingers performed specific 
roles in governing the DPF binding pattern. Using GST pulldowns with constructs 
PHD1 (194-263) and PHD2 (250-323) and biotinylated histone peptides it was 
observed that PHD1 was able to bind unmodified H4 only, whereas PHD2 could bind 
both unmodified H3 and H4. Remarkably, PHD2 showed robust interactions with all 
modified N-terminal H3 peptides, including the trimethylated H3K4 mark. Noting the 
intolerance of the MOZ DPF protein for H3K4me3 binding, this result indicates that 
PHD1 and PHD2 functionally cooperate to determine the histone PTM binding 
selectivity of the DPF, in particular with regards to the discrimination of H3K4me3. 
Thus, advocating that PHD1 and PHD2 functionally cooperate to determine the 
histone PTM binding selectivity of the DPF, in particular to the sensitivity to 
H3K4me3. To establish functional cooperation, structural data would need to be 
obtained, to check that both PHD fingers make contacts with the histone peptide 
substrate. In fact, the latter cocrystallisation of the MOZ DPF and an H3 peptide 
confirms that residues from both PHD1 and PHD2 engage the N-terminal histone H3 
peptide. 
 ChIP analysis and immunofluorescence revealed that MOZ could associate 
with chromatin enriched with H3Kac PTMs and, in part, with trimethylated H3K9. 
These data corroborate other in vivo studies showing that MOZ is required for the 
acetylation of H3K9 at transcriptionally active Hox gene loci (Voss et al., 2009). 
Conversely, MOZ was not immunoprecipitated or colocalised with chromatin 
containing the H3K4me3 modification. MOZ has been shown to activate certain 
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genes, including Hox genes (Voss et al., 2009), however our results showed that 
MOZ is excluded from chromatin regions that contain H3K4me3; a modification 
generally associated with transcriptional activation. However, it is not clear whether 
all transcribed genes contain this PTM, so our results suggested that the function of 
MOZ in gene regulation either precedes or comes after the deposition of H3K4 
trimethylation. These in vivo data are consistent with our in vitro binding studies. It 
would be interesting to examine the occupation of genomic sites associated with 
MOZ complexes, once better ChIP-grade antibodies specific to MOZ become 
available. Using the ChIP-Seq technique MOZ-tagged binding sites can be correlated 
with one or more chromatin PTMs to verify our results in a promoter context. In 
addition, after the identification of MOZ binding sites, the affects of MOZ deficiency 
on histone PTMs at specific gene regions could be assessed by histone PTM-specific 
ChIP followed by quantitative genomic PCR.  
 The coexistence of multiple modifications on one or more histone tails of the 
same nucleosome suggests that chromatin regulators can sense multiple PTMs 
cooperatively or simultaneously. Evidence for the combinatorial recognition of 
multiple PTMs is emerging, for example the mouse TAF1 homologue, Brdt, which 
cooperatively binds two acetylation marks on a single H4 tail (Moriniere et al., 2009). 
Thus, we investigated as to how combinations of H3 and H4 PTMs influence the 
engagement of MOZ DPF. Using GST pulldowns with equimolar mixtures of 
peptides, it was demonstrated that the ability of MOZ DPF to bind H3, H3K9/14ac 
and H4 peptides was unaffected by H3K4me3, but inhibited by mono- or hyper-
acetylation of H4. These results suggested a model where H3K4me3 acts as a 
recessive exit signal that does not affect the simultaneous binding to PTM residues on 
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neighbouring histone tails, whereas H4Kac exerts a dominant inhibitory signalling 






Acetylation of H4 blocks the interaction of MOZ DPF with other histone 
PTMs. How this occurs is puzzling, given that in vitro binding assays demonstrated 
that binding of H4Kac peptides to the DPF is below the detection limit of the assay. 
Using fluorescence polarisation anisotropy revealed that GST-MOZ DPF was able to 
bind a FITC-labelled H4K16ac peptide, albeit with a much lower affinity compared 
to H4. There are a number of possible explanations for the dominant inhibitory affect 
observed for H4Kac with regards to the binding of other histone PTMs. Firstly, the 
interaction with H4 may be transient, but sufficient to reduce binding of H3 peptides 
to DPF; it is possible that even a weak affinity for an acetylated H4 tail might induce 
Figure 3.29. Schematic model depicting how combinations of H3 and H4 PTMs 
influence the engagement of MOZ DPF to chromatin. 
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a conformational change to displace the H3 tail, if the two peptides bind at two 
distinct pockets within the DPF. The MOZ DPF was also demonstrated to bind 
histone H3 with a substantial increase in affinity compared to H4 and thus, given this 
apparent difference in binding strengths, displacement of H3 through competitive 
binding at one binding pocket seems a less likely explanation. It will be necessary to 
generate a crystal structure for DPF/H4 complexes to establish whether H3 and H4 
N-terminal tails dock at similar or distinct site(s) on MOZ DPF. Finally, H3 and H4 
N-terminal tails might interact with each other in a PTM dependent manner; however, 
preliminary experiments to detect H3 and H4 interactions failed to support this 
hypothesis. 
 Binding studies thus far have been conducted with histone peptide surrogates, 
however little is currently known how the combinations of histone PTMs are 
interpreted at the level of nucleosomes; a more physiologically relevant substrate. 
Recently, it has been reported that histone marks constitute unique nucleosomal 
patterning, which dictates critical chromatin associations (Ruthenburg et al., 2011). It 
would therefore, be important to assess the binding preference of MOZ DPF for 
histone PTMs at the nucleosomal level. Nucleosomal substrates could be obtained via 
two different methods; firstly, the reconstitution of semi-synthetic histones, bearing 
the desired combinations of PTMs, into octamers. Alternatively, by the preparation of 
mono- or oligo-nucleosomes from native chromatin extracts by MNase digestion and 
sucrose gradient ultracentrifugation. These substrates would then be used to assess 
the enrichment or exclusion of the selected nucleosomal PTMs with or from MOZ.  
 The cocrystallisation of MOZ DPF with an N-terminal histone H3 peptide has 
produced a high resolution structure that provides mechanistic insight into how both 
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PHD1 and PHD2 contribute to engage the first thirteen N-terminal residues of H3. 
The assignment of DPF interactions with the entire length of the H3 peptide is still 
ongoing, however interactions mediating H3K4 recognition have been defined. H3K4 
was inserted into a binding pocket constituted by PHD1 and PHD2 residues and 
further, shown to be stabilised by multiple hydrogen bonds involving DPF main chain 
carbonyls and a water molecule. These results rationalised the exclusion of H3K4me3 
from the MOZ DPF binding site and are consistent with biochemical binding studies, 
whereby both PHD fingers of the DPF composite cooperate to sense the H3K4 
modification status. Remarkably, the complex structure revealed that the H3 peptide 
DGRSWHGDQĮ-helical structure, which to our knowledge has not yet been observed for 
the H3 N-terminus in interactions with PHD domains. Future work will entail the 
cocrystallisation of the MOZ DPF with H3K9ac, in order to determine the effect of 
the H3K9 modification on the fold of the H3 peptide. We also wish to characterise 
the DPF/H4 complex to examine whether the H3 and H4 peptides bind in similar or 
two distinct binding site(s). Each of the above structures would also be useful to 
guide the mutagenesis of DPF residues involved in sensing permissive and non-
permissive PTMs. Binding studies would then be carried out with such mutants, to 
examine how the structure-function influences the MOZ DPF engagement with 
histones. 
 In summary, our data shows that the MOZ DPF allows it to engage chromatin 
that is enriched in H3Kac but that lacks H3K4me3 and acetylation at H4. The binding 
preference of MOZ DPF has been established however, the order of PTM binding is 
not clear. Thus, to provide insight into MOZ function and the sequence of events that 
takes place, further probing is required into the complexes in which MOZ resides. For 
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instance the MOZ/EAF6/BRPF/ING5 complex harbours multiple FKURPDWLQµUHDGHU¶
modules each with distinct, and in some cases, opposing, binding specificities. The 
trimethylation of H3K4 is bound by the ING5 PHD finger (Champagne et al., 2008), 
but is excluded from the MOZ DPF. It has recently been shown that the 
combinatorial action of multiple PHD domains is essential in regulating the 
chromatin binding and substrate specificity of HBO1 HAT-containing complexes 
(Saksouk et al., 2009). Thus, it would also be important to analyse MOZ DPF binding 
function in the context of affinity purified complexes.  
 MOZ has also been found in complexes containing the methyltransferase 
MLL and the adaptor protein WDR5, which catalyses the trimethylation of H3K4 
(Paggetti et al., 2010). Such complexes provide a link between histone acetylation 
and methylation events at gene promoters. Recruitment of MLL and WDR5 by MOZ 
may then drive the deposition of H3K4me3, which is incompatible with MOZ and 
thus, serves as a release signal from chromatin, unless a free H4 tail is available. 
Conversely, MOZ could interact with chromatin bound MLL/WDR5, which 
facilitates MOZ acetylation of the same or neighbouring histone tails (Figure 3.30). 
These recruitment/release events might allow MOZ complexes to propagate selected 
PTMs in chromatin. Interrogation of such models will begin to shed light on the 
molecular mechanisms by which MOZ functions. 





Figure 3.30. Schematic model depicting the possible sequence of events involved 
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 The previous chapter has demonstrated that the MOZ DPF functions to 
engage chromatin by binding the histone tails of H3 and H4. The two PHD fingers 
cooperate to determine selective interactions with histone PTMs. Intriguingly, MOZ 
appears unable to make a stable association with the acetylated form of histone H4. 
This is of particular interest due to the presence of an adjacent MYST domain in 
MOZ, which contains an in vitro acetyltransferase activity shown to target H4 
acetylation (Champagne et al., 2001) and more recently, the acetylation of non-
histone substrates (Ullah et al., 2008) (Collins and Heery, unpublished data). Thus 
MOZ may regulate its own recruitment to and exit from chromatin. A conundrum in 
the field is that knockout studies revealed that MOZ ablation leads to reduced H3K9 
acetylation, whereas H4 acetylation is unaffected (Voss et al., 2009). This chapter 
describes work carried out to investigate the substrate specificity of MOZ and 
whether the DPF influences the target of MOZ acetylation.   
,Q DGGLWLRQ WR D KLVWRQH 370 µZULWLQJ¶ FDSDFLWy, the majority of chromatin 
PRGLI\LQJHQ]\PHVDOVRFRQWDLQDµUHDGHU¶PRGXOHDQGUHFHQWVWXGLHVVKRZWKDWERWK
these activities can cooperate in synergy to obtain the overall desired function. For 
example, the bromodomain of p300 is required for stimulating p300 HAT activity in 
order to maintain the basal level of histone acetylation and to induce transcriptional 
activation of p300-dependent genes (Chen et al., 2010). Further, the bromodomain is 
important for p300 to function at full coactivator activity, whereby the bromodomain 
recognises acetylated lysine residues and stabilises the association of p300 to specific 
chromatin sites (Zeng et al., 2008b). Examples of functional synergy between 
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µUHDGHU¶ DQG µZULWHU¶ PRGXOHV ZLWKLQ WKH VDPH SURWHLQ DUH emerging and so, this 
chapter also describes work carried out to test whether the DPF module affects other 
functional properties of the MOZ protein; including its acetyltransferase and 
transcriptional coactivator activities and its subcellular localisation.  
 
4.2. The MOZ DPF contains an intrinsic HAT activity 
 To investigate whether the DPF influences the histone acetyltransferase 
activity of MOZ, three constructs incorporating the individual DPF and MYST 
domains alone and the DPF+MYST domains together (Figure 4.1(A)), were cloned 
into the bacterial GST-expression plasmid. GST-fusion proteins were expressed in 
the Rosetta E. coli strain and purified via the high affinity of GST for glutathione 
using glutathione cross-linked sepharose beads. Proteins were eluted off the beads 
and their concentrations normalised by SDS-PAGE and Coomassie staining to ensure 
equal amounts of protein were used in subsequent in vitro assays (Figure 4.1(B)). The 
Coomassie gel highlighted normalised concentrations of GST-MOZ DPF and GST-
MOZ DPF+MYST proteins, however it also showed an unequal concentration of 
GST-MOZ MYST in comparison (Figure 4.1(B)- compare lanes 2&3 with 4). To 
rectify this, five times the amount of GST-MOZ MYST protein loaded onto the gel 
was used in the following HAT assays. 
 The constructs GST-MOZ MYST, GST-MOZ DPF+MYST and the control 
construct GST-MOZ DPF were then utilised in both filter binding and in-gel HAT 
assays. Firstly, filter binding assays, as described in the Materials and Methods, were 
carried out to measure the total acetylation of substrate, where fusion proteins were 
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incubated with core histone extracts as a substrate and [3H]-Acetyl-CoA as the acetyl 
group donor. Samples were incubated at 30 °C for 30 minutes to allow the reaction to 
reach completion and spotted onto filter paper. Filters were washed thoroughly with 
sodium carbonate solution to remove residual radioactive isotope and incubated in 
scintillation fluid overnight. Tritium counts were measured using a scintillation 
counter and results calculated relative to a background reading carried out without 
HAT enzyme or with the GST tag protein alone. 
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Figure 4.1. Purification of the MOZ DPF and MYST domains. (A) Schematic 
representation of GST-MOZ fusion constructs used in subsequent assays. (B) 
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             As shown in Figure 4.2, the DPF+MYST exhibited an 8-fold acetylation 
activity on substrate histones compared to a 6-fold activity for the MYST domain 
alone (Figure 4.2(A)- compare bars 3&4 to 1). This suggests that in the presence of 
the DPF the MYST domain acetyltransferase activity is slightly enhanced, perhaps 
due to the gain of a histone docking module. Surprisingly, the DPF alone, included in 
the assay as a negative control, exhibited an acetylation activity of histones that was 
3-fold over background (Figure 4.2(A)- bar 2). 
To investigate this further, an in-gel HAT assay was conducted to obtain data 
on the specific histone target of enzyme acetylation. Amendments to the above 
protocol included the use of [14C]-Acetyl-CoA radioisotope as the acetyl group donor 
and following the 30 minute incubation, reactions were subjected to SDS-PAGE and 
autoradiography. As shown in Figure 4.2, GST-MYST and GST-DPF+MYST both 
showed an ability to acetylate H4. However, the DPF+MYST substrates also included 
the acetylation of H3 and possibly H2A. In contrast, the control showed no detectable 
acetylation of core histones (Figure 4.2 (B)). This also shows that the histone 
preparations did not contain measurable levels of contaminant HATs. Remarkably, 
DPF was found to acetylate histone H3 but not other histones (Figure 4.2 (B)). This 
result suggests that the DPF appears to have a H3-specific HAT activity and its 
presence with the MYST domain extends the range of histone substrates for MOZ. 
This represents, to our knowledge, the first report of a mild acetyltransferase activity 
described for a PHD domain. 
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Figure 4.2. The MOZ DPF contains an intrinsic HAT activity. In vitro HAT 
assays using 1.5 µg of HAT enzyme, 10 µg core histones as substrate and either 
(A) [3H]-Acetyl-CoA or (B) [14C]-Acetyl-CoA as acetyl group donors. HAT 
reactions were followed by either (A) filter binding and liquid scintillation 
counting or (B) SDS-PAGE and autoradiograph analysis.  Error bars represent 
the average of a minimum of two data sets.  
(B) 
(A) 
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  To investigate the nature of the intrinsic HAT activity of the DPF module, 
HAT assays were performed with MOZ-DPF, MOZ-PHD1 and MOZ-PHD2 
constructs. Both in-gel autoradiograph and filter binding tritium counts confirm 
previous results whereby the MOZ-DPF shows a 3-fold increase in acetylation 
activity towards histone H3 (Figure 4.3(A)(B)- lane 2). However, neither PHD1 nor 
PHD2 individually showed any HAT activity in these assays (Figure 4.3(A)(B)- 
compare lane 2 to 3 & 4). This result indicates that the acetyltransferase activity is an 
intrinsic property of the intact DPF module, as disrupting the tandem PHD finger 
structure obliterates activity. Comparable to the definition of DPF histone PTM 
binding selectivity, the recent results suggest that PHD1 and PHD2 also functionally 
cooperate to govern acetyltransferase activity. 
 In order to verify the specificity of histone acetylation activity for the full-
length MOZ protein alternative expression methods were required, as the MOZ 
protein was too large to express efficiently as a GST-MOZ fusion. Therefore, the full-
length protein and construct MOZ 1-810 (H1/5+DPF+MYST) were over-expressed 
as FLAG-tagged constructs in HEK293 cells. After 48 hours post-transfection, cells 
were lysed and the proteins immunoprecipitated with anti-MOZ (127A) antibody. 
This antibody was produced by Leukaemia and Lymphoma Research and purified by 
Dr. Hilary Collins. The MOZ 127A antibody is raised against the MOZ 172-321 
epitope.  IP samples were then used in an in-gel HAT assay. As shown in Figure 4.4, 
both FLAG-MOZ constructs were successfully immunoprecipitated, however it 
should be noted that the IP of the full-length protein was much weaker (Figure 
4.4(A)- compare lanes 4&6). These results indicate that the MOZ protein contains 
two distinct acetyltransferase activities; the DPF which appears to selectively target 
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H3 and the MYST domain for which H4 is the major target. Together as DPF+MYST 
or in the context of the 1-810 protein, these domains appear to acetylate both H3 and 
H4, although 1-810 shows a preference to acetylate H3. How this substrate preference 
is established and what the lysine targets are, remain to be established. Moreover, 
whether histone PTMs affect these activities is also of great interest. The full-length 
MOZ also appears to target H3 and H4 in in vitro assays, consistent with our 
findings. However, these activities may be modulated by other proteins in vivo, such 
as suggested for the ING5 complex (Doyon et al., 2006). 





Figure 4.3. HAT activity is a property of the intact DPF module. In vitro 
HAT assays using 1.5 µg HAT enzyme, 10 µg of core histones as substrate and 
either (A) [3H]-Acetyl-CoA or (B) [14C]-Acetyl-CoA as acetyl group donors. 
HAT reactions were followed by either (A) filter binding and liquid scintillation 
counting or (B) SDS-PAGE and autoradiograph analysis. Error bars represent 
the average of a minimum of two data sets.  
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Figure 4.4. Acetylation activity of the full-length MOZ protein. HEK293 cells 
were mock transfected or transiently transfected with expression plasmids 
encoding FLAG-MOZ. After 48 hours post-transfection, cells were lysed and the 
proteins were immunoprecipitated with anti-MOZ 127A antibody. IP constructs 
were used as enzymes in in vitro HAT assays with 10 µg core histones as 
substrate and [14C]-Acetyl-CoA as an acetyl group donor. HAT reactions were 
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4.3. Trimethylation of histone H3K4 blocks acetylation of 
histone H3  
 MOZ contains two distinct acetyltransferase activities that may cooperate to 
establish histone acetylation events in chromatin. As the DPF appears to have a dual 
function; as a H3/H4 PTM sensor and an acetyltransferase this raised the question 
regarding how existing PTMs on histones might affect the HAT activity. In other 
words we were interested to determine whether PTMs that promote or disrupt MOZ 
DPF binding to histones would influence the ability of MOZ to acetylate H3 and H4 
N-terminal tails.  
In order to investigate the effect of histone PTMs on MOZ HAT activity, in 
vitro HAT assays (filter) were conducted as previously described, using unmodified 
and modified histone peptides as substrates. We focussed on the following range of 
PTMs that included both modifications that promoted and those that disrupted DPF 
binding to the histone tails. All data was expressed as a fold activity relative to a 
background reading achieved without HAT enzyme. The GST-MOZ PHD2 protein 
was used as an assay negative control due to its strong histone binding capability but 
inability to acetylate histones. 
 Both no HAT and PHD2 controls detected no acetylation of any of the five 
peptides or core histones. DPF alone was able to acetylate core histones and the H3 
(1-21) peptide (Figure 4.5, orange and dark blue bars), but not the histone H3 (21-44) 
peptide (Figure 4.5, purple bar). This suggests that the target for MOZ DPF 
acetylation is located at the N-terminus of histone H3 at either lysine 9, 14 or 18, 
rather than in internal H3 sequences. No acetylation of the H3 peptide was observed 
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when modified at H3K4me3 or H3K9me3 (Figure 4.5 red and green bars). This result 
can be explained in several ways. We have previously shown that MOZ DPF does not 
bind trimethylated H3K4, hence it may not be able to acetylate the peptide. DPF can 
however bind to trimethylated H3K9 and so this indicates that K9 may be a major 
target of MOZ acetylation, thus no additional acetylation is possible. This suggests 
that K14 or other lysines may not be the target of MOZ DPF acetylation. In order to 
support this finding, HAT assays were carried out with the GST-MOZ DPF protein, 
unmodified histone H3 peptide substrate and the [3H]-Acetyl-CoA acetyl group 
donor. HAT reactions were then spotted onto nitrocellulose and subjected to 
LPPXQREORWWLQJZLWKĮ-+.DFDQGĮ-H3K14ac antibodies. Control reactions show 
no background acetylation of histones underscoring the validity of the assay (Figure 
4.6- lanes 1&2). MOZ DPF+MYST appears to acetylate both lysine residues 9 and 14 
(Figure 4.6- lane 4, top & bottom panel respectively), however in comparison the 
MOZ DPF domain showed a preference for acetylating lysine 9 over 14 (Figure 4.6- 
lane 3, compare the spot intensity of top & bottom panel). These results suggest a 
HAT activity targeting H3K9 for the MOZ DPF. 
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Figure 4.5. Trimethylation of histone H3K4 blocks the acetylation of histone 
H3. In vitro HAT assays using 1.5 µg HAT enzyme, 0.75 µg/12.5 µM histone 
peptides as substrate and [3H]-Acetyl-CoA as an acetyl group donor. HAT 
reactions were followed by filter binding and liquid scintillation counting. Error 
bars represent the average of a minimum of two data sets.  
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Figure 4.6. MOZ DPF primarily acetylates lysine 9 of histone H3. In vitro 
HAT assays using 1.5 µg HAT enzyme, 0.75 µg/12.5 µM of unmodified H3 
peptide as substrate and [3H]-Acetyl-CoA as an acetyl group donor. HAT 
reactions were spotted onto nitrocellulose membrane and followed by 
immunodetection of the indicated post-translational modifications. 
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 The MYST domain was able to acetylate histone H4 to a greater extent than 
H3 (1-21), but not H3 (21-44) in the context of surrogate peptide substrates (Figure 
4.5- light blue, blue, purple bars respectively). No acetylation of H3 was detected 
with a H3K4me3 peptide, although some acetylation of H3K9me3 was observed 
(Figure 4.5- red and green bars). The combined DPF+MYST construct showed strong 
acetylation of H3 and H4 which was blocked by H3K4me3 (Figure 4.5). H3K9me3 
modified peptide only slightly decreased the ability of MOZ MYST and DPF+MYST 
to acetylate the H3 peptide (Figure 4.5- green bar). This suggests that the MOZ 
MYST domain not only acetylates H3K9, accountable for the slight decrease in 
acetylation counts, but also other lysine residues within the H3 peptide as acetylation 
is not completely abolished. The specific lysine target of MOZ acetylation still 
remains elusive, however this data implies that rather than searching for a single 
target, MOZ could acetylate multiple lysine residues within the H3 peptide. Indeed, 
HAT reactions followed by dot blot immunodetection suggest both H3K9 and H3K14 
as targets for MOZ-DPF+MYST acetylation (Figure 4.6). 
Remarkably, not one of the MOZ DPF, MYST or DPF+MYST proteins was 
able to catalyse the acetylation of a H3 peptide tri-methylated at lysine 4, despite all 
target lysine residues being free for modification (Figure 4.5- red bar). The lack of 
acetylation displayed by the MOZ HAT activities could possibly be a result of two 
mechanisms. Firstly, previous binding assay results show that the MOZ DPF exhibits 
an intolerance for the H3K4me3 modification. This finding suggests that MOZ is 
unable to dock onto peptides containing the H3K4me3 mark, preventing further 
acetylation of lysine residues on the same histone tail. Secondly, it was seen in the 
peptide acetylation assays that the MOZ MYST domain was also unable to acetylate 
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the H3K4me3 peptide. This implies that modification at H3K4 could possibly prevent 
or affect the entry of the substrate into the MYST catalytic active site, either by size 
or charge exclusion or a change to the conformation of the histone peptide, impeding 
acetylation of the histone lysine substrate. 
Again, utilising peptides in the HAT assay enables the prediction of several 
possible lysine residues (K5, 8, 12, 16 or 20) on H4 as targets of MOZ acetylation. 
Further, to identify which histone H4 lysine residue is acetylated by MOZ, peptide 
binding assays were conducted with mono-acetylated histone H4 peptides to see 
whether blocking a specific residue would prevent acetylation of the peptide. Rather 
than identifying a specific target of acetylation, it appears that none of the mono-
acetylated H4 peptides could be additionally acetylated by MOZ DPF+MYST (Figure 
4.7). This suggests that H4Kac serves as a prevention signal for MOZ DPF+MYST 
binding to chromatin and the further acetylation of the same histone H4 tail. Whether 
this is because of the inability of H4Kac to interact with MOZ DPF remains to be 
established.  
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Figure 4.7. Acetylation of histone H4 blocks further acetylation by MOZ. In 
vitro HAT assays using 1.5 µg HAT enzyme, 0.75 µg/12.5 µM histone peptides as 
substrate and [3H]-Acetyl-CoA as an acetyl group donor. HAT reactions were 
followed by filter binding and liquid scintillation counting. Error bars represent 
the average of a minimum of two data sets.  
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4.4. Cooperative histone acetylation by the DPF+MYST 
module 
From previous acetylation assays using both peptides and core histones as 
substrates, it is evident that the acetylation activity of GST-MOZ DPF+MYST is 
higher than that of either domain alone (Figures 4.2, 4.3 & 4.5). These results may 
indicate the two domains cooperate to enhance the rate of histone acetylation. In 
order to test this hypothesis, time course HAT assays were conducted to compare the 
specific activity (amount of substrate the enzyme converts per mg of protein per unit 
of time) between core histones substrates, the [3H]-Acetyl-CoA acetyl group donor 
and GST-MOZ-DPF, -MYST, -DPF+MYST protein constructs. Protein quantities 
were normalised (Figure 4.1(B)) to ensure that the same amount of each construct 
was used in the assays. It is assumed that all three proteins are correctly folded due to 
significant binding and HAT activity in prior assays (Figure 3.11 & 4.2). In addition, 
the MOZ MYST domain has been structurally characterised by X-ray crystallography 
(Holbert et al., 2007) and the MOZ DPF domain has been structurally characterised 
by our laboratory in collaboration with Ingrid Dreveny (Chapter 3). 
Filter binding assays were carried out as before, except that instead of taking a 
single point measurement after the reaction has reached steady-state, numerous 
samples were taken over a time course of 960 seconds in order to determine the rate 
of histone acetylation by each construct. To convert the scintillation counts (Dpm) 
into the more relevant measurement of pmol of acetylated histones, a fixed amount of 
tritium was spotted onto a filter and used as a standard. 
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 The GST-MOZ MYST (Figure 4.8- pink) and GST-MOZ DPF+MYST 
(Figure 4.8- black) proteins are both active in this acetylation assay. Two main 
conclusions can be obtained from this kinetic plot; firstly, there is a clear difference 
in the extent of histone acetylation by the two constructs. For example at the fixed 
time value of 240 seconds, GST-MOZ MYST acetylates 0.48 pmol of histone 
substrate and GST-MOZ DPF+MYST acetylates 2.17 pmol of histone lysine 
residues; a 4.5 fold difference.  Thus, a clear increase in the total acetylation output is 
observed in the presence of the DPF domain. 
Secondly, the gradient of the plotted slopes differs significantly, where a 
steeper slope is observed for GST-MOZ DPF+MYST compared to GST-MOZ MYST 
(Figure 4.8). The slope represents the rate of acetylation catalysis, thereby depicting 
that the rate of histone acetylation by DPF+MYST is significantly faster than that of 
the MYST domain alone (Figure 4.8). In addition, these data show a difference in the 
rate at which the steady state is achieved by the two proteins. A linear relationship 
between time and activity can be observed for the GST-MOZ MYST protein plot, 
showing that the reaction has not yet begun to plateau and thus, has not reached a 
steady-state (Figure 4.8- pink plot). In comparison, the plot for GST-MOZ 
DPF+MYST can be divided into two sections. The plot is linear over the intial 240 
seconds but begins to plateau between 240 and 960 seconds, indicating that the 
reaction has reached steady-state (Figure 4.8- black plot).  
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Figure 4.8. The DPF domain enhances the HAT activity of MOZ. In vitro 
HAT assays using 1.5 µg of HAT enzyme, 10 µg core histones as a substrate 
and [3H]-acetyl-CoA as an acetyl group donor. Numerous samples were taken 
over a time course of 960s at intervals of 0, 30, 60, 120, 240, 480 and 960s. 
HAT reactions were stopped and samples were subjected to filter binding and 
liquid scintillation counting. Error bars represent the average of a minimum of 
two biological replicates.  
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            To determine initial reaction rates for the DPF, MYST and DPF+MYST 
domain proteins, the first four data points for each construct were plotted. The slopes 
represent the initial rate of catalysis performed by the constructs and these data show 
that both the DPF and MYST domains alone undergo a much slower rate of 
acetylation compared to when both domains are present together (Figure 4.9(A)). 
Linear regression analysis was used to obtain the initial rate of catalysis, in pmol 
acetylated histones per second (pmol/s), from the slope of the fitted line. 
Subsequently, the rates were converted as ratios relative to the DPF+MYST rate of 
catalysis (Figure 4.9(B)). From this data it is evident that the DPF+MYST domain 
shows a 12.5- or 5-fold increase in specific activity over the individual DPF and 
MYST domains respectively.  
These results could be attributed to the supplementary intrinsic HAT activity 
of the DPF domain, where both the DPF and MYST domains acetylate histones, 
enhancing the total output and rate of acetylation. Thus, the DPF+MYST module 
together is more likely to constitute the functional acetyltransferase domain of MOZ. 
In addition, the DPF could facilitate and augment catalysis by the MYST domain 
through its binding affinity for the substrate (Kd-dissociation constant), whereby it 
binds and docks onto the histone substrates that require acetylation. This would 
permit a specific targeted acetylation of the substrate rather than a random process, 
increasing the probability of successful catalysis. 
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Figure 4.9. The DPF domain enhances the rate of histone acetylation by 
MOZ.  In vitro HAT assays using 1.5 µg HAT enzyme, 10 µg core histones as a 
substrate and [3H]-Acetyl-CoA as an acetyl group donor. Samples at early time 
intervals 0, 30, 60, 120s were taken and subjected to filter binding and liquid 
scintillation counting. (A) Graphical representation of data. Slopes represent the 
initial rate of reaction of each MOZ construct. (B) Linear regression analysis was 
used to calculate the initial rate of reaction, in pmol acetylated histones s-1, from the 
slope of the fitted line. Enzyme specific activity values were calculated considering 
WKHȝJRISURWHLQXVHG LQHDFKDVVD\DQGFRQVHTXHQWO\VLQJOH'3F and MYST 
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4.6. Acetylation of histone H3 by MOZ DPF promotes its 
interaction with H3 
 Binding studies revealed that acetylation of an unmodified histone H3 peptide 
stimulated interaction with MOZ DPF, whereas the hyperacetylation of histone H4 
was not tolerated (Figure 3.11(B)). MOZ DPF and MYST domains also exhibit the 
capacity to acetylate both the H3 and H3/H4 substrates respectively (Figure 4.2(A)). 
We therefore investigated whether MOZ acetylation of the histone N-terminal tails 
could influence its binding preference for the substrate. 
 Histone peptide binding assays were performed with GST-MOZ DPF, -PHD2 
or -DPF+MYST proteins and unmodified H3/H4 peptides in the absence or presence 
of acetyl-CoA. Western blots were used to detect the amount of GST protein retained 
on biotinylated peptide beads and assessed quantitatively using densitometry. The 
increasing presence of acetyl-CoA enhanced the binding of DPF and DPF+MYST to 
histone H3 in a dose-dependent manner (Figure 4.10- compare lanes 3 with 4 & 5, 
top and bottom left panel). No effect on the binding of PHD2 to histone N-terminal 
tails was observed (Figure 4.10- middle panel), consistent with its lack of 
acetyltransferase activity (Figure 4.3). These results indicate that acetylation of 
histone H3 by DPF or DPF+MYST promotes the interaction of MOZ to the H3 N-
terminus. Thus, MOZ appears likely to promote its own recruitment to chromatin via 
the acetylation of and binding to histone H3. 
 In addition, binding of the DPF and PHD2 proteins to histone H4 was 
unaltered by the presence of excess acetyl-CoA (Figure 4.10- compare lane 8 with 9 
& 10, top and middle right panel). This result corroborates previous findings where 
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PHD2 lacks total histone acetyltransferase activity and MOZ DPF exhibits HAT 
activity towards histone H3 only and, is therefore, unable to acetylate histone H4 
(Figure 4.3).  In contrast, DPF+MYST, which can bind and acetylate unmodified H4, 
showed a net increase in binding in the presence of acetyl-CoA. Although DPF-
MYST can acetylate H4, it is unable to form a stable association with acetyl-H4 as 
previously described. The observed increase may reflect an interim stabilisation 
through docking with the unmodified H4 peptide. This suggests that instead of 
functioning as an exit signal, rather pre-written or deposited H4 lysine acetylation 
serves to prevent the initial docking of MOZ to chromatin rich in this modification. 
Alternatively, acetyl-CoA may change the conformation of the DPF+MYST protein 
structure, rendering acetyl-H4 binding as favourable. 
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Figure 4.10. Acetylation of histone H3 by MOZ DPF promotes its interaction 
with H3. In vitro HAT assays were conducted with 1.5 µg of the indicated GST-
MOZ fusion protein, 0.75 µg/12.5 µM biotinylated unmodified histone H3 or H4 
peptides as substrate and increasing concentrations of cold Acetyl-CoA (0, 1.5 and 3 
µM) as an acetyl group donor. Subsequently, histone peptide pulldowns were carried 
out where samples were incubated overnight in binding buffer and subjected to 
immunodetection witKĮ-GST. Densitometry readings were calculated, relative to the 
protein input, using the Image J software. 
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 Hyperacetylation of histone H4 influences the ability of the DPF domain to 
bind other H3 PTMs, but it is unclear whether this dominant inhibitory affect is also 
extended to its HAT activity. In order to address this question, single peptides or an 
equimolar mixture of peptides were used as substrates in an in vitro HAT assay with 
GST-MOZ DPF and DPF+MYST. Firstly, as a control assay, peptides representing 
the N-terminal tails of both unmodified H3 and H4 were incubated together in the 
HAT assay. As shown in Figure 4.11, the presence of the H4 unmodified peptide 
does not alter the ability of the DPF to acetylate histone H3 (Figure 4.11(A)- compare 
green bar 1 with 3). In addition, the total acetylation level with DPF+MYST and a 
50:50 ratio of H3 and H4 peptides appears not to be affected (Figure 4.11(A)- 
compare black bars 1 & 2 with 3). However, as both peptides are targets for the 
DPF+MYST HAT activity, it is not clear whether the acetylation level of H3 and H4 
individually is affected in the presence of the other peptide. Secondly, the unmodified 
histone H3 peptide was incubated with the hyperacetylated histone H4 peptide. As 
only the H3 peptide is a target for acetylation in this assay, due to the use of a pre-
acetylated H4 peptide (Figure 4.11(B)- compare green & black bars 1 & 2), a direct 
comparison can be made between the level of H3 acetylation in the absence and 
presence of the H4Kac peptide. As shown in Figure 4.11, the level of H3 acetylation 
for both the DPF and DPF+MYST proteins is unchanged in the presence of the 
H4Kac peptide (Figure 4.11(B)- compare green & black bars 1 & 3). This suggests 
that pre-acetylated histone H4 exerts a dominant inhibitory affect over binding of 
MOZ DPF to chromatin, but does not influence its ability to acetylate neighbouring 
H3 N-terminal tails. 
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Figure 4.11. H4 acetylation does not affect the acetylation of histone H3. In 
vitro HAT assays using 1.5 µg HAT enzyme, a total mass/concentration of 0.75 
µg/12.5 µM histone peptides (A) H3 (1-21) and H4 or (B) H3 (1-21) and pre-
acetylated H4Kac as substrate(s) and [3H]-Acetyl-CoA as an acetyl group donor. 
HAT samples were then subjected to filter binding and liquid scintillation 
counting.  
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4.7. The MOZ DPF domain is required for AML-1 mediated 
transcription 
 MOZ functions as a transcriptional coactivator for several transcription 
factors, particularly factors involved in the regulation of haematopoiesis. MOZ has 
been shown to interact with AML1 and stimulate the transcription of AML-dependent 
genes (Kitabayashi et al., 2001a). Intriguingly, it has been shown that mutations that 
disable the MYST HAT domain did not affect the coactivator properties of MOZ, but 
rather the function of a C-terminal transactivation domain (serine-, proline & 
glutamine-, methionine-rich regions) and the N-terminal H1/5 domain was required 
for transcriptional activity (Kitabayashi et al., 2001a). To investigate whether the 
MOZ DPF domain was required for the stimulation of AML1-mediated transcription, 
luciferase reporter assays were conducted. U2OS cells were transiently transfected 
with the AML1-responsive luciferase reporter plasmid (pT109-3x AML1-luc), the 
AML1 and FLAG-02=FRGLQJH[SUHVVLRQYHFWRUV DQG WKHȕ-galactosidase internal 
control plasmid. Luciferase activity was assayed 48 h post transfection using the 
Dual-OLJKW /XFLIHUDVH DQG ȕ-Galactosidase reporter gene assay system (Applied 
Biosystems) and Luminometer Orion (Berthold). 
 AML1 was cotransfected with either the full-length MOZ construct, MOZ N 
(breakpoint fusion protein, lacking the C-terminus), MOZ-TIF2 oncogenic fusion 
protein or empty vector and were all tested in the luciferase reporter assay to examine 
their affect on AML1-mediated transcription. Full-length MOZ was able to activate 
transcription at the AML1 promoter (Figure 4.12(A)- compare bars 2 & 3). These 
findings are consistent with previously published results from our group (Collins et 
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al., 2006), underscoring the necessity of the C-terminal domains for transcriptional 
activation. Single DPF mutants were therefore created in the full-length MOZ 
expression plasmid for testing in subsequent reporter assays. Both the PHD1 (C233A) 
and PHD2 (C307A) mutants abolished the transactivation potential of MOZ at the 
AML1 promoter (Figure 4.12(B)- compare lane 3 with 4 & 5), suggesting that the 
DPF domain is required for coactivator function. These DPF mutants should not 
disrupt activation through altering the direct interaction of MOZ with AML1, as the 
two binding regions for AML1 have been mapped outside of this domain 
(Kitabayashi et al., 2001a). Mutating zinc-coordinating cysteine residues is likely to 
disrupt the structure of the DPF, however little is known about the affect these 
mutants may have on the overall protein structure. Yet, immunofluorescence data 
accentuates that the protein mutants are expressed in these cells (Figure 4.13). These 
factors imply that the abrogation of AML1-mediated transcription is caused by the 
disruption of the MOZ DPF domain, albeit via a mechanism that is independent of 
the AML1-MOZ interaction. The PHD domain has also been cited as functioning as a 
protein-protein interaction domain (Bienz 2006) and possibly mutating the MOZ DPF 
prevents the recruitment of additional factors required for the stimulation of AML1-
mediated transcription. Alternatively, it has been shown that the role of MOZ HAT 
activity in gene regulation is dependent on promoter contexts, where the MYST 
domain is required for NF-ț%-dependent transcription (Chan et al., 2007), but not for 
AML1-dependent transcription (Kitabayashi et al., 2001a). This suggests that H4 
acetylation by MOZ MYST is not required for coactivator function but the DPF 
domain is. Earlier results demonstrate that the MOZ DPF can function as a chromatin 
binding module (Figure 3.11) or as a mild H3-specific acetyltransferase (Figure 4.2). 
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Thus, its HAT activity may also be required for coactivator properties at a specific 
subset of promoters. The abolished transactivation of AML1-mediated transcription 
could therefore, be a result of a lack of DPF-mediated histone H3 acetylation or a 
result of the loss of ability to bind chromatin.  
Chapter Four: Results 
249 
 
Figure 4.12. MOZ DPF mutants inhibit transcription activation of the AML1 
reporter. U20S cells were transiently transfected with 500 ng of pT109-3x AML1-
luc, 100 QJRI$0/DQGȕ-GAL and 500 ng FLAG-MOZ construct in 12-well plates. 
Luciferase activity was assayed as described in Materials and Methods for (A) MOZ 
wild-type or (B) MOZ DPF mutant constructs. Reporter activation is represented as a 
fold induction over the control value (reporters in the absence of coactivators). The 
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4.8. Mutation of MOZ DPF does not affect its subcellular 
localisation 
The mutation of the DPF domain within the context of FLAG-MOZ led to a 
loss of coactivator function in reporter assays. To determine if this resulted in the 
destruction or mislocalisation of MOZ, we examined the subcellular localisation of 
MOZ using IF staining. 
Previous reports from our group showed that MOZ was concentrated into 
subnuclear foci or speckles and was excluded from nucleoli. Moreover, co-staining 
for other nuclear proteins divulged that MOZ foci were distinct from splicing 
speckles, Cajal bodies and PML bodies, suggesting that MOZ inhabits a separate 
nuclear subdomain (Kindle et al., 2005). FLAG-tagged MOZ N and MOZ N DPF 
mutants were transiently transfected and over-expressed in HEK-293 cells. Cells 
were then stained with anti-FLAG and an Alexa-594-conjugated secondary antibody. 
Cell nuclei were also stained with the Hoechst 33258 nuclear stain. 
The MOZ N WT, MOZ C233A and MOZ C307A proteins showed similar 
distribution patterns within the nucleus of transfected HEK293 cells. All three 
proteins exhibited punctate nuclear staining where proteins are concentrated into 
discrete foci (Figure 4.13). This suggests that although the DPF is essential for the 
engagement of chromatin with regards to histone PTMs, other domains within MOZ 
may provide additional contacts with chromatin or other nuclear structures. 
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Figure 4.13. Subcellular localisation of exogenously expressed MOZ proteins. 
HEK-293 cells were seeded onto coverslips and transfected after 24 hours with 
expression plasmids encoding WT FLAG-MOZ N, C233A or C307A FLAG-MOZ N 
mutants. After 48 hours post-transfection, cells were fixed in 4 % paraformaldehyde, 
permeabilised and stained with mouse anti-FLAG (red). Staining was followed by 
incubation in an anti-mouse Alexa594 secondary antibody. Hoechst 33258 (blue) was 
used as a stain of DNA. 
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4.9. Summary  
In Chapter 3 it was shown that the MOZ DPF functions as a chromatin 
binding module by engaging specifically with the N-terminal tails of histones H3 and 
H4. MOZ appears to be incapable of forming a stable interaction with the 
trimethylated H3K4 and hyperacetylated form of histone H4. The inability to bind 
acetylated forms of H4 is intriguing, given that the MOZ MYST domain has been 
reported to target histone H4 acetylation in vitro (Champagne et al., 2001) (Fraga et 
al., 2005). However, isolated ING5/MOZ complexes, which also contain the proteins 
BRPF1 and EAF6, have been reported to target H3 acetylation in particular H3K14. 
It was suggested that the substrate specificity of MOZ is altered by ING proteins 
(Doyon et al., 2006). More recently, Voss et al. reported that MOZ ablation leads to 
hypoacetylation at H3K9, whereas neither H3K14 nor H4 acetylation was greatly 
affected (Voss et al., 2009). This presented a conundrum regarding MOZ histone 
substrate specificity, which appears to be different in opposing studies. Previous data 
from our lab using MOZ MYST domain (510-810) in HAT assays agreed with the 
finding that H4 is the major target of this domain, at least in vitro. It was therefore 
decided to assess whether the presence of the DPF would influence the substrate 
targeting of the MOZ MYST domain. To investigate this, we performed in vitro HAT 
assays using DPF, MYST or DPF+MYST contructs. Interestingly, these preliminary 
experiments uncovered a function for the MOZ DPF as a mild H3-specific 
acetyltransferase. Moreover, assays conducted with the individual PHD finger 
proteins (PHD1 and PHD2) elucidated that this acetyltransferase activity was an 
intrinsic property of the composite DPF module. To our knowledge, this constitutes 
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the first description of a possible acetyltransferase function attributed to a DPF 
domain or PHD finger. To progress with this study, it will be important to determine 
whether MORF or the DPF1/2/3 proteins also share the ability to acetylate histones 
and whether they have similar or distinct substrate preferences. 
While PHD motifs are well established as independent protein ligand 
interaction domains (Bienz, 2006), a recent study has reported an enzymatic activity 
associated with the PHD finger, e.g. as a functional E3 ligase for SUMO molecules. 
The PHD domain of the KAP1 corepressor protein functions as a unique E3 ligase 
that directs the intramolecular SUMOylation of the adjacent bromodomain; an event 
required for KAP1-mediated repression of target genes (Ivanov et al., 2007). Thus, 
the PHD domain appears to act as a mediator module to stimulate and stabilise the 
functional outputs of the protein.  
As we have shown that MOZ DPF has dual functionality, as a mild histone 
H3-specific acetyltransferase and a chromatin binding module, we investigated how 
this would impact on the activity of the MYST domain. We therefore conducted in 
vitro HAT assays in order to explore whether the DPF affects the acetyltransferase 
function of MOZ. With regards to substrate specificity, the MOZ MYST domain was 
shown to preferentially acetylate histone H4 as previously reported. However, a 
construct containing both the DPF and MYST domains appears to have an extended 
range of histone substrates, targeting H3, H4 and possibly H2A. Thus, the full-length 
MOZ protein contains two distinct acetyltransferase activities; the DPF which 
appears to selectively acetylate H3 and the MYST for which H4 is the main target. 
However, these activities may be modulated by other proteins in vivo, such as by 
those proteins found in complex with MOZ including ING5 and BRPF1 (Doyon et 
Chapter Four: Results 
254 
 
al., 2006). Substrate specificity may also change depending on the form that the 
histone substrate is presented. For example, the MORF MYST domain was shown to 
acetylate free histones H3 and H4, but only has activity toward nucleosomal histone 
H3 (Ullah et al., 2008).  
In addition to influencing the substrate specificity of MOZ, the presence of 
the DPF domain was also found to enhance the kinetics of histone acetylation by 
MOZ. Kinetic studies revealed that the DPF+MYST construct had significantly 
increased total acetylation output, as well as performing at a considerably faster rate 
of catalysis compared to either module functioning separately. Thus, it is likely that 
the DPF+MYST domains together constitute the MOZ functional acetyltransferase 
domain. Together they exhibit a 12.5- or 5-fold increase in specific activity compared 
to the individual DPF and MYST counterparts respectively. At present the DPF 
exhibits two functions and which of these functions, if not both, is responsible for the 
observed enhancement of HAT activity has not yet been resolved. Possibly, the 
combined acetyltransferase activities of the DPF+MYST protein towards an extended 
range of histone substrates could lead to the augmentation of the rate of catalysis. 
Alternatively, the DPF could strengthen the binding affinity of the MOZ protein for 
the substrate, thus facilitating the docking onto the histone that requires acetylation. 
To determine this, fluorescence polarisation or isothermal titration calorimetry 
experiments could be carried out to measure the Kd (dissociation constant) value. The 
Kd is a measurement of the strength of binding between receptor and ligand, thus this 
would elucidate whether the DPF+MYST bound with a greater affinity to the histone 
substrate than the MYST domain alone. Other examples of interplay between histone 
µUHDGHU¶ DQG µZULWHU¶ PRGXOHV KDYH EHHQ GRFXPHQWHG LQ WKH OLWHUDWXUH 2QH VXFK
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example is the synergy between the bromodomain and HAT domain of the 
acetyltransferase p300. Studies by Chen et al. reveal the importance of the 
bromodomain for p300 to exert its HAT activity, whereby the bromodomain 
stimulates p300 HAT activity (Chen et al., 2010) by recognising acetylated lysine 
residues and stabilising the association of p300 to specific chromatin sites (Zeng et 
al., 2008b). 
As the DPF exhibits dual function; as an acetyltransferase and a H3/H4 PTM 
sensor, we next investigated how existing PTMs might affect MOZ HAT activity. We 
performed in vitro HAT assays using a range of peptides, which included both 
modifications that promoted and those that disrupted DPF binding to histones, to test 
whether MOZ DPF binding to histones would influence the ability of MOZ to 
acetylate H3 and H4 N-terminal tails. We found that the MOZ DPF was able to 
acetylate the N-terminus of histone H3 (1-21), but not a histone H3 internal sequence 
(21-44). This implies that lysine residues within the first 21 amino acids of the 
histone H3 tail are targets for MOZ DPF acetylation. Trimethylation at K4 and K9 
prevented the acetylation of the H3 peptide by the MOZ DPF. We have previously 
demonstrated that the MOZ DPF cannot bind H3K4me3 and that it is excluded from 
chromatin enriched with this modification, hence it may not be able to acetylate this 
peptide. The MOZ DPF is able to bind the H3K9me3 modification and so this 
indicates K9 as a likely target of MOZ DPF acetylation. Indeed, immunodetection 
analysis of HAT assays supported H3K9 as a preferred substrate for MOZ DPF 
acetylation. 
The MOZ MYST domain acetylated histone H4 to a greater extent than H3 
(1-21) and the combined DPF+MYST construct showed strong acetylation of both 
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H3 and H4. For both constructs, H3 acetylation was partially reduced by H3K9me3 
but completely blocked by trimethylation at H3K4. A partial reduction of H3 
acetylation in the presence of K9me3 suggests that, as well as K9 being an 
acetylation target, the MOZ MYST and DPF+MYST constructs are able to acetylate 
other lysine residues within the H3 peptide. In accordance, immunodetection analysis 
of HAT assays supported both H3K9 and H3K14 as preferred substrates for MOZ 
DPF+MYST acetylation. 
All three constructs, MOZ-DPF, -MYST and -DPF+MYST were unable to 
acetylate a histone H3 peptide trimethylated at K4. The diminished activity for this 
particular substrate could in part be due to the intolerance of MOZ DPF for 
H3K4me3 binding. This suggests that MOZ is unable to tether and stabilise the 
association of the protein onto peptides containing H3K4me3, preventing further 
acetylation of lysine residues on the same histone tail. To investigate these findings in 
an in vivo setting, it would be desirable to conduct the ChIP-Seq protocol in order to 
identify genome-wide MOZ binding sites and their association with PTMs. MOZ-
tagged genomic sites could then be used to map the proximity of complexes to 
promoters and further, be correlated with one or more histone PTMs. The MYST 
domain was also unable to acetylate the H3K4me3 peptide. This suggests that 
modification of H3K4 could possibly prevent the entry of the substrate into the active 
site, either by size or charge exclusion or a change to the conformation of the histone 
peptide, impeding acetylation of the histone lysine substrate.  
We have established that the MOZ DPF and DPF+MYST domains acetylate 
the H3 and H3/H4 substrates respectively. We have also previously shown through 
binding studies that acetylation of H3 stimulated the interaction with MOZ DPF, 
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whereas conversely the acetylation of H4 prevented the interaction with MOZ DPF. 
Therefore, we next investigated whether MOZ-mediated acetylation of H3 and H4 N-
terminal tails could influence its binding preference for the substrate, and thus 
regulate its own recruitment or exit from chromatin. We performed histone peptide 
binding assays with H3 and H4 peptides in the absence or presence of acetyl-CoA, 
and found that the increasing presence of acetyl-CoA enhanced the binding of the 
DPF and DPF+MYST to histone H3. This indicates that MOZ promotes its own 
recruitment to chromatin via the acetylation and binding of histone H3. In addition, 
DPF+MYST, which can bind and acetylate H4, also showed an increase in binding in 
the presence of acetyl-CoA. This increase is likely to represent binding to the interim 
unmodified H4 peptide, suggesting that MOZ-mediated histone H4 acetylation does 
not function as a release mechanism for MOZ from the H4 peptide. In contrast, 
peptide acetylation assays show that mono-acetylated peptides could not be 
additionally acetylated by MOZ DPF+MYST. This implies that pre-written H4Kac 
serves as a prevention signal for MOZ to avert binding to chromatin and further 
acetylation of the same H4 tail. However, this H4Kac signal was not shown to 
influence the ability of MOZ to acetylate neighboring H3 N-terminal tails. All our 
studies, thus far, investigate the affect of existing PTMs and the DPF on MOZ HAT 
activity in the context of immobilised peptides and free histones. The next stage 
would be to extend the study to a more physiologically relevant substrate such as 
mono- and oligo-nucleosomes.  
 The p300 bromodomain is not only required for stimulating p300 HAT 
activity, but is also important for p300 to function at full coactivator activity in the 
activation of p300-dependent genes (Chen et al., 2010). This led to the investigation 
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as to whether the DPF module could also affect other functional properties of the 
MOZ protein. MOZ functions as a coactivator for several transcription factors, 
especially those with hematopoietic specificity. MOZ has been shown to be essential 
for AML1-mediated transcription, whereby the C-terminal transactivation domain 
and the H1/5 domain were required for transcription activity of AML1-dependent 
genes. Interestingly, it was shown that the MYST domain was not important for 
coactivator function (Kitabayashi et al., 2001a), implying that H4 acetylation is not 
required. We carried out luciferase reporter assays, using the AML1-responsive 
luciferase reporter, to determine whether the DPF domain was important for the 
stimulation of AML1-mediated transcription. Both the PHD1 and PHD2 mutants 
diminished the transactivation potential of MOZ at the AML1 promoter, suggesting 
that the composite DPF domain is required for coactivator function. It is possible that 
the abolished transactivation of AML1-mediated transcription could be as a result of 
the loss of the ability to bind chromatin or the lack of DPF-mediated histone H3 
acetyltransferase activity. Further, to determine whether the mutation of MOZ 
resulted in the mislocalisation of the protein, we performed immunofluorescence 
studies. Mutants revealed similar distribution patterns to the wild-type protein, thus it 
appears that other domains within MOZ may provide additional contacts with 
chromatin or other nuclear structures. Indeed, the H1/5 domain has been shown to be 
important for the nuclear localisation of MOZ (Kitabayashi et al., 2001a). 
In summary, we have uncovered a second function for the MOZ DPF in 
histone acetylation. Preliminary results indicate that the DPF domain acts as a H3-
specific acetyltransferase, which acts to extend the range of histone substrates and 
enhance the acetyltransferase kinetics of MOZ. Results also begin to explore the 
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affect of DPF PTM binding preference on the HAT activity of MOZ, however it is 
clear that more experimental data is required to fully elucidate the mechanisms of 
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 5.1. Introduction 
In the previous chapters, it was shown that the MOZ DPF domain can 
associate with chromatin enriched in the tri-methylated H3K9 PTM, but not 
H3K4me3, as supported by peptide binding studies (Figure 3.11). H3K4me3 is 
generally considered a marker of active genes, whereas H3K9me3 is a hallmark of 
heterochromatin, a densely compacted chromatin conformation associated with 
transcriptional silencing. The SUV39H1 lysine methyltransferase enzyme specifically 
mediates the trimethylation of histone H3 lysine 9, which consequently creates a 
binding site for the protein machinery involved in promoting the formation of 
heterochromatin (Melcher et al., 2000). The heterochromatin HP1 proteins can bind 
H3K9me3 enriched chromatin and additionally interact with SUV39H1. Thus, in 
general, SUV39H1 methylation of histone H3K9 creates a high-affinity binding site 
for the HP1 chromodomain, in addition to direct recruitment of HP1 via the 
chromoshadow domain. Thereby, these proteins function in at least a three 
component complex to facilitate the spreading of higher order chromatin states (Fanti 
and Pimpinelli, 2008). 
As described in chapter 4, MOZ interacts with AML1 (Kitabayashi et al., 
2001a) and cooperatively stimulates the expression of AML1-dependent target genes 
(Collins et al., 2006). AML1 also forms a complex with SUV39H1, which conversely 
abrogates the DNA binding and transactivating properties of AML1 (Chakraborty et 
al., 2003). The association between AML1 and SUV39H1 provides a molecular 
mechanism for gene repression mediated by AML1 and further, the distinct 
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interactions with these coregulators determine the strength of AML1 in promoter 
regulation. 
SUV39H1 activity is regulated by the acetylation of lysine 266 in its catalytic 
domain (Vaquero et al., 2007). The deacetylase SIRT1 interacts directly with and 
deacetylates SUV39H1, enhancing levels of SUV39H1 enzymatic activity and 
resulting in the increased trimethylation of histone H3 lysine 9 (Vaquero et al., 2007). 
The identity of the KAT enzyme responsible for the acetylation of SUV39H1 and the 
successive regulation and impairment of SUV39H1 activity remains elusive.  
MOZ associates with the repressive H3K9me3 modification in vitro. The 
literature details that both MOZ and SUV39H1, the methyltransferase responsible for 
the catalytic deposition of this mark, function as coregulators of AML1-dependent 
gene expression. Moreover, the link between SUV39H1 and KAT enzymes is 
strengthened as the regulation of its own activity is governed by post-translational 
acetylation. This chapter therefore, describes work carried out to examine whether the 
MOZ KAT can associate with proteins involved in the formation of heterochromatin 
and the regulation of gene silencing, including HP1 and SUV39H1. Moreover, 
preliminary studies begin to uncover the functional ramifications of such interactions. 
 
5.2. MOZ interacts with HP1 
In this study evidence has been provided that MOZ associates with H3K9me3. 
HP1 is a well-established H3K9me3 binding protein, thus we first investigated 
whether MOZ might interact with HP1 proteins. 
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The GST-MOZ N-terminus (1-321) and DPF (172-321) fusion proteins were 
expressed and purified as described in previous sections (section 3.4 and 4.2). Protein 
concentrations were normalised by SDS-PAGE and Coomassie staining to ensure that 
equal amounts of GST proteins were used in pulldown assays (Figure 5.1(A)). The 
WKUHH+3LVRIRUPV+3ĮȕDQGȖ(provided as gifts from Dr. B Le Douarin) were in 
vitro translated using 35S-PHWKLRQLQH:KLOH+3ĮDQGȕLVRIRUPVZHUHVXFFHVVIXOO\
produced to give proteins of the expected molecular weights (as shown in the input 
lanes-Figure 5.1), no band was obtained for the +3ȖLVRIRUP. Although the sequence 
LQGLFDWHGWKDWWKH+3ȖF'1$LQVHUWZDVRIWKHFRUUHFWRULHQWDWLRQDQGVHTXHQFHZH
were unable to detect in vitro translated protein. Thus, it was not possible to test the 
interaction of +3Ȗ DQG 02= LQ WKLV in vitro system. As shown in Figure 5.1, no 
interaction was observed between *67 DQG +3 Į DQG ȕ SURWHLQV indicating that 
interaction does not occur through the GST tag (Figure 5.1(B)- lane 2). +3Į ZDV
pulled down, to an equal degree, by both the MOZ N-terminus and the DPF domain 
(Figure 5.1(B)- WRSSDQHOODQHV	7KH+3ȕLVRIRUPDOVRVKRZHGDQLQWHUDFWLRQ
with the MOZ N-terminus, although a much weaker interaction with the DPF domain 
alone was observed (Figure 5.1(B)- bottom panel, lanes 3 & 4). This result suggests 
WKDW+3ĮDQGȕLVRIRUPVFDQLQWHUDFW directly with the N-terminus of MOZ in vitro, 
and that the HP1Į binding site is likely to be located adjacent to or within the DPF 
domain of MOZ (amino acids 172-321).  
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)LJXUH+3ĮDQGȕ LQWHUDFWLRQZLWK WKH1-terminus of MOZ in vitro. (A) 
Normalisation of GST-MOZ constructs concentration by SDS-PAGE and Coomassie 
staining. (B) Pulldown assays with in vitro-translated 35S-PHWKLRQLQHODEHOOHG+3Į
ȕDQG*67-MOZ 1-321 (H1/5 & DPF domains) and 172-321 (DPF domain) followed 
by autoradiograph analysis.  
(B) 
(A) 
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          To validate that MOZ and HP1 can interact with one another in mammalian 
cells, co-immunoprecipitations were performed with the FLAG-MOZ N-terminus (1-
 DQG +3Ȗ SURWHLQV expressed in HEK293 cells. Attempts to co-
immunoprecipitate +3ĮDQG+3ȕusing a commercial antibody, raised to detect all 
three isoforms, were unsuccessful. However, one of the constructs we obtained 
FRQVLVWHGRI+3ȖIXVHGWRWKH<)3SURWHLQVRZHZHUHDEOHWo use this construct in 
co-IP and immunofluorescence studies. 
FLAG-MOZ 1-321 and YFP-+3Ȗ H[RJHQRXV SURWHLQV ZHUH WUDQVLHQWO\
transfected into HEK293 cells and 48 hours post-transfection, cells were harvested 
and lysed to release soluble proteins. Input lanes verify the expression of each 
transfected protein in the cell lysates (Figure 5.2(A)- lane 1). FLAG-MOZ protein 
was then immunoprecipitated from cell lysates using the MOZ (127A) antibody and 
WHVWHG IRU +3Ȗ LQWHUDFWLRQ E\ LPPXQRGHWHFWLRQ Zith the GFP antibody (Figure 
5.2(A)). To determine the efficiency of the IP, the blot was also probed with the MOZ 
(127A) antibody. As expected, the MOZ (127A) antibody immunoprecipitated a band 
at approximately 35kDa (Figure 5.2(A)- bottom panel) only in lanes that expressed 
FLAG-MOZ. A protein at ~45kDa was detected when both FLAG-MOZ 1-321 and 
YFP-+3Ȗ ZHUH FR-expressed, but not in control mock transfected lysates or no 
antibody IPs (Figure 5.2(A)- top panel, compare lanes 2 & 6 with 5). The identity of 
the HP1 protein was confirmed using the GFP antibody. This result shows that the 
MOZ N-terminus can form a complex ZLWK+3Ȗin vivo.  
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)LJXUH  02= LQWHUDFWV ZLWK +3Ȗ in vivo. (A) HEK293 cells were mock 
transfected or transiently cotransfected with YFP-+3Ȗ DQG )/$*-MOZ 1-321. 
After 48 h post-transfection, cells were lysed and the proteins were 
coimmunoprecipitated with Į-MOZ. Proteins were separated by electrophoresis and 
subjecteGWRLPPXQREORWWLQJXVLQJĮ-02=DQGĮ-GFP antibodies. (B) Alignment of 
an N-terminal MOZ/MORF pentapeptide sequence with other HP1-associated 
protein sequences containing the pentapeptide consensus (pink). Numbers denote the 
positions of the amino acids shown.   
(B) 
(A) 
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         Many HP1-binding proteins contain a consensus pentapeptide sequence, which 
is sufficient for specific interaction with the HP1 chromoshadow domain. This 
consensus comprises a proline at position 1, valine at position 3 and hydrophobic ȥ 
residues at positions 4 and 5 (Cowieson et al., 2000). As the MOZ N-terminus has 
been shown to interact with HP1, we next analysed the MOZ sequence (1-321) for 
this PxVȥȥPRWLI. As shown in Figure 5.2, the MOZ sequence proline 189 to leucine 
193 fits this consensus (PPVSL), which is also fully conserved in the homolog 
MORF (Figure 5.2(B)). An alignment of MOZ and MORF sequence with PxVxL 
motifs in other HP1-associated proteins is shown in Figure 5.2(B). The GST 
pulldown data shown in this study indicated that the MOZ sequence 172-321 was 
sufficient to interact with +3 Į DQG ȕ in vitro (Figure 5.1(B)). This pentapeptide 
sequence (highlighted in green) is located adjacent to the first zinc coordinating 
cysteines of PHD1 within the DPF domain (highlighted in yellow). This region has 
rather poor electron density in the DPF/H3 crystal, although the sequence 
immediately adjacent to the PXVXL motif is an D-helix (highlighted in blue).  
 
        189-PPVSLLPHEKDKPVAEPIPICSFC-212 
 
Using site-directed mutagenesis, we have generated FLAG-MOZ constructs that 
contain a double substitution, P189A and V-191A, to test whether when mutated the 
MOZ-HP1 interaction is compromised. However, there was not sufficient time to 
complete this experiment before thesis submission.  
Chapter Five: Results 
268 
 
Preliminary results indicate that MOZ is able to interact with all three HP1 
isoforms. Further studies are required to reinforce the in vivo evidence and to map the 
region of MOZ responsible for the HP1 interaction. However, this data collectively 




in vivo and that this PD\EHGXHWRD3[9ȥȥPRWLIDGMDFHQWWRWKH02='3)GRPDLQ
To investigate this further, we next examined the subcellular localisation of 
exogenous FLAG-MOZ 1- DQG +3Ȗ SURWHLQV XVLQJ LPPXQRIOXRUHVFHQFH
microscopy. As previously explained, +3ĮRU+3ȕ could not be tested using this 
protocol due to the unavailability of suitable antibodies or epitope-tagged constructs.  
To examine the subcellular localisation of MOZ 1-321 DQG+3Ȗ, U2OS cells 
were seeded onto coverslips and transfected with the FLAG-MOZ 1-321 and YFP-
+3Ȗ H[SUHVVLRQ SODVPLGV $IWHU  KRXUV SRVW-transfection cells were fixed, 
permeabilised and incubated with anti-FLAG antibody. YFP-+3ȖIOXRUHVFHVGLUHFWO\
so primary and secondary antibodies were not required to visualise the localisation of 
+3Ȗ %RWK SURWHLQV ZHUH DOVR WHVWHG IRU WKHLU DVVRFLDWLRQ ZLWK WKH HQGRJHQRXV
histone H3K9me3 PTM using the anti-H3K9me3 specific antibody. Incubation with 
either a mouse Alexa594-conjugated or a mixture of mouse Alexa594- and rabbit488-
conjugated secondary antibodies followed. FLAG (red), +3ȖJUHHQ and H3K9me3 
(red/green - secondary used depended on the protein the PTM was being colocalised 
with) images were merged (yellow) to check for the nuclear localisation of the three 
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markers. The nucleus was visualised with Hoechst 33258 stain which intercalates 
with DNA (blue).  
As shown in Figure 5.3, YFP-+3ȖZDVSUHVHQWLn the nucleus of transfected 
U2OS cells. The distribution pattern showed that it is non-uniformly distributed in the 
nucleus, being excluded from nucleolar centres and  FRQFHQWUDWHGLQQXFOHRODUµFDSV¶ 
and other foci, as well as foci close to the nuclear periphery. These are presumably 
regions of heterochromatin. Staining for endogenous H3K9me3 revealed similar non-
uniform, non-nucleolar distribution into nuclear foci. Merging of the images revealed 
a t least partial colocalisation of HP1J and H3K9me3, suggesting that some of these 
foci are heterochromatic regions (Figure 5.3- top panel). FLAG-MOZ 1-321 protein 
was also entirely nuclear suggesting that this region of MOZ contains a nuclear 
localisation sequence, or that association with chromatin or nuclear proteins keeps it 
localised to the nucleus. The distribution of FLAG-MOZ 1-321 was different from 
that of full-length MOZ (Collins et al., 2006; Kindle et al., 2010; Kindle et al., 2005) 
in that it was quite uniformly distributed throughout the nucleus. Full-length MOZ 
shows a non-nucleolar, speckled pattern much more similar to that of HP1J (Kindle et 
al., 2005).  Although partial localisation may be occuring between the N-terminus of 
MOZ and HP1 and H3K9me3 (Figure 5.3- middle and bottom panels), these data are 
insufficient to concluGHZKHWKHU02=DQG+3Ȗ are colocalised in vivo. However, it 
can be concluded here that other sequences in full length MOZ are likely to be 
required for its proper targeting to chromatin, especially heterochromatic regions. 
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Figure 5.3. Colocalisation of MOZ with H3K9me3 and HP1Ȗ. U20S cells were seeded 
onto coverslips and transfected after 24 hours with expression plasmids encoding FLAG-
MOZ 1-321 and YFP-+3Ȗ $IWHU  KRXUV SRVW-transfection, cells were fixed in 4 % 
paraformaldehyde, permeabilised and stained with antibodies raised against mouse anti-
FLAG (red) and the rabbit anti-H3K9me3 (green). Staining was followed by incubation in 
anti-mouse Alexa594 and anti-rabbit Alexa488/594 secondary antibodies. Merged scans 
(yellow) highlight colocalisation and Hoechst 33258 (blue) was used as a stain of DNA. 
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5.4. 'LIIHUHQWLDO HIIHFWVRI02=DQG+3ȖRQ$0/-mediated 
transcription 
The in vitro evidence presented here suggests a potential interaction between 
MOZ and the three isoforms of HP1. Thus, to explore the functional consequences of 
the MOZ-HP1 interaction on the transcriptional activation properties of MOZ, 
luciferase reporter assays were conducted using the AML1-responsive promoter 
reporter system. It has been well-established that MOZ binds AML1 and strongly 
stimulates the transcription of AML1-dependent genes (Kitabayashi et al., 2001a), 
however despite a role for SUV39H1 in AML1 reporter repression (Chakraborty et 
al., 2003), a function for HP1 has yet to be investigated. 
U2OS cells were transiently co-transfected with the pT109 3X-AML1 
responsive luciferase reporter plasmid, a CMV-ȕ-galactosidase internal control 
reporter in addition to AML1, FLAG-02= DQGRU +3ĮȕȖ H[SUHVVLRQ YHFWRUV DV
indicated. Luciferase activity was assayed 48 h post transfection using the Dual-Light 
/XFLIHUDVH DQG ȕ-Galactosidase reporter gene assay system (Applied Biosystems), 
measuring these activities using a Luminometer Orion (Berthold) as described in the 
Materials and Methods. The efficiency of FLAG-MOZ expression was checked by 
immunodetection using antibodies raised against the FLAG-tag (Figure 5.4). The 
expression of the HP1 proteins was not assessed due to previously described antibody 
LVVXHVKRZHYHU+3ȖKDVDOUHDG\EHHQ shown to express efficiently in U2OS cells 
via other protocols, such as immunofluorescence. 
Firstly, in agreement with previous reports from our group (Collins et al., 
2006), AML1 activated the reporter approximately 8-fold over background and this 
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was further stimulated (to 12-fold) by co-expression with MOZ (Figure 5.4- compare 
bars 1 with  	  ,Q FRQWUDVW ERWK +3ȕ DQG +3Ȗ ZHUH IRXQG WR UHSUHVV WKH
AML1-mediated reporter activity, resulting in 75% and 40% residual activity, 
respectively (Figure 5.4- compare bars 2 with 5 & 6). HP1D did not appear to be able 
to act as a corepressor of AML1-driven transcription (Figure 5.4- compare bars 2 & 
4). However, we were unable to confirm the expression of the HP1 proteins by 
western blots. 1RQHWKHOHVV WKLV UHVXOW SURYLGHVSUHOLPLQDU\ HYLGHQFH WKDW WKH+3Ȗ
isoform acts as a repressor of AML1-dependent gene activity, although whether this 
affect is a consequence of an AML1-+3Ȗ LQWHUDFWLRQ WKH IRUPDWLRQRI DQ$0/-
+3Ȗ-SUV39H1 co-repressor complex or via an alternative mechanism requires 
further investigation.  
Having esWDEOLVKHGWKDW+3ȕDQGȖUHSUHVV$0/-mediated transcription, we 
next assessed what effect adding the coactivator MOZ and repressor HP1 
simultaneously would have on reporter activation. As before, AML1-MOZ activated 
the reporter 12-fold above background and this was uneffected by coexpression of 
+3ĮZLWKWKHFDYHDWWKDWH[SUHVVLRQRI+3Į needs to be confirmed) (Figure 5.4- 
compare bars 3 & 7). The co-H[SUHVVLRQ RI 02= DQG +3ȕ UHSUHVVHG WKH $0/
reporter activity to that observed in the absence of MOZ (Figure 5.4- compare bars 5 
& 8), whereas reporter activation in tKHSUHVHQFHRIERWK02=DQG+3Ȗ was only 4- 
fold above background (Figure 5.4- compare bars 6 & 9). These results suggest that 
MOZ and HP1 proteins, and in particular HP1J, have opposing effects on the ability 
of AML1 to drive reporter gene transcription, acting as coactivators and corepressors 
respectively.  
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,QWHUHVWLQJO\ ZKHUHDV +3Įȕ ORFDOLVH WR SHULFHQWURPHULF KHWHURFKURPDWLQ
+3Ȗ LVGLVSHUVHGWKURXJKRXW WKHQXFOHXVDQGDVVRFLDWHVZLWK the coding regions of 
active genes (Maison and Almouzni, 2004). These results suggest two separate 
activities for MOZ at an active AML1-responsive promoter, possibly dependent on 
the associated proteins. Other groups have shown that MOZ is part of a possible 
coactivator complex, containing other HATs such as p300 and CBP, that was isolated 
by the affinity purification of AML1 (Yoshida and Kitabayashi, 2008). On the other 
hand, our data show that MOZ may also have a role in recruiting corepressors such as 
SUV39H1 (see later sections) and HP1J, to repress AML1 target genes. This may be 
particularly important for understanding the action of oncogenic fusion proteins such 
as AML1-ETO, which appear to function principally as gene repressors. Further 
studies will be required to understand the possible role of MOZ in functional switches 
regulating gene expression.   
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Figure 5.4. Over-H[SUHVVLRQRI02=GRHVQRWUHVFXH+3Ȗ-mediated repression 
at the AML1 promoter. U2OS cells were cotransfected as follows: with reporter 
plasmid pT109-3xAML1-luciferase (bar 1) and AML1 in the absence (bar 2) or 
SUHVHQFHRI02=EDU+3ĮEDU+3ȕEDURU+3ȖEDU02=	 +3Į
(bar 7), MOZ & +3ȕ EDU  or MOZ & +3Ȗ EDU  $ SODVPLG HQFRGLQJ ȕ-
galactosidase was used to normalise the transfection efficiency. Reporter activation is 
represented as a fold induction over the control value (reporters in the absence of 
coactivators). The data are presented as averages and standard errors of the means 
from triplicate samples. 
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5.5. MOZ and SUV39H1 interact in vitro 
 Given that MOZ can associate with histone H3 tri-methylated K9 and HP1 
proteins, we asked whether it can also form a functional complex with SUV39H1. 
GST-SUV39H1 WT and mutant fusion proteins were expressed and purified as 
described in previous sections (sections 3.4 & 4.2). Protein concentrations were 
normalised by SDS-PAGE and Coomassie staining to ensure equal amounts of 
protein were used in subsequent in vitro assays (Figure 5.5(A)). To assess whether 
MOZ and SUV39H1 interact with one another in vitro, GST pulldown assays were 
conducted using WT GST-SUV39H1 or GST-SUV39H1 containing the mutation 
H324L (a point mutant that renders the SET methyltransferase domain inactive) and 
FLAG-MOZ N protein that had been in vitro translated in the presence of 35S-
methionine. The GST-SUV39H1 constructs were provided as gifts by Dr. Thomas 
Jenuwein, whereas FLAG-MOZ N was described previously (Kindle et al., 2005) . 
The input lane shows efficient IVT of the MOZ protein (Figure 5.5(B)-lane 1). As a 
control reaction, MOZ was incubated with the GST protein alone. No interaction was 
observed between the GST-conjugated beads and MOZ, proving an interaction does 
not occur through the GST tag (Figure 5.5(B)-lane 2). MOZ was however pulled 
down with both GST-SUV39H1 WT and H324L-conjugated beads (Figure 5.5(B)-
lanes 3&4). This result shows that MOZ can interact with SUV39H1 in vitro, 
irrespective of its methyltransferase activity. 
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Figure 5.5. MOZ interacts with the lysine methyltransferase SUV39H1 in 
vitro. (A) Normalisation of GST-SUV39H1 constructs concentration by SDS-
PAGE and Coomassie staining. (B) Pulldown assays with 1.5 µg/32 nM GST-
SUV39H1 and in vitro-translated 35S-methionine labelled FLAG-MOZ N 
followed by autoradiograph analysis.  
(A) (B) 
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5.6. MOZ interacts with SUV39H1 in vivo 
To validate that MOZ and SUV39H1 can interact with one another in 
mammalian cells, co-immunoprecipitations were performed with FLAG-MOZ and 
myc-SUV39H1 proteins expressed in HEK293 cells. The myc-SUV39H1 constructs 
were provided as gifts from Dr. Thomas Jenuwein. FLAG-MOZ and myc-SUV39H1 
exogenous proteins were transiently transfected into HEK293 cells and 48 hours post-
transfection, cells were harvested and lysed to release the soluble proteins. Input lanes 
verify the expression of each transiently transfected protein in the cell lysates (Figure 
5.6(A)- lanes 1 & 3 and (B)- lanes 1 & 2). FLAG-MOZ proteins were then 
immunoprecipitated from the cell lysates with a FLAG antibody and tested for the 
SUV39H1 interacting partner by immunodetection with the anti-Myc antibody 
(Figure 5.6). To determine the efficiency of the immunoprecipitation, blots were also 
probed with the FLAG antibody. As expected, the FLAG antibody 
immunoprecipitated a band at ~220kDa (Figure 5.6(A)-top panel), only in lanes that 
expressed FLAG-MOZ.  A protein at ~50kDa was detected when both FLAG-MOZ 
(full-length) and myc-SUV39H1 were co-expressed, but not in control mock 
transfected lysates (Figure 5.6(A)- bottom panel, compare lanes 2&4). The identity of 
this protein was confirmed using the antibody recognising the myc tag. This result 
confirms that MOZ and the SUV39H1 methyltransferase interact in vivo as well as in 
vitro. Co-immunoprecipitation was also carried out with exogenously expressed 
FLAG-MOZ 1-321. Western blot analysis using FLAG antibody showed 
immunoprecipitation of a ~37kDa (Figure 5.6(B)-bottom panel) band only in lanes 
that expressed FLAG-MOZ 1-321. Subsequent blotting using the myc antibody 
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revealed the detection of no protein around the 50kDa molecular weight when both 
proteins were co-expressed (Figure 5.6(B)-top panel, lane 6), despite the availability 
of SUV39H1 in the input lysate (Figure 5.6(B)-top panel, lane 2). This indicates that 
myc-SUV39H1 was not co-immunoprecipitated with FLAG-MOZ 1-321, therefore 
the interaction with SUV39H1 does not appear to be mediated via the DPF or other 
sequences in the N-terminus of MOZ. 
 




Figure 5.6. MOZ interacts with the lysine methyltransferase SUV39H1 in 
vivo. HEK293 cells were mock transfected (lanes (A) 1 & 2 and (B) 3) or 
transiently cotransfected with Myc-SUV39H1 and (A) FLAG-MOZ (lanes 3 & 
4) or (B) FLAG-MOZ 1-321 (lanes 4-6). 48 h post-transfection cells were lysed 
and the proteins were coimmunoprecipitated with (A) Į-MOZ or (B) Į-FLAG. 
Proteins were separated by electrophoresis and subjected to immunoblotting 
using (A) Į-MOZ or (B) Į-)/$*DQGĮ-myc antibodies. 
(B) 
(A) 
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5.7. SUV39H1 interacts with two regions of MOZ 
Having observed an interaction between MOZ and SUV39H1 both in vitro 
and in vivo, we subsequently set out to identify the region of MOZ responsible for the 
interaction. To map the MOZ-SUV39H1 interaction, a panel of FLAG-MOZ 
constructs covering all regions of MOZ was generated. The constructs FLAG-MOZ 
1-171, 1-321, MOZ N, MOZ (full-length) were described previously (Collins et al., 
2006; Kindle et al., 2005). In addition, FLAG-MOZ 194-323, 321-810, 510-810, 810-
1117 and 1317-2004 were generated by PCR subcloning. The primers are listed in 
appendix table A.1. All constructs were verified by PCR and sequence analysis. The 
FLAG-MOZ constructs were in vitro translated and incubated in a GST pulldown 
assay with either the GST control protein or GST-SUV39H1. Input lanes show the 
efficient in vitro translation of each of the MOZ proteins (Figure 5.7-lane 1). No 
interaction was observed between the GST control protein and MOZ (Figure 5.7-lane 
2). Confirming previous results, both the full-length and MOZ N proteins were able 
to interact with the methyltransferase (Figure 5.7- panels 1 & 2), suggesting binding 
of SUV39H1 does not require the C-terminal half of the MOZ protein. Consequently, 
a variety of N-terminal constructs were tested for interaction with SUV39H1 (Figure 
5.7- panels 3-5). Results indicate that both the H1/5 and DPF modules individually 
(panel 3-4 respectively) and together (panel 5) are unable to associate with the 
methyltransferase. A faint band can be seen for MOZ 1-171 (panel 3), which 
calculated by densitometry, represents 0.8 % total binding relative to control. 
However, due to a very weak signal and no interaction established for MOZ 1-321 
(panel 5) this was discarded as background binding. This data also corroborates 
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previous in vivo results, whereby SUV39H1 was unable to coimmunoprecipitate with 
the MOZ N-terminus (amino acids 1-321) (Figure 5.6(B)). Next, constructs 
representing internal MOZ protein sequences were tested for interaction (Figure 5.7-
panels 6-8). The MOZ 321-810 construct, which contains sequence of unknown 
function and the MYST domain, showed a robust association with SUV39H1 (panel 
6). However, the MYST domain alone (510-810) did not interact with SUV39H1 
(panel 7). This suggests that the linker region between the DPF and MYST domains, 
corresponding to amino acids 321-510, constitutes a SUV39H1 binding site. The N-
terminal region of the acidic domain, amino acids 810-1117, also failed to bind to 
SUV39H1 (panel 8). To explore whether the C-terminus of MOZ has any role in 
SUV39H1 interaction we finally tested FLAG-MOZ 1317-2004, containing the acidic 
and S/M-rich region, in the GST pulldown assays. This identified a second strong 
SUV39H1 binding site in the MOZ C-terminus (panel 9) and indicates that the 
methyltransferase interacts with two regions of the MOZ protein (summarised in red 
above the full-length schematic). Intriguingly, the SUV39H1 binding sites identified 
here overlap with those identified previously for the MOZ/AML1 interaction, 
whereby MOZ recruits AML1 via two sites mapped to 312-664 and 1517-2004 
(Kitabayashi et al., 2001a). This raises the possibility that SUV39H1 and AML1 may 
be recruited to similar regions of the MOZ protein, or alternatively might indicate 
competitive binding to MOZ. There was not sufficient time to pursue this hypothesis. 
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5.8. MOZ does not rescue SUV39H1-mediated repression of 
AML1 transactivation  
 To investigate the functional consequences of the MOZ-SUV39H1 interaction 
on the transcriptional activation properties of MOZ, luciferase reporter assays were 
conducted utilising an AML1 responsive promoter/reporter system. Previous 
literature shows that MOZ interacts with AML1 and strongly stimulates transcription 
of AML1-dependent genes (Kitabayashi et al., 2001a) yet, conversely, SUV39H1 
also forms a stable complex with AML1 resulting in the abrogation of DNA-binding 
and transactivation properties of AML1 (Chakraborty et al., 2003). Thus, to explore 
the opposing effects of these cofactors on AML1 function, we performed reporter 
assays. 
 U2OS cells were transiently co-transfected with the pT109 3X-AML1 
responsive luciferase reporter plasmid, a CMV-ȕ-galactosidase internal control 
reporter, in addition to AML1, FLAG-MOZ and/or myc-SUV39H1 expression 
vectors as indicated. Luciferase activity was assayed 48 h post transfection using the 
Dual-OLJKW /XFLIHUDVH DQG ȕ-Galactosidase reporter gene assay system (Applied 
Biosystems), measuring these activities using a Luminometer Orion (Berthold) as 
described in the Materials and Methods. Firstly, we assessed the effect of SUV39H1 
WT or the SET domain mutant SUV39H1 H324L on AML1 driven reporter activity. 
Expression levels of exogenous proteins were assessed by immunodetection using 
antibodies raised against the myc tag and the AML1 protein itself (Figure 5.8). The 
western blots showed that both proteins were expressed at similar levels only in cell 
lysates that were transfected with that given protein. As shown in Figure 5.8, AML1 
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activated the reporter approximately 8-fold over the basal activity, consistent with 
previous reports. Co-expression of SUV39H1 reduced AML1-mediated reporter 
activation in a dose-dependent manner (Figure 5.8- compare bars 2 & 3). A similar 
repressive activity was observed using the H324L mutant, indicating that the 
methyltransferase activity of SUV39H1 is not essential for repression of the AML1 
reporter (Figure 5.8- compare bars 2 & 4). In agreement with our previous data 
(Collins et al., 2006), co-expression of AML1 with MOZ further enhanced the 
reporter activation to 12-fold above basal level (Figure 5.9- compare bars 2 & 3). 
Expression of FLAG-MOZ was also verified by western blots (Figure 5.9). 
Interestingly, when MOZ and SUV39H1 were expressed together with AML1, the 
transactivation property of AML1 was still impaired (Figure 5.9-compare bars 3 & 4 
with 5), both by the WT and mutant SUV39H1 proteins (Figure 5.9- compare bars 3 
& 6 with 7). Thus, MOZ cannot rescue SUV39H1-mediated repression at an AML1 
targeted promoter. This suggests that the repressive activities of SUV39H1 dominate 
over the stimulating transactivation properties of MOZ at the AML1-responsive 
promoter. These results combined with in vitro mapping data suggest a possible 
model where SUV39H1 sequesters the MOZ protein by blocking the MOZ-AML1 
interaction regions. In vitro data show a clear overlapping of the two regions required 
for AML1 (312-664 & 1517-2004) and SUV39H1 (321-510 & 1317-2004) binding, 
implying that only one of the proteins can bind at any given time. Interaction with 
SUV39H1 might therefore prevent MOZ from binding the AML1 protein, allowing 
free access for the methyltransferase to act as a corepressor at the AML1-responsive 
reporter. Of course this mechanism of SUV39H1 dominance over MOZ may only 
occur at the AML1-responsive promoter and in order to test this theory the reporter 
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activity should be monitored at other MOZ driven target genes, such as the Hox 
genes. 
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Figure 5.8. SUV39H1 represses the transcriptional activity of AML1. 
U2OS cells were cotransfected as follows: with reporter plasmid pT109-3x 
AML1-luciferase (bar 1) and AML1 in the absence (bar 2) or presence of 
SUV39H1 (bar 3) or an inactive point mutant SUV39H1 (bar 4). A plasmid 
eQFRGLQJ ȕ-galactosidase was used to normalise the transfection efficiency. 
Reporter activation is represented as a fold induction over the control value 
(reporters in the absence of coactivators). The data are presented as averages 
and standard errors of the means from triplicate samples. 
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Figure 5.9. Over-expression of MOZ does not rescue SUV39H1-mediated 
repression at the AML1 promoter. U2OS cells were cotransfected as follows: with 
reporter plasmid pT109-3x AML1-luciferase (bar 1) and AML1 in the absence (bar 2) 
or presence of MOZ (bar 3), SUV39H1 (bar 4) an inactive point mutant SUV39H1 
(H324L) (bar 6), MOZ & SUV39H1 (bar 5) or MOZ & SUV39H1 H324L (bar 7). A 
SODVPLGHQFRGLQJȕ-galactosidase was used to normalise the transfection efficiency. 
Reporter activation is represented as a fold induction over the control value (reporters 
in the absence of coactivators). The data are presented as averages and standard errors 
of the means from triplicate samples. 
  




 Studies in the literature, including genome wide ChIP mapping, have revealed 
that H3K4me3 generally correlates with transcriptionally active genes, whereas, 
H3K9me3 is associated with the formation of heterochromatic, transcriptionally inert 
regions (Kouzarides, 2007). In chapter three, MOZ was shown to readily associate 
with chromatin enriched in trimethylated H3K9, but to be excluded from chromatin 
containing H3K4me3. These binding properties were shown to be determined by the 
DPF. These findings can be interpreted in a number of ways with respect to the 
context of understanding the role of MOZ as a co-regulator of gene transcription. 
MOZ has been suggested to function as a coactivator, such as for the Runx family of 
transcription factors including AML1. Recruitment of MOZ to chromatin containing 
repressive marks such as H3K9me3 may indicate that MOZ functions at an early 
stage of the gene activation process. The ability of MOZ to associate with 
heterochromatic PTMs, may allow it to induce the removal of repressive PTMs and 
catalyse the deposition of activating PTMs such as H3K9 and H3K14 acetylation. 
This in turn may lead to the recruitment of other factors such as the MLL/WDR5 
complex which signal the exit of MOZ from chromatin, e.g. as directed by H3K4me3 
allowing it to process neighbouring heterochromatic regions, or be recycled to other 
gene promoters. MOZ may stimulate this itself through the acetylation of H4, a 
second exit signal recognised by the DPF.  
Although protein interaction studies will not address the sequence of events 
that occur in realtime during the activation process, they will be useful in shedding 
light on the nature of molecular interactions that can occur and how these might be 
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regulated by posttranslational modifications. We therefore undertook binding studies 
to try to better understand the relationship between MOZ and H3K9me3. SUV39H1 
is the methyltransferase which catalyses the trimethylation of H3K9 that 
consequently serves as a binding site for HP1. Thus, we began by asking whether 
MOZ could associate with such proteins that impart and sense the trimethylation of 
H3K9.  
Using GST pulldown assays and coimmunoprecipitation experiments, it was 
demonstrated that MOZ and SUV39H1 could associate directly with each other, and 
associate in complexes both in vitro and in vivo. This ability to interact was 
independent of the methyltransferase activity of SUV39H1, as both WT and a SET 
domain point mutant were competent to bind MOZ. Mapping studies excluded a role 
for the H1/5 and DPF domains in SUV39H1 binding and identified two regions that 
appear to be independently capable of SUV39H1 binding. Immunofluorescence 
studies were hampered by poor quality of the commercial myc-antibody. To progress 
with this study, an epitope-tagged version of SUV39H1 will need to be generated.   
The two distinct regions of MOZ that bind SUV39H1 were mapped to the 
sequence between the DPF and MYST domains, (amino acids 321-510) and a C-
terminal fragment of MOZ, containing the acidic and S/M-rich region (1317-2004). 
Interestingly, these sites overlap with binding sites identified for  AML1 and p53 
protein interactions,  mapped to the linker region between DPF and MYST (312-664) 
and the C-terminus (1517-2004) (Kitabayashi et al., 2001a; Rokudai et al., 2009). 
MOZ functions as a transcriptional coactivator for AML1-mediated transcription 
(Kitabayashi et al., 2001a), whereas AML1 interaction with SUV39H1 leads to the 
repression of AML1-dependent target genes (Chakraborty et al., 2003). Thus, both 
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MOZ and SUV39H1 function as coregulators of AML1-dependent gene expression.  
Therefore, we next asked how the MOZ-SUV39H1 interaction affects the 
transactivation properties at an AML1-dependent promoter. Reporter assays utilising 
an AML1-responsive reporter system in U2OS mammalian cells revealed that MOZ 
activates AML1-mediated expression of the reporter, whereas SUV39H1 repressed 
the reporter activity.  Co-expression of MOZ and SUV39H1 also resulted in the 
repression of the reporter. Although the result may be influenced by the relative 
expression levels of both proteins, it also indicates that MOZ is unable to prevent the 
repression by SUV39H1 under these conditions. The methyltransferase activity of 
SUV39H1 was not required for the repression in these assays. This indicated that 
repression was not enforced by the post-translational methylation of either AML1 or 
MOZ by SUV39H1 itself. The reporter assay results, in association with in vitro 
mapping data, suggest a model where SUV39H1 competitively blocks the interaction 
between MOZ and AML1, preventing the transcriptional upregulation of AML1-
dependent genes (Figure 5.10).  
  









SUV39H1 interacts and functions in complex with HP1, thus we next 
investigated whether MOZ could also interact with the HP1 protein. GST-pulldown 
assays revealed an interaction between the N-terminus of MOZ (1- DQG +3Į
DQG ȕ DQG FRLPPXQRSUHFLSLWDWLRQ experiments showed that MOZ 1-321 could 
GLUHFWO\ DVVRFLDWH ZLWK +3Ȗ In vivo DQDO\VLV RI WKH +3Į DQG ȕ LVRIRUPV ZHUH
hindered by the poor quality of the commercial HP1-antibody, thus to progress with 
this study, an epitope-WDJJHG YHUVLRQ RI +3Į DQG ȕ Zill need to be generated. 
However, preliminary results indicated that the N-terminus of MOZ is able to interact 
with all three isoforms of HP1.  
Figure 5.10. Schematic model illustrating possible events at the AML1 reporter. 
SUV39H1 competitively blocks the MOZ-AML1 binding site, displacing or 
sequestering MOZ from the AML1 complex and preventing the activation of the 
AML1-dependent reporter.  
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Analysis of the MOZ N-terminal sequence highlighted the presence of a 
FRQVHUYHGSHQWDPHULFPRWLI 3[9ȥȥ  - wherHȥ UHSUHVHQWVDK\GURSKRELF UHVLGXH
which may be sufficient for specific interaction with the HP1 chromoshadow domain 
(Cowieson et al., 2000). The disruption of this motif in MOZ by site-directed 
mutagenesis will be required to test whether, when mutated, the MOZ-HP1 
interaction is compromised. Of course, multiple binding sites for HP1 cannot be ruled 
out at this stage, as the full-length protein requires testing in all binding assays and 
the entire sequence needs to be analysed to predict other possible HP1-binding sites.  
SUV39H1 has been shown to act as a corepressor at AML-responsive 
promoters, however whether HP1 also functions in the repression of AML1-
dependent genes remains unclear. Therefore, we next asked whether the MOZ-HP1 
interaction affects the transactivation properties at the AML1 promoter. Preliminary 
assays utilising an AML1-responsive reporter system in U2OS mammalian cells 
demonstrated that the HP1ȕ DQG Ȗ LVRIRUPs acted as repressors of AML1-mediated 
WUDQVFULSWLRQ ZKHUHDV +3Į had no affect on AML1 transactivation. However, 
H[SUHVVLRQRI WKH+3ĮȕȖ LVRIRUPVQHHGV WREHFRQILUPHG Coexpression of MOZ 
DQG +3ȕ DQG, in particular 02= DQG +3Ȗ also resulted in repression of the 
reporter; results reminiscent of the affect observed for SUV39H1 at the AML1-
responsive reporter. Although the result may be influenced by relative expression 
levels of each of the proteins, these results indicate that MOZ is unable to prevent the 
repression by HP1 under these conditions.  
,QWHUHVWLQJO\ ZKHUHDV +3Įȕ ORFDOLVH WR SHULFHQWURPHULF KHWHURFKURPDWLQ
+3Ȗ LVGLVSHUVHGWKURXJKRXW WKHQXFOHXVDQGDVVRFLDWHVZLWK WKHFRGLQJUHJLRQVRI
active genes (Maison and Almouzni, 2004). Little is known of the specific 
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biochemical mechanism by which HP1 inactivates a gene. However, it is understood 
that a promoter-proximal localisation of HP1 triggers silencing, concurrent with 
localised chromatin condensation and an increase in H3K9me3 (Maison and 
Almouzni, 2004). Moreover, it was discovered that HP1-mediated silencing targets 
RNAPII coactivator complexes, interacting with primary PIC components and 
inhibiting the assembly of the PIC at gene promoters (Smallwood et al., 2008). The 
above results suggested that as well as targeting RNAPII coactivator complexes, 
+3Ȗ(possibly in coordination with SUV39H1) may also interact with and inhibit the 
activities of regulatory complexes, such as the MOZ-AML1 complex, at active gene 
promoters. This would suggest a model whereby MOZ is able function as part of both 
a coactivator and corepressor complex. Firstly, MOZ may function as a coactivator 
during the early stages of the gene activation process, inducing the removal of 
repressive PTMs and catalysing the deposition of activating PTMs such as H3K9ac. 
Evidence now suggests that MOZ may also act to recruit other chromatin modulators 
to facilitate a repressive chromatin environment. Our data suggests this is through the 
recruitment of SUV39H1 by MOZ to the active coding region of genes, which 
consequently induces the trimethylation of H3K9, HP1 binding and the initiation of 
gene silencing (Figure 5.11).  
 







To investigate further into the existence of a MOZ/SUV39H1/HP1 
corepressor complex, it would be important to utilise protocols that could validate 
these interactions in a promoter context. Thus, ChIP analysis could be used to check 
the occupancy of MOZ and SUV39H1 at AML1-dependent gene promoters, such as 
myeloperoxidase or at Hox gene loci. However, as the targets of MOZ and 
SUV39H1/HP1 are yet to be completely defined, ChIP Seq would be the most 
informative approach. This would allow the identification of the genome-wide 
binding sites associated with MOZ/SUV39H1/HP1 and enable mapping of their 
proximity to promoters and TSS regions. ChIP seq could also be used to correlate 
these binding sites to chromatin PTMs, such as H3K9me3. Interestingly, recent data 
from our group shows that MOZ expression is up-regulated during DNA damage, 
thus this novel corepressor complex may be induced in response to cellular genotoxic 
stress to halt transcription until DNA repair has prevailed. Indeed, the p53-MOZ 
Figure 5.11. Model showing the hypothesised recruitment of transcriptional 
modulators by MOZ to chromatin.  
Chapter Five: Results 
295 
 
complex has been shown to function in response to genotoxic stress (Rokudai et al., 
2009). Affinity purification of MOZ complexes from cells subjected to various DNA 
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MOZ is a histone acetyltransferase that functions as an essential coactivator 
for genes that are involved in haematopoietic and developmental processes. The 
MOZ MYST domain contains acetyltransferase activity towards histone H4 in vitro 
(Champagne et al., 2001). However, much remains to be discovered regarding how 
chromatin regulators, like MOZ, deposit PTMs onto chromatin and how these signals 
DUH µUHDG¶ FRPELQDWRULDOO\ Chromatin binding is a widespread property of PHD 
fingers, thus it was predicted that the N-terminal double PHD fingers of MOZ may 
function in targeting the enzyme to chromatin. In this study, we have shown that the 
MOZ DPF can sense selected acetyl and methyl PTMs in H3 and H4 and that the 
integrity of both PHD fingers was required for these interactions. Interactions with 
the DPF occurred via H3 (1-21) and H4 (2-24) N-terminal tails. Whereas 
dimethylation of H3K4 had no effect on binding, it was demonstrated that H3K4me3 
strongly reduced interaction with MOZ. Similarly, H4 acetylation (K5,8,12,16) 
abrogated histone binding (Figure 6.1). In contrast, other PTMs such as H3R2me2a, 
H3K9me3 and H3K9/14ac did not adversely affect MOZ recruitment to histones or 
native chromatin. Furthermore, we showed that the separate PHD1 and PHD2 entities 
of the DPF displayed differential histone binding properties and functionally 
cooperate to engage chromatin PTMs bivalently; in particular to the discrimination of 
H3K4 trimethylation. 
It is emerging that chromatin regulators can sense multiple PTMs on different 
histones simultaneously (Ruthenburg et al., 2007b). In our studies we showed that the 
availability of unmodified H3 or H4 histone tails rescued the lack of DPF association 
to H3K4me3, suggesting that H3K4me3 acts as a recessive exit signal that does not 
affect the simultaneous binding to PTM residues on neighbouring histone tails. 
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Conversely, H4Kac exerted a dominant inhibitory affect, preventing binding to 
unmodified H3, H3Kac and H3K9me3 histone tails (Figure 6.1). Quantitative 
experiments revealed a weak affinity of H4K16ac for MOZ DPF, indicating that 
H4Kac tail binding might induce a conformational change to displace H3 histone 
tails.  
Figure 6.1. Schematic model depicting the recruitment and release signals for 
MOZ to and from chromatin. MOZ recruitment is facilitated by binding to 
unmodified H3/H4 tails and is further stabilised by the acetylation of H3K9/14 by 
DPF+MYST. In addition, MOZ is targeted to chromatin enriched in H3Kac and 
H3K9me3 PTMs. Release signals include the presence of H3K4me3 and the induced 
or pre-written H4Kac histone PTMs. 
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            The MOZ DPF motif is shared by only a few other PHD-containing proteins, 
including the DPF protein family (Lange et al., 2008). A high conservation is shared 
between MOZ and DPF2/3 sequences and our studies revealed that the overall 
structural fold is conserved, but differences are apparent in the loop regions of the 
structure. However, structural analysis revealed a striking difference between the H3 
peptide fold in the two complexes. The H3 peptide in the MOZ complex structure 
adopted DQĮ-helical conformation, compared to an unstructured conformation in the 
DPF3b complex; this to our knowledge has not been previously observed for the H3-
terminus in interactions with PHD domains.  
 5HFHQWO\ WKH LQWHUSOD\ EHWZHHQ KLVWRQH µUHDGHU¶ DQG µZULWHU¶ PRGXOHV KDV
been documented in the literature, including the synergy between the bromodomain 
and HAT domain of the acetyltransferase p300 (Chen et al., 2010). Remarkably, our 
preliminary data shows that the DPF domain can function as a mild H3-specific 
acetyltransferase. Neither PHD1 nor PHD2 alone could acetylate histones, thus 
indicating that the composite DPF is required for activity. These studies provide the 
first report of a possible enzymatic role in chromatin modification attributed to a 
PHD finger. The DPF was found to work in conjunction with the H4-specific MYST 
domain to direct histone acetylation and to extend the range of histone substrates 
targeted by MOZ. Moreover, the DPF domain was found to enhance the kinetics of 
MOZ-induced histone acetylation. We have also shown that trimethylation of H3K4 
and monoacetylation of H4, prevented further acetylation of the H3 and H4 peptide 
respectively by MOZ. Conversely, the acetylation of H3 by MOZ DPF or 
DPF+MYST promotes binding to the H3 N-terminus, suggesting that MOZ may 
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promote its own recruitment to chromatin via acetylation of and binding to H3 
(Figure 6.1). 
 Our studies revealed that the MOZ DPF could associate with histones and 
native chromatin enriched in H3K9me3. H3K9me3 is associated with the formation 
of heterochromatin and transcriptionally inert regions (Kouzarides, 2007), thus we 
carried out studies to better understand the relationship between MOZ and H3K9me3. 
In this study we provide evidence demonstrating that MOZ could interact with the 
H3K9me3-specific methyltransferase, SUV39H1 and the H3K9me3-binding protein 
HP1. The two distinct regions of MOZ that bind SUV39H1 were similar to the 
mapped regions that have been established for AML1 (Kitabayashi et al., 2001a). 
Furthermore, it was shown that MOZ was unable to prevent SUV39H1- and HP1-
mediated repression at the AML1-dependent reporter. This suggested a model 
whereby SUV39H1 competitively blocks the interaction between MOZ and AML1, 
preventing the upregulation of AML1-dependent genes. 
Multicomponent nuclear machines are likely to use multivalent interactions 
with histone PTMs to engage chromatin and to install sequential or opposing signals 
leading to gene activation or repression. Thus, to provide insight into MOZ function 
and the sequence of events that takes place, further probing is required into the 
complexes in which MOZ resides. Based on our data and previous reports in the 
literature we propose the following model of events that influence the dynamic 
association of MOZ to chromatin (Figure 6.2). In this study we found that although 
MOZ DPF itself could not bind H3K4me3, this modification did not hinder its 
subsequent binding and acetylation activity towards another histone tail. MOZ DPF 
binds unmodified H3 or H4 tails in chromatin and this interaction is stabilised by 
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acetylation of H3K9/14 by DPF+MYST. This recruitment could also involve the 
BRPF/ING5 complex proteins that could target MOZ within the vicinity of histone 
tails containing the H3K4me3 modification (Figure 6.2). 
MOZ has also been found in complexes containing the methyltransferase 
MLL and the adaptor protein WDR5, which catalyses the trimethylation of H3K4 
(Paggetti et al., 2010). Recruitment of MLL and WDR5 by MOZ may then drive the 
deposition of H3K4me3, which is incompatible with MOZ and thus, serves as a 
release signal from chromatin unless a free H4 tail is available. Conversely, MOZ 
could interact with chromatin bound MLL/WDR5, which facilitates MOZ acetylation 
of the same or neighbouring histone tails. Induced H4 acetylation serves as a second 
exit signal recognised by the MOZ DPF and so may then stimulate the dissociation of 
MOZ from chromatin (Figure 6.2).  
Our studies implicate that MOZ functions within coactivator and corepressor 
complexes. Evidence now suggests that MOZ may also act to recruit other chromatin 
modulators to facilitate a repressive chromatin environment. Our data suggests this is 
through the recruitment of SUV39H1 by MOZ to the active coding region of genes, 
which consequently induces the trimethylation of H3K9, HP1 binding and the 
initiation of gene silencing (Figure 6.2). Thus, like several other chromatin-associated 
proteins, MOZ is a multi-functional regulator of chromatin modification and gene 
expression. 





























Vector Insert Source 
pcDNA3.0-PT FLAG-MOZ (full-length) Phillip Troke 
pcDNA3.0-PT FLAG-MOZ N Phillip Troke 
pGEX-DMH MOZ 1-321 Phillip Troke 
pGEX-DMH MOZ 1-171 Phillip Troke 
pGEX-DMH MOZ 172-321 Phillip Troke 
pEYFP-C1 YFP-FLAG-MOZ Phillip Troke 
pcDNA3.1 HA-MOZ 1-171 Nijjareeya Sirisriro 
pcDNA3.1 FLAG-MOZ 1-321 Nijjareeya Sirisriro 
pcDNA3.1 FLAG-MOZ-TIF2 Phillip Troke 
pSG5 P+3Į B. Le Douarin 
pSG5 P+3ȕ B. Le Douarin 
pCMV (Myc)3-SUV39H1 T. Jenuwein 
pCMV (Myc)3-SUV39H1 H324L T. Jenuwein 
pGEX SUV39H1 T. Jenuwein 
pGEX SUV39H1 H324L T. Jenuwein 
pcDNA3.1(-) FLAG-MORF Xiang-Jiao Yang 
pSG424 (GAL4) - Martin Dickens 
PET3a TIP60 Eric Kalkhoven 
pGEX CBP  1098-1758 Andrew Bannister 
pGEX p300 1097-1722 Andrew Bannister 
pCH110 Lac-Z Pharmacia 
pT109 3xAML1-luc Arthur Zelent 
pCMV5 AML1 D.E Zhong 
peYFP (C1) +3Ȗ Angus Lamond 
pSG5 TDG Simak Ali 
pcDNA3.1 FLAG-HIPK1 Hilary Collins 
pGEX-2T SUMO-1 Ron Hay 
pGEX-2T SUMO-2 Ron Hay 
 
Table A.3. Origin of Plasmids. Plasmids utilised during the research described in this 




Insert Vector Mutation 
GAL4-MOZ HAT pSG424 8 
GAL4-MORF HAT pSG424 8 
GAL4-P300 HAT pSG424 8 
GST-TIP60 HAT pGEX-DMH 8 
GAL4-TIP60 HAT pSG424 8 
GST-MOZ HAT pGEX-DMH 8 
GST-MOZ 510-776 pGEX-DMH 8 
GST-MORF HAT pGEX-DMH 8 
GST-PCAF HAT pGEX-DMH 8 
GAL4-PCAF HAT pSG424 8 
FLAG-MOZ 321-770 pcDNA3.1 + 8 
FLAG-MOZ 321-810 pcDNA3.1 + 8 
FLAG-MOZ 510-770 pcDNA3.1 + 8 
FLAG-MOZ 510-810 pcDNA3.1 + 8 
FLAG-MOZ 810-1117 pcDNA3.1 + 8 
FLAG-MOZ 1317-2004 pcDNA3.1 + 8 
FLAG-MOZ 1-770 pcDNA3.1 + 8 
FLAG-MOZ 1-779 pcDNA3.1 + 8 
FLAG-MOZ 1-784 pcDNA3.1 + 8 
FLAG-MOZ 1-810 pcDNA3.1 + 8 
FLAG-MOZ 321-430 pcDNA3.1 + 8 
FLAG-MOZ 410-510 pcDNA3.1 + 8 
FLAG-MOZ 194-265 pcDNA3.1 + 8 
FLAG-MOZ 194-323 pcDNA3.1 + 8 
FLAG-MOZ N (1-1117) pcDNA3.1 + V779A/I780A 
FLAG-MOZ N (1-1117) pcDNA3.1 + V779A/V781A 
GST-MOZ 194-810 pGEX-DMH 8 
GST-MOZ 510-810 pGEX-DMH V779A/V781A 
GST-MOZ 194-265 pGEX-DMH 8 
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GST-MOZ 194-323 pGEX-DMH 8 
GST-MOZ 250-323 pGEX-DMH 8 
FLAG-MOZ 321-510 pcDNA3.1 + 8 
FLAG-MOZ N (1-1117) pcDNA3.1 + C233A 
FLAG-MOZ N (1-1117) pcDNA3.1 + C307A 
FLAG-MOZ N (1-1117) pcDNA3.1 + C233A/C307A 
FLAG-MOZ N (1-1117) pcDNA3.1 + W257E 
FLAG-MOZ N (1-1117) pcDNA3.1 + W305E 
FLAG-MOZ N (1-1117) pcDNA3.1 + W257E/W305E 
FLAG-MOZ N (1-1117) pcDNA3.1 + P189A/V191A 
FLAG-MOZ pcDNA3.1 + C233A 
FLAG-MOZ pcDNA3.1 + C307A 
FLAG-MOZ pcDNA3.1 + W257E 
FLAG-MOZ-TIF2 pcDNA3.1 + C233A 
FLAG-MOZ-TIF2 pcDNA3.1 + W257E 
FLAG-MOZ-TIF2 pcDNA3.1 + W305E 
FLAG-MOZ-TIF2 pcDNA3.1 + W257E/W305E 
FLAG-MOZ-TIF2 pcDNA3.1 + P189A/V191A 
GST-MOZ 1-321 pGEX-DMH C233A 
GST-MOZ 1-321 pGEX-DMH C307A 
GST-MOZ 1-321 pGEX-DMH C233A/C307A 
GST-MOZ 1-321 pGEX-DMH W257E 
GST-MOZ 1-321 pGEX-DMH W305E 
GST-MOZ 1-321 pGEX-DMH W257E/W305E 
GST-MOZ 1-321 pGEX-DMH P189A/V191A 
GST-MOZ 1-172 pGEX-DMH P189A/V191A 
GST-MORF 201-330 pGEX-DMH 8 
GST-MORF 201-1001 pGEX-DMH 8 
 
Table A.4. Plasmids Created by Cloning or Site-directed Mutagenesis. Plasmids 
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Table A.5. Origin and Dilutions of Antibodies. Antibodies utilised during the research 
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